EP3349853B1 - Prodrugs of fencamfamine - Google Patents
Prodrugs of fencamfamine Download PDFInfo
- Publication number
- EP3349853B1 EP3349853B1 EP16847141.5A EP16847141A EP3349853B1 EP 3349853 B1 EP3349853 B1 EP 3349853B1 EP 16847141 A EP16847141 A EP 16847141A EP 3349853 B1 EP3349853 B1 EP 3349853B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- prx
- ethyl
- prodrug
- phenylbicyclo
- heptan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000651 prodrug Substances 0.000 title claims description 178
- 229940002612 prodrug Drugs 0.000 title claims description 178
- IKFBPFGUINLYQI-UHFFFAOYSA-N fencamfamin Chemical compound CCNC1C(C2)CCC2C1C1=CC=CC=C1 IKFBPFGUINLYQI-UHFFFAOYSA-N 0.000 title description 158
- 229960001938 fencamfamin Drugs 0.000 title description 99
- 239000000203 mixture Substances 0.000 claims description 114
- 150000001875 compounds Chemical class 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 67
- -1 elixir Substances 0.000 claims description 44
- 238000001990 intravenous administration Methods 0.000 claims description 33
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 208000024714 major depressive disease Diseases 0.000 claims description 5
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 235000002639 sodium chloride Nutrition 0.000 description 41
- 238000009472 formulation Methods 0.000 description 40
- 239000007788 liquid Substances 0.000 description 36
- 239000003814 drug Substances 0.000 description 33
- 150000003839 salts Chemical class 0.000 description 31
- 238000013222 sprague-dawley male rat Methods 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 238000012360 testing method Methods 0.000 description 23
- 238000012453 sprague-dawley rat model Methods 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000036470 plasma concentration Effects 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 239000003480 eluent Substances 0.000 description 15
- 206010016256 fatigue Diseases 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 239000001768 carboxy methyl cellulose Substances 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 12
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 12
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 12
- 229940105329 carboxymethylcellulose Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 201000009032 substance abuse Diseases 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000008227 sterile water for injection Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 230000006742 locomotor activity Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 238000010241 blood sampling Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 229960002725 isoflurane Drugs 0.000 description 6
- 238000011275 oncology therapy Methods 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- IKFBPFGUINLYQI-QPSCCSFWSA-N (1r,2r,3s,4s)-n-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine Chemical compound C1([C@H]2[C@@H]3CC[C@@H](C3)[C@@H]2NCC)=CC=CC=C1 IKFBPFGUINLYQI-QPSCCSFWSA-N 0.000 description 4
- IKFBPFGUINLYQI-GBJTYRQASA-N (1s,2s,3r,4r)-n-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine Chemical compound C1([C@@H]2[C@H]3CC[C@H](C3)[C@H]2NCC)=CC=CC=C1 IKFBPFGUINLYQI-GBJTYRQASA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- HHVUPVVGVRTICC-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl octadecanoate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC HHVUPVVGVRTICC-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010002942 Apathy Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 208000014094 Dystonic disease Diseases 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 4
- MVSSDLYSAIRDNP-UHFFFAOYSA-N chloromethyl N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamate Chemical compound ClCOC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC MVSSDLYSAIRDNP-UHFFFAOYSA-N 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 208000010118 dystonia Diseases 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 235000021313 oleic acid Nutrition 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- HBKGEJBTMMONSQ-ALJDKOKLSA-N (2S)-2,6-diamino-N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)hexanamide Chemical compound N[C@@H](CCCCN)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC HBKGEJBTMMONSQ-ALJDKOKLSA-N 0.000 description 3
- ZDHKSTNMKFRHSN-NNGLDNROSA-N (2S)-2-amino-N-ethyl-3-methyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)butanamide Chemical compound N[C@@H](C(C)C)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC ZDHKSTNMKFRHSN-NNGLDNROSA-N 0.000 description 3
- PMLUMUCSMMQINA-AYXRGOPHSA-N (2S)-2-amino-N-ethyl-3-phenyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)propanamide Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC PMLUMUCSMMQINA-AYXRGOPHSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- PGYJGCHWFUVCMT-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl 2,2-dimethylpropanoate Chemical compound CC(C(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC)(C)C PGYJGCHWFUVCMT-UHFFFAOYSA-N 0.000 description 3
- ZDIVCZJREMAGGK-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl acetate Chemical compound C(C)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC ZDIVCZJREMAGGK-UHFFFAOYSA-N 0.000 description 3
- YBWFVBIDRQSAFP-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl butanoate Chemical compound C(CCC)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC YBWFVBIDRQSAFP-UHFFFAOYSA-N 0.000 description 3
- IBEZEEDVHXCRRY-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl decanoate Chemical compound C(CCCCCCCCC)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC IBEZEEDVHXCRRY-UHFFFAOYSA-N 0.000 description 3
- WUTNLTFJWAQISZ-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl octanoate Chemical compound C(CCCCCCC)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC WUTNLTFJWAQISZ-UHFFFAOYSA-N 0.000 description 3
- BUERVHUTYPTUKU-UHFFFAOYSA-N 1-chloroethyl N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamate Chemical compound ClC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC BUERVHUTYPTUKU-UHFFFAOYSA-N 0.000 description 3
- HECLRDQVFMWTQS-RGOKHQFPSA-N 1755-01-7 Chemical compound C1[C@H]2[C@@H]3CC=C[C@@H]3[C@@H]1C=C2 HECLRDQVFMWTQS-RGOKHQFPSA-N 0.000 description 3
- BPFNJJSNQAJUOG-UHFFFAOYSA-N 2-amino-N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)acetamide Chemical compound NCC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC BPFNJJSNQAJUOG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 3
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- SYJROZRBJMKYKL-QXMHVHEDSA-N [ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxymethyl (Z)-octadec-9-enoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)OCOC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC SYJROZRBJMKYKL-QXMHVHEDSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000013020 final formulation Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- CVFSMSTXULJISA-UHFFFAOYSA-N n-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine;hydrochloride Chemical compound Cl.CCNC1C(C2)CCC2C1C1=CC=CC=C1 CVFSMSTXULJISA-UHFFFAOYSA-N 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IKFBPFGUINLYQI-LXTVHRRPSA-N (1r,2s,3r,4s)-n-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine Chemical compound C1([C@@H]2[C@@H]3CC[C@@H](C3)[C@H]2NCC)=CC=CC=C1 IKFBPFGUINLYQI-LXTVHRRPSA-N 0.000 description 2
- IKFBPFGUINLYQI-XGUBFFRZSA-N (1s,2r,3s,4r)-n-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine Chemical compound C1([C@H]2[C@H]3CC[C@H](C3)[C@@H]2NCC)=CC=CC=C1 IKFBPFGUINLYQI-XGUBFFRZSA-N 0.000 description 2
- DIXONBDHLBVBIA-UHFFFAOYSA-N (2-methyl-5-propan-2-ylphenyl) N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamate Chemical compound CCN(C1C2CCC(C2)C1c1ccccc1)C(=O)Oc1cc(ccc1C)C(C)C DIXONBDHLBVBIA-UHFFFAOYSA-N 0.000 description 2
- WWKAVYMUZNWULJ-WTUWNYANSA-N (2S)-2-amino-N-[(2S)-1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-3-methyl-1-oxobutan-2-yl]-3-methylbutanamide Chemical compound N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC WWKAVYMUZNWULJ-WTUWNYANSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- SEPNJBXXGBBIIY-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl dodecanoate Chemical compound C(CCCCCCCCCCC)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC SEPNJBXXGBBIIY-UHFFFAOYSA-N 0.000 description 2
- SABBRCUKGLNUBV-UHFFFAOYSA-N 1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxyethyl tetradecanoate Chemical compound C(CCCCCCCCCCCCC)(=O)OC(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC SABBRCUKGLNUBV-UHFFFAOYSA-N 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101100214695 Staphylococcus aureus aacA-aphD gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- WGELNYIGBODOPY-UHFFFAOYSA-N [ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxymethyl acetate Chemical compound C(C)(=O)OCOC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC WGELNYIGBODOPY-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 208000014679 binge eating disease Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- ZAVOVMIJAFVNME-UHFFFAOYSA-N ethyl N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamate Chemical compound C(C)OC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC ZAVOVMIJAFVNME-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940116871 l-lactate Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- YRHYCMZPEVDGFQ-UHFFFAOYSA-N methyl decanoate Chemical compound CCCCCCCCCC(=O)OC YRHYCMZPEVDGFQ-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 231100000736 substance abuse Toxicity 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- YREYBCWLGYBHOH-LZMFWSBISA-N (2S)-2,6-diamino-N-[(5S)-5-amino-6-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-6-oxohexyl]hexanamide Chemical compound N[C@@H](CCCCN)C(=O)NCCCC[C@H](N)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC YREYBCWLGYBHOH-LZMFWSBISA-N 0.000 description 1
- VKXWDJFVGWGBKN-UWVORMCJSA-N (2S)-2-[(2-aminoacetyl)amino]-N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)propanamide Chemical compound NCC(=O)N[C@H](C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC)C VKXWDJFVGWGBKN-UWVORMCJSA-N 0.000 description 1
- WWKAVYMUZNWULJ-UFQNLXJHSA-N (2S)-2-amino-N-[(2R)-1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-3-methyl-1-oxobutan-2-yl]-3-methylbutanamide Chemical compound N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC WWKAVYMUZNWULJ-UFQNLXJHSA-N 0.000 description 1
- PHMRVIYMQHITKG-NFBNZKMMSA-N (2S)-2-amino-N-[(2S)-1-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC PHMRVIYMQHITKG-NFBNZKMMSA-N 0.000 description 1
- VBUVZLFUHYLKOR-UWVORMCJSA-N (2S)-2-amino-N-[2-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-2-oxoethyl]propanamide Chemical compound N[C@H](C(=O)NCC(N(CC)C1C2CCC(C1C1=CC=CC=C1)C2)=O)C VBUVZLFUHYLKOR-UWVORMCJSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 1
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- IPFQKAXEBZILDW-UHFFFAOYSA-N (5-methyl-2-propan-2-ylphenyl) N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamate Chemical compound CCN(C1C2CCC(C2)C1c1ccccc1)C(=O)Oc1cc(C)ccc1C(C)C IPFQKAXEBZILDW-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- BXAOQVPNOMFMOR-UHFFFAOYSA-N 2-amino-N-[2-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-2-oxoethyl]acetamide Chemical compound NCC(=O)NCC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC BXAOQVPNOMFMOR-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- ABLIRAIUNBLRPK-UHFFFAOYSA-N 3-nitro-2-phenylbicyclo[2.2.1]hept-5-ene Chemical compound [O-][N+](=O)C1C(C=C2)CC2C1C1=CC=CC=C1 ABLIRAIUNBLRPK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XNEUXOFUXTVCGX-UHFFFAOYSA-N 4-[ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)amino]-4-oxobutanoic acid Chemical compound C(C)N(C(CCC(=O)O)=O)C1C2CCC(C1C1=CC=CC=C1)C2 XNEUXOFUXTVCGX-UHFFFAOYSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-M 4-acetamidobenzoate Chemical compound CC(=O)NC1=CC=C(C([O-])=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-M 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 description 1
- CDSSYLTXYXEANW-UHFFFAOYSA-N 5,7-Dimethoxyisoflavone Chemical compound C=1C(OC)=CC(OC)=C(C2=O)C=1OC=C2C1=CC=CC=C1 CDSSYLTXYXEANW-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- HYNILEBOABAXPI-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(=O)OC(C)OC(=O)N(CC)C1C2CCC(C2)C1c1ccccc1 Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)OC(=O)N(CC)C1C2CCC(C2)C1c1ccccc1 HYNILEBOABAXPI-UHFFFAOYSA-N 0.000 description 1
- WDDGGWMHRXFBBX-SEYXRHQNSA-N CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)OC(=O)N(CC)C1C2CCC(C2)C1c1ccccc1 Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)OC(=O)N(CC)C1C2CCC(C2)C1c1ccccc1 WDDGGWMHRXFBBX-SEYXRHQNSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 239000005640 Methyl decanoate Substances 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- XJJMWGSNBXRGMJ-UHFFFAOYSA-N N-ethyl-N-(3-phenyl-2-bicyclo[2.2.1]heptanyl)acetamide Chemical compound C(C)(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC XJJMWGSNBXRGMJ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Chemical class 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- RMPQFDVGWILAOH-UHFFFAOYSA-N [ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxymethyl decanoate Chemical compound C(CCCCCCCCC)(=O)OCOC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC RMPQFDVGWILAOH-UHFFFAOYSA-N 0.000 description 1
- YYRFELKOELHYOU-UHFFFAOYSA-N [ethyl-(3-phenyl-2-bicyclo[2.2.1]heptanyl)carbamoyl]oxymethyl octadecanoate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)OCOC(=O)N(C1C2CCC(C1C1=CC=CC=C1)C2)CC YYRFELKOELHYOU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229950010741 aceturate Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940113720 aminosalicylate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940110710 fusidate Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-O lysinium(1+) Chemical compound [NH3+]CCCCC([NH3+])C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-O 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229950005216 napadisilate Drugs 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940068492 thiosalicylate Drugs 0.000 description 1
- NBOMNTLFRHMDEZ-UHFFFAOYSA-N thiosalicylic acid Chemical compound OC(=O)C1=CC=CC=C1S NBOMNTLFRHMDEZ-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- PIAOLBVUVDXHHL-VOTSOKGWSA-N β-nitrostyrene Chemical compound [O-][N+](=O)\C=C\C1=CC=CC=C1 PIAOLBVUVDXHHL-VOTSOKGWSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Definitions
- the present disclosure relates to prodrug derivatives of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine or any of its stereoisomers. More particularly disclosed herein are pharmaceutical prodrug compositions of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, and methods of synthesizing the same.
- Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as a treatment for reduced performance and rehabilitation from prolonged and debilitating diseases; treatment of depressive day-time fatigue, lack of concentration and lethargy (Brazil, European countries, South Africa, etc.).
- a fencamfamine prodrug comprises fencamfamine, a linker conjugated to the fencamfamine, and a fatty acid or at least one amino acid conjugated to the linker.
- a prodrug composition comprising at least on compound of or
- the prodrug composition is for use in a method for treating cancer-related fatigue .
- Other targeted therapeutic applications include apathy in Alzheimer's Disease, major depression, attention deficit-hyperactivity disorder, etc.
- the use comprises administering to the subject an effective amount of any one or more of the compounds provided herein to a subject in need thereof.
- CRF Cancer-related fatigue
- CRF interferes with usual functioning and has a devastating effect on almost all aspects of patients' lives. It has a pervasive effect on motivation. Additionally, attending and completing a task becomes difficult. The most unusual characteristic of CRF is that it is unrelieved by rest or additional sleep (Holly, 2000). Most of the current pharmacological and non-pharmacological treatments offered by health care professionals are based on anecdotal evidence.
- fencamfamine Glucoenergan, Reactivan
- Fencamfamine acts as an indirect dopamine agonist.
- the drug seems to inhibit the dopamine transporter (DAT) that removes dopamine from the synapses.
- DAT dopamine transporter
- This inhibition of DAT blocks the reuptake of dopamine and norepinephrine into the presynaptic neuron, increasing the amount of dopamine in the synapse.
- fencamfamine does not appear to inhibit the action of monoamine oxidase enzymes and so is somewhat safer.
- prodrug compositions of fencamfamine can provide a treatment for CRF while avoiding and/or reducing the drug-abuse profile but still providing the abilty to dose via routine administration routes, e.g. oral.
- prodrug versions of fencamfamine allow for greater amounts of fencamfamine to be present in the plasma of the subject. In some embodiments, it allows for greater amounts of fencamfamine to be present in the plasma of the subject from oral administration of the prodrug to the subject.
- prodrug versions of fencamfamine allow for a particular isomer of fencamfamine to be provided to the subject.
- the present disclosure provides derivatives and/or combinations thereof of fencamfamine (or N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine) in prodrug form (including particular isomers thereof).
- the fencamfamine is conjugated to at least one acyloxyalkoxycarbonyl moiety (group Y) or which are novel prodrug compositions of N-ethyl-3- phenylbicyclo[2.2.1] heptan-2-amine.
- group Y acyloxyalkoxycarbonyl moiety
- a blocker and linker work together to form the prodrug, and thus, there is no necessary distinction between the two in terms of functional aspects for each embodiment.
- the designation of linker and blocking moiety is a short hand to describe structural aspects, rather than functional aspects.
- the group Y forms the prodrug.
- the prodrugs provided herein allow for a reduced risk of abuse or addiction by a user or patient. In some embodiments, this can be achieved by providing a release profile such that there is only an adequate amount of the active compound if the prodrug is taken orally. However, when the prodrug is taken by IV, it is not broken down into its active form in a substantial amount in the subject. With this release aspect, a subject's ability to receive, via IV, a large amount of the active form of the molecule is reduced (as taking a large amount of the prodrug via IV does not necessarily result in an increase of the active in the plasma levels, for various embodiments).
- Some exemplary embodiments of such prodrugs include PRX-P5-006 and PRX-P4-003 (which include a (-) isomer of fencamfamine).
- the prodrug composition provided herein allows for an increase in a total amount of exposure of an active form of the drug in the subject's plasma.
- the prodrug described herein as PRX-P6-011 (which includes the (+) isomer of fencamfamine) can be used to provide a higher level of the active form of the drug over a desired time period.
- Such embodiments need not have the above noted IV vs oral selective activation aspects.
- the prodrug can have the (+) or (-) isomer of fencamfamine; however, as shown by the data provided herein, the type of Y group employed for the (+) or (-) isomers can vary and change the properties of the prodrug.
- various fencamfamine isomer prodrugs can have further unique characteristics and/or components, as outlined herein.
- prodrugs are provided that delay the time in which the active drug (fencamfamine) is made available to the brain (or within the plasma). In some embodiments, prodrugs are provided that allow for higher levels of the active drug to be present in the plasma.
- N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine herein is meant to include any of the stereoisomer forms of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, including the four stereoisomers: (1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2R,3S,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2S,3R,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and (1S,2R,3S,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and the salts and derivatives thereof.
- N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine includes all salt forms. N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine is also known by its trade name Fencamfamine ® , Glucoenergan ® , and Reactivan ® (E Merck, Germany).
- the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine used in the present disclosure can be any stereoisomer of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, including, but not limited to, (1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2R,3S,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2S,3R,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and (1S,2R,3S,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
- the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine can be a mixture of two or more racemates.
- the resulting prodrug conjugates can be optically active mixtures of isomers, racemic mixtures, single isomers or combinations thereof.
- the various isomers of fencamfamine are depicted below.
- RX-002 consists of racemic fencamfamine.
- the (+)- and (-)-isomers designate the optical rotation of the resolved fencamfamine enantiomers.
- the two Exo-phenyl,endo-amino isomers are PRX 002 (+) and (-).
- PRX 002 (+) and (-).
- One of skill in the art can obtain the desired (+) or (-) enantiomers by chromatography on a chiral column (as outlined in the examples below).
- the (+)-enantiomer of fencamfamine is (1S,2S,3R,4R)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
- the (-)-enantiomer of fencamfamine is (1R,2R,3S,4S)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
- the (1R,2R,3S,4S)-compound can be used as any of the prodrug compounds provided herein (including any of the methods).
- the (1S,2S,3R,4R)-compound can be used as any of the prodrug compounds provided herein (including any of the methods).
- the (1R,2R,3S,4S)-compound can be used as any of the prodrug compounds provided herein (including any of the methods).
- the (1S,2S,3R,4R)-compound can be used as any of the prodrug compounds provided herein (including any of the methods).
- any one of the above isomers can be used as the active in any one of the prodrug arrangements provided herein.
- it is one or more of the Exo isomers noted above.
- it is one or more of the Endo isomers noted above.
- pharmaceutically acceptable salt refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound.
- the salt is an acid addition salt of the compound.
- Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid and phosphoric acid.
- compositions can also be obtained by reacting a compound with an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids, for example formic, acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, ethanesulfonic, p-toluensulfonic, salicylic or naphthalenesulfonic acid.
- organic acid such as aliphatic or aromatic carboxylic or sulfonic acids
- Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C 1 -C 7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine, and salts with amino acids such as arginine and lysine.
- a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C 1 -C 7 alkylamine, cyclohexy
- each center may independently be of R-configuration or S-configuration or a mixture thereof.
- the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture.
- each double bond may independently be E or Z a mixture thereof.
- the compounds disclosed herein may exist as individual enantiomers and diastereomers or as mixtures of such isomers, including racemates. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included in the scope of the compounds disclosed herein. Furthermore, compounds disclosed herein may exist in one or more crystalline or amorphous forms. Unless otherwise indicated, all such forms are included in the scope of the compounds disclosed herein including any polymorphic forms. In addition, some of the compounds disclosed herein may form solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
- each chemical element as represented in a compound structure may include any isotope of said element.
- a hydrogen atom may be explicitly disclosed or understood to be present in the compound.
- the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium).
- reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
- the term "prodrug” generally refers to a compound, which is pharmaceutically acceptable and upon administration is converted to a desired active compound, here fencamfamine.
- the prodrug can be therapeutically inactive until cleaved to release the active compound.
- the prodrug will contain an "active" component, in this case fencamfamine, and a Y moiety as defined. Removal of some or all of the Y moiety will convert the prodrug from an inactive form to an active drug. This is done in the body by a chemical or biological reaction.
- the prodrug is a conjugate of at least one drug, N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, and an additional Y moiety that can be removed and/or altered within the body.
- the conjugates of the present disclosure are prodrugs and the prodrugs of the present disclosure are conjugates.
- blocking moiety denotes a chemical moiety, which may be removed from a larger prodrug, but when present, reduces and/or alters a property of the active component of the prodrug.
- linker denotes a chemical moiety, which may link the blocking moiety to the active in a prodrug.
- the Y moiety itself may be removable from the prodrug, or the Y moiety (or a part thereof) can remain associated with the active, after the removal of at least part of the prodrug.
- active is used herein to refer to fencamfamine, and/or N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (or a particular isomer or collection thereof) to distinguish it from the prodrug form. Thus, it does not necessarily denote any other metabolite or derivative from fencamfamine (such as whether or not the fencamfamine is altered further when administered to a subject).
- active also encompasses the prodrug compounds that have been activated by proper exposure in vivo and/or in vitro.
- the active form of a prodrug may include fencamfamine that is still bonded to some subpart of the prodrug form (for example, whatever remains after the body has removed an adequate section of the Y moiety).
- the "activated prodrug” denotes the form of the molecule after it has been processed by the body and is in an active form of fencamfamine.
- any of the four isomers of fencamfamine noted above can be used in the prodrug, and thus, result in the isomer for the activated prodrug.
- the prodrug can be easier to administer or process than the parent or active form of the drug. They may, for instance, be more bioavailable by oral administration whereas the active drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the active drug.
- a prodrug is an N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine conjugate that is metabolized to reveal the active moiety.
- a prodrug upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically more active form of the compound.
- a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
- a pharmaceutically active compound is modified such that the active compound will be regenerated upon in vivo administration.
- the prodrug is designed to alter the metabolism or the transport characteristics of a drug in certain embodiments, to mask side-effects or toxicity, to improve bioavailability and/or water solubility, to improve the flavor of a drug, to reduce the risk of abuse, or to alter other characteristics or properties of a drug in other discrete embodiments.
- cancer-related fatigue encompasses any unusual and persistent sense of tiredness that can occur with cancer and cancer therapy.
- support oncology encompasses the treatment of a subject receiving or a subject that has received a cancer therapy.
- phrases such as “decreased,” “reduced,” “diminished” or “lowered” is meant to include at least a 10% change in pharmacological activity with greater percentage changes being preferred for reduction in abuse potential and overdose potential.
- the change may also be greater than 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95%, 96%, 97%, 98%, 99%, or increments therein.
- naturally occurring refers to occurring in nature, for example, in bacteria or in a mammal (e.g., a human).
- buse encompasses uses that are inconsistent with a doctor's or manufacturer's instructions.
- the at least one prodrug formed can be either a neutral (uncharged), a free acid, a free base or a pharmaceutically acceptable anionic or cationic salt form or salt mixtures with any ratio between positive and negative components.
- anionic salt forms can include, but are not limited to, for example, acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, l-tartrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsufate, 2-napsylate, nicotinate, nitrate, orotate, stearate,
- pharmaceutically acceptable carriers includes, but is not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer, or in another embodiment 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be in another embodiment aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- the carrier can be a) 10% PEG 400 (v/v) + 30% (v/v) HP ⁇ CD, 50% w/v + 60% (v/v) Sterile Water for Injection or b) 0.1% (v/v) Tween 80 + 0.5% (w/v) Carboxymethylcellulose in water.
- subject refers to a mammal, such as humans, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, and cats, avian species, such as chickens, turkeys, and songbirds.
- the subject can be, for example, a child, such as an adolescent, or an adult.
- treatment refers to any treatment of a pathologic condition in a subject, such as a mammal, particularly a human, and includes: (i) preventing and/or reducing the risk of a pathologic condition from occurring in a subject which may be predisposed to the condition but has not yet been diagnosed with the condition and, accordingly, the treatment constitutes prophylactic treatment for the disease condition; (ii) inhibiting and/or reducing the speed of development of the pathologic condition, e.g., arresting its development; (iii) relieving the pathologic condition, e.g., causing regression of the pathologic condition; or (iv) relieving the conditions mediated by the pathologic condition and/or symptoms of the pathologic condition.
- Treatment to subjects who have previously and/or are currently, and/or are about to receive a cancer therapy are contemplated herein.
- therapeutically effective amount refers to that amount of a compound of the invention that is sufficient to effect treatment, when administered to a subject in need of such treatment.
- the therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- some of the embodiments of the prodrugs/conjugates provided herein undergo enzyme hydrolysis of the ester bond in vivo, which subsequently leads to a cascade reaction resulting in provision of of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and the respective, metabolites thereof and/or derivatives and/or components thereof.
- the blocking moieties of the present disclosure are non-toxic or have very low toxicity at the given dose levels and are preferably known drugs, natural products, metabolites, or GRAS (Generally Recognized As Safe) compounds (e.g., preservatives, dyes, flavors, etc.) or non-toxic mimetics or derivatives thereof.
- the methods and combinations described herein include crystalline forms (also known as polymorphs, which include the different crystal packing arrangements of the same elemental composition of a compound), amorphous phases, salts, solvates, and hydrates.
- the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, or the like.
- the compounds described herein exist in unsolvated form.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, or the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol.
- the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- a fencamfamine prodrug comprises fencamfamine, a Y group conjugated to the fencamfamine, such as the Y moiety comprises 1-Acyloxyethoxycarbonyl, (R 3 C(O)OCH(Me)OCO-).
- this fencamfamine prodrug comprises a linear saturated C18 fatty acid.
- the fencamfamine is the 002(-) isomer.
- the Y group comprises acyloxymethoxycarbonyl , (R 3 C(O)OCH 2 OCO-).
- this prodrug comprises a linear saturated C18 fatty acid and the fencamfamine is the PRX-002 (-) isomer or PRX-002 (+) isomer.
- the fencamfamine component within the prodrug comprises any one or more of the isomers of fencamfamine as provided herein. In some embodiments, the fencamfamine comprises 1, 2, 3, or 4 of the isomers of fencamfamine. In some embodiments, the fencamfamine is only one of the isomers
- the prodrug compound is selected from the group of at least one of the following:
- a pharmaceutical composition comprising the compound of any embodiment provided herein regarding fencamfamine and a pharmaceutically acceptable carrier is provided.
- one or more prodrug compositions of the present disclosure will surprisingly exhibit a slower rate of release over time as compared to unmodified fencamfamine.
- one or more prodrug compositions of the present disclosure provides reduced side effects as compared to unconjugated fencamfamine when administered at equimolar doses, and also provide reduced abuse potential as compared to unconjugated fencamfamine.
- the amount of fencamfamine present in the subject's plasma is at least 5% less than if fencamfamine had been administered to the subject orally, for example, at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% or less, or 100%, including any range above any one of the preceding values and any range between any two of the preceding values.
- one or more fencamfamine prodrug compositions of the present disclosure provides an amount sufficient to provide an extended T max when compared to unconjugated fencamfamine when administered at equimolar doses, and/or provides an equivalent T max when compared to unconjugated fencamfamine when administered at equimolar doses.
- one or more fencamfamine prodrug compositions of the present disclosure provides an increased level of the active drug (fencamfamine) in the plasma, when the prodrug compound is administered orally, in comparison to the amount of active present in the plasma when fencamfamine itself is administered (not as a prodrug).
- the composition results in a higher level of active in the plasma, than would be present if the active itself had been administered.
- the increase is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 400% or more at any given point in time.
- X is CH 3 (CH 2 ) 16 C(O)OCH 2 - or CH3(CH2)16C(O)OCH(CH 3 )-
- the fatty acid bonded prodrug is prepared by the reaction of PRX-002 with chloromethyl chloroformate or 1-chloroethyl chloroformate, followed by the reaction with various carboxylic acids in the presence of cesium cartbonate and potassium iodide in DMF, as illustrated in the scheme 4.2.
- the compounds can be in a form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt as used herein are broad terms, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to salts prepared from pharmaceutically acceptable, non-toxic acids or bases.
- Suitable pharmaceutically acceptable salts include metallic salts, e.g., salts of aluminum, zinc, alkali metal salts such as lithium, sodium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts; organic salts, e.g., salts of lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine, and tris; salts of free acids and bases; inorganic salts, e.g., sulfate, hydrochloride, and hydrobromide; and other salts which are currently in widespread pharmaceutical use and are listed in sources well known to those of skill in the art, such as, for example, The Merck Index. Any suitable constituent can be selected to make a salt of the therapeutic agents discussed herein, provided that it is non-toxic and does not substantially interfere with the desired activity.
- the compounds of preferred embodiments can include isomers, racemates, optical isomers, exo-isomers, endo-isomers, enantiomers, diastereomers, tautomers, and cis/trans conformers. All such isomeric forms are included within preferred embodiments, including mixtures thereof.
- the compounds of preferred embodiments may have chiral centers, for example, they may contain asymmetric carbon atoms and may thus exist in the form of enantiomers or diastereoisomers and mixtures thereof, e.g., racemates.
- Asymmetric carbon atom(s) can be present in the (R)- or (S)-configuration, or can be present as mixtures of the (R)- and (S)- forms.
- N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine can exist as the Exo-phenyl,endo-amino and endophenyl,exo-amino substituted diastereomers. Each diastereomer is a pair of enantiomers.
- the Exo-phenyl,endo-amino diastereomer is a mixture of the following two enantiomers, namely, (1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and (1R,2R,3S,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
- the compounds can be in amorphous form, or in crystalline forms.
- the crystalline forms of the compounds of preferred embodiments can exist as polymorphs, which are included in preferred embodiments.
- some of the compounds of preferred embodiments may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of the preferred embodiments.
- contemplated routes of administration include but are not limited to oral, parenteral, intravenous, and subcutaneous.
- the prodrugs can be formulated into liquid preparations for, e.g ., oral administration. Suitable forms include suspensions, syrups, elixirs, and the like.
- Particularly preferred unit dosage forms for oral administration include tablets and capsules.
- Unit dosage forms configured for administration once a day can be employed; however, in some embodiments it can be desirable to configure the unit dosage form for administration twice a day, or more.
- compositions intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and can include one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives.
- Aqueous suspensions can contain the prodrug in admixture with excipients suitable for the manufacture of aqueous suspensions.
- Formulations for oral use can also be provided as hard gelatin capsules, wherein the prodrug(s) are mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules.
- the prodrugs can be dissolved or suspended in suitable liquids, such as water or an oil medium, such as peanut oil, olive oil, fatty oils, liquid paraffin, or liquid polyethylene glycols.
- Stabilizers and microspheres formulated for oral administration can also be used.
- Capsules can include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredient in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- Tablets can be uncoated or coated by known methods to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time.
- a time delay material such as glyceryl monostearate can be used.
- the solid form When administered in solid form, such as tablet form, the solid form typically comprises from about 0.001 wt. % or less to about 50 wt. % or more of active ingredient(s), preferably from about 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 wt. % to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 45 wt. %.
- Tablets can contain the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients including inert materials.
- a tablet can be prepared by compression or molding, optionally, with one or more additional ingredients.
- Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, antiadherents, coatings, disintegrants, fillers, flavors and colors, preservatives, sorbens, sweeteners, inert diluent, surface active or dispersing agent.
- Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered prodrug moistened with an inert liquid diluent.
- each tablet or capsule contains from about 1 mg or less to about 1,000 mg or more of an prodrug of the preferred embodiments, more preferably from about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg to about 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 900 mg.
- tablets or capsules are provided in a range of dosages to permit divided dosages to be administered. A dosage appropriate to the patient and the number of doses to be administered daily can thus be conveniently selected.
- Suitable inert materials include diluents, such as carbohydrates, mannitol, lactose, anhydrous lactose, cellulose, sucrose, modified dextrans, starch, and the like, or inorganic salts such as calcium triphosphate, calcium phosphate, sodium phosphate, calcium carbonate, sodium carbonate, magnesium carbonate, and sodium chloride.
- diluents such as carbohydrates, mannitol, lactose, anhydrous lactose, cellulose, sucrose, modified dextrans, starch, and the like
- inorganic salts such as calcium triphosphate, calcium phosphate, sodium phosphate, calcium carbonate, sodium carbonate, magnesium carbonate, and sodium chloride.
- Disintegrants or granulating agents can be included in the formulation, for example, starches such as corn starch, alginic acid, sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite, insoluble cationic exchange resins, powdered gums such as agar, karaya or tragacanth, or alginic acid or salts thereof.
- starches such as corn starch, alginic acid, sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite, insoluble cationic exchange resins, powdered gums such as agar, karaya or tragacanth, or alginic acid or salts thereof.
- Binders can be used to form a hard tablet. Binders include materials from natural products such as acacia, tragacanth, starch and gelatin, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, and the like.
- Lubricants such as octadecanoic acid or magnesium or calcium salts thereof, polytetrafluoroethylene, liquid paraffin, vegetable oils and waxes, sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol, starch, talc, pyrogenic silica, hydrated silicoaluminate, and the like, can be included in tablet formulations.
- Surfactants can also be employed, for example, anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate, cationic such as benzalkonium chloride or benzethonium chloride, or nonionic detergents such as polyoxyethylene hydrogenated castor oil, glycerol monostearate, polysorbates, sucrose fatty acid ester, methyl cellulose, or carboxymethyl cellulose.
- anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate
- cationic such as benzalkonium chloride or benzethonium chloride
- nonionic detergents such as polyoxyethylene hydrogenated castor oil, glycerol monostearate, polysorbates, sucrose fatty acid ester, methyl cellulose, or carboxymethyl cellulose.
- Controlled release formulations can be employed wherein prodrug is incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms. Slowly degenerating matrices can also be incorporated into the formulation.
- Other delivery systems can include timed release, delayed release, or sustained release delivery systems.
- Coatings can be used, for example, nonenteric materials such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols, or enteric materials such as phthalic acid esters.
- Dyestuffs or pigments can be added for identification or to characterize different combinations of prodrug doses.
- the pharmaceutical compositions of the prodrugs can be isotonic with the blood or other body fluid of the recipient.
- the isotonicity of the compositions can be attained using sodium tartrate, propylene glycol or other inorganic or organic solutes.
- Sodium chloride is particularly preferred.
- Buffering agents can be employed, such as acetic acid and salts, citric acid and salts, boric acid and salts, and phosphoric acid and salts.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
- Viscosity of the pharmaceutical compositions can be maintained at the selected level using a pharmaceutically acceptable thickening agent.
- methylcellulose can be used.
- suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like.
- concentration of the thickener will depend upon the thickening agent selected. An amount is preferably used that will achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
- a pharmaceutically acceptable preservative can be employed to increase the shelf life of the pharmaceutical compositions.
- Benzyl alcohol can be suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, or benzalkonium chloride can also be employed.
- a suitable concentration of the preservative is typically from about 0.02% to about 2% based on the total weight of the composition, although larger or smaller amounts can be desirable depending upon the agent selected. Reducing agents, as described above, can be advantageously used to maintain good shelf life of the formulation.
- the prodrugs can be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, or the like, and can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired.
- a suitable carrier diluent, or excipient
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired.
- Such preparations can include complexing agents, metal ions, polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, and the like, liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts.
- Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. The presence of such additional components can influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application, such that the characteristics of the carrier are tailored to the selected route of administration.
- a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils can be added to the active ingredient(s).
- Physiological saline solution, dextrose, or other saccharide solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol are also suitable liquid carriers.
- the pharmaceutical compositions can also be in the form of oil-in-water emulsions.
- the oily phase can be a vegetable oil, such as olive or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof.
- Suitable emulsifying agents include naturally-occurring gums such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate.
- the emulsions can also contain sweetening and flavoring agents.
- Pulmonary delivery can also be employed.
- the compound is delivered to the lungs while inhaling and traverses across the lung epithelial lining to the blood stream.
- a wide range of mechanical devices designed for pulmonary delivery of therapeutic products can be employed, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art.
- These devices employ formulations suitable for the dispensing of compound.
- each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants, and/or carriers useful in therapy.
- the compound and/or other optional active ingredients can be prepared for pulmonary delivery in particulate form with an average particle size of from 0.1 ⁇ m or less to 10 ⁇ m or more, more preferably from about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 ⁇ m to about 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, or 9.5 ⁇ m.
- Pharmaceutically acceptable carriers for pulmonary delivery of prodrug include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol.
- ingredients for use in formulations can include DPPC, DOPE, DSPC, and DOPC.
- Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran.
- Bile salts and other related enhancers, as well as cellulose and cellulose derivatives, and amino acids can also be used.
- Liposomes, microcapsules, microspheres, inclusion complexes, and other types of carriers can also be employed.
- compositions suitable for use with a nebulizer typically comprise the prodrug dissolved or suspended in water at a concentration of about 0.01 or less to 100 mg or more of prodrug per mL of solution, preferably from about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg to about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 mg per mL of solution.
- the formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure).
- the nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the prodrug caused by atomization of the solution in forming the aerosol.
- Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the active ingredients suspended in a propellant with the aid of a surfactant.
- the propellant can include conventional propellants, such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, and hydrocarbons.
- Preferred propellants include trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, 1,1,1,2-tetrafluoroethane, and combinations thereof.
- Suitable surfactants include sorbitan trioleate, soya lecithin, and oleic acid.
- Formulations for dispensing from a powder inhaler device typically comprise a finely divided dry powder containing prodrug, optionally including a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in an amount that facilitates dispersal of the powder from the device, typically from about 1 wt. % or less to 99 wt. % or more of the formulation, preferably from about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt. % to about 55, 60, 65, 70, 75, 80, 85, or 90 wt. % of the formulation.
- a bulking agent such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in an amount that facilitates dispersal of the powder from the device, typically from about 1 wt. % or less to 99 wt. % or more of the formulation, preferably from about 5,
- a compound When a compound is administered by intravenous, parenteral, or other injection, it is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution or oleaginous suspension.
- Suspensions can be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The preparation of acceptable aqueous solutions with suitable pH, isotonicity, stability, and the like, is within the skill in the art.
- a preferred pharmaceutical composition for injection preferably contains an isotonic vehicle such as 1,3-butanediol, water, isotonic sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, lactated Ringer's solution, or other vehicles as are known in the art.
- an isotonic vehicle such as 1,3-butanediol, water, isotonic sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, lactated Ringer's solution, or other vehicles as are known in the art.
- sterile fixed oils can be employed conventionally as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono or diglycerides.
- fatty acids such as oleic acid can likewise be used in the formation of injectable preparations.
- the pharmaceutical compositions can also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art
- the duration of the injection can be adjusted depending upon various factors, and can comprise a single injection administered over the course of a few seconds or less, to 0.5, 0.1, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours or more of continuous intravenous administration.
- the prodrugs can be provided to an administering physician, other health care professional, or subject in the form of a kit.
- the kit is a package which houses a container which contains the compound in a suitable pharmaceutical composition, and instructions for administering the pharmaceutical composition to a subject.
- the kit can optionally also contain one or more additional therapeutic agents, e.g ., chemotherapeutics currently employed for treating a cancer as described herein.
- additional therapeutic agents e.g ., chemotherapeutics currently employed for treating a cancer as described herein.
- a kit containing one or more compositions comprising one or more prodrug in combination with one or more additional chemotherapeutic agents can be provided, or separate pharmaceutical compositions containing a prodrug of the preferred embodiments and additional therapeutic agents can be provided.
- the kit can also contain separate doses of a prodrug for serial or sequential administration.
- the kit can optionally contain one or more diagnostic tools and instructions for use.
- the kit can contain suitable delivery devices along with instructions for administering the prodrug(s) and any other therapeutic agent.
- the kit can optionally contain instructions for storage, reconstitution (if applicable), and administration of any or all therapeutic agents included.
- the kits can include a plurality of containers reflecting the number of administrations to be given to a subject.
- the kit can also include different types of fencamfamine prodrugs, as described herein.
- the instructions can be inline with one or more of the methods outlined herein.
- one or more prodrug compositions can be used for treating cancer-related fatigue by administering an effective amount of the composition to a subject in need thereof.
- any of the prodrugs provided herein can be used.
- the subject is human.
- the subject has or had cancer.
- the subject has gone through one or more rounds of a cancer therapy.
- the subject has or has been diagnosed with cancer related fatigue.
- the subject to be treated is in need of one or more of the benefits or properties of fencamfamine.
- the subject to be treated is in need of one or more of the benefits or properties of fencamfamine.
- the subject to be treated is in need of one or more of the benefits or properties of fencamfamine.
- the subject to be treated is at risk of abusing fencamfamine.
- the risk is that the subject will or has taken fencamfamine via IV or injection.
- some of the embodiments provided herein allow for a reduced risk that the subject will, or will repeat an IV administration of the prodrug.
- one or more prodrug compositions can be used for treating neurological disorders such as Parkinson's disease, Alzheimer's disease, and/or dopamine responsive dystonia by administering an effective amount of the composition to a subject in need thereof.
- the present disclosure provides at least one prodrug composition having an extended or controlled release profile as measured by plasma concentrations of released fencamfamine when compared to unconjugated fencamfamine when administered orally at equimolar doses.
- the plasma concentration of fencamfamine released from the prodrug increases more slowly and over a longer period of time after oral administration, resulting in a delay in peak plasma concentration of released fencamfamine and in a longer duration of action when compared to unconjugated fencamfamine.
- this can be the PRX-P6-011 using the + isomer) and/or PRX-P5-006 (using the - isomer) and/or PRX-P4-003 (using the - isomer).
- the subject is mammalian. In some embodiment, the subject is human.
- one or more of the fencamfamine produgs provides for an increase in an amount of fencamfamine present in a subject, compared to the administration of fencamfamine to the subject.
- a method is provided for providing to a subject greater levels of fencamfamine by administering a prodrug of fencamfamine as described herein.
- this can be a prodrug with a valine-valine Y moiety.
- this can be the PRX-P6-011 compound.
- two or more of the fencamfamine prodrugs provided herein are combined into a compostition of two or more of the fencamfamine prodrugs provided herein are administered to a subject.
- the two or more fencamfamine prodrugs can be administered serially or in parallel (either at overlapping volumes or over the same period of time).
- this combination can be a first prodrug that provides delayed release and/or effects, while a second produg and provide a greater level of availability of the active than would be present if fencamfamine were given directly.
- this can be achieved by having PRX-P5-006 as the first prodrug, to provide a delayed onset and/or abuse-resistance, while having PRX-P6-011 as the second prodrug so as to provide a greater initial and/or sustained level of fencamfamine isomer compared to parent.
- the prodrugs or conjugate compositions of the present disclosure can be administered orally and, upon administration, release N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof (which would include some part of the Y moiety from the prodrug) or combinations thereof, after being hydrolyzed in the body.
- the acyloxyalkoxycarbonyl bonded fatty acids that are conjugated to the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, of the present disclosure are naturally occurring metabolites, pharmaceutically active compounds or mimetics thereof or derivatives thereof.
- prodrugs or conjugates of the present disclosure can be recognized by physiological systems resulting in hydrolysis and release of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (or a derivative thereof), when taken orally, but not when taken via IV injection.
- prodrugs are believed to have no or limited pharmacological activity themselves and consequently may follow a metabolic pathway that differs from the parent drug (i.e., N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine).
- a suitable blocking moiety such as an acyl group from a carboxylic acid
- the release of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine into the systemic circulation can be controlled even when the prodrug is administered via routes other than oral administration.
- the prodrugs of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, of the present disclosure surprisingly release N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, similar to free or unmodified N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine. That is, the activated prodrug is identical or similar in its properties to the original form of the drug (fencamfamine).
- the at least one conjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, of the present disclosure are believed to be released in a controlled or sustained form.
- the at least one prodrug or conjugate generates a T max value of released N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine that is longer than the T max value produced by "unconjugated" N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (i.e., the active) when administered at equimolar doses.
- the at least one prodrug or conjugate generates a T max value of released N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine that is similar to the T max value produced by unconjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, when administered at equimolar doses.
- the AUC is about 50% or smaller of the AUC of unconjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, when administered intranasally or intravenously at equimolar doses, for example about 50% to about 0.1%, alternatively from about 25% to about 0.1%, alternatively from about 50% to about 1%, including, but not limited to, about 50%, about 40%, about 30%, about 20%, about 10%, about 1% or any amounts in between, in increments of about 0.5%, about 1%, about 2%, about 2.5%, about 5% or about 10%.
- the compounds, prodrugs, compositions and/or methods of the present disclosure provide reduced potential for overdose, reduced potential for abuse and/or improve the characteristics of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof with regard to toxicities or suboptimal release profiles.
- compositions may have no or a substantially decreased pharmacological activity when administered through intravenous injection or intranasal routes of administration. However, they remain orally bioavailable.
- overdose protection may occur due to the conjugates being exposed to different enzymes and/or metabolic pathways after oral administration whereby the conjugate of the present disclosure is exposed to the gut and first-pass metabolism as opposed to exposure to enzymes in the circulation or mucosal membranes in the nose which limits the ability of the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, from being released from the conjugate. Therefore, in some embodiments, abuse resistance is provided by limiting the effectiveness of alternative routes of administration.
- the bioavailability can be a result of the hydrolysis of the chemical linkage (such as a covalent linkage) following oral administration.
- the prodrugs of the present disclosure are envisioned to not hydrolyze or to hydrolyze at a reduced rate or to a limited extent via non-oral routes. As a result, they are believed to not generate high plasma or blood concentrations of released N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine when injected or snorted compared to free N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine administered through these routes.
- compositions of the present disclosure comprising the prodrugs of one or more N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, are resistant to abuse by parenteral routes of administration, such as intravenous "shooting,” or intranasal "snorting,” that are often employed during illicit use.
- parenteral routes of administration such as intravenous "shooting,” or intranasal "snorting,” that are often employed during illicit use.
- release of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof is reduced when the composition of the present disclosure is delivered by parenteral routes.
- the conjugates since they are believed to include covalently bound N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, are not able to be physically manipulated to release the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, from the conjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, by methods, for example, of grinding up or crushing of solid forms.
- some compositions containing prodrugs or conjugates of the present disclosure preferably have no or a substantially decreased pharmacological activity when administered through injection or intranasal routes of administration. However, they remain orally bioavailable.
- the present disclosure provides a stimulant based treatment modality and dosage form for certain disorders requiring the stimulation of the CNS such as, cancer-related fatigue, chronic fatigue syndrome, major depressive disorder, narcolepsy, advanced Parkinson's Disease, ADHD, substance-abuse disorders, binge-eating disorder Alzheimer's disease (such as apathy in Alzheimer's disease), or Dopamine Responsive Dystonia.
- a stimulant based treatment modality and dosage form for certain disorders requiring the stimulation of the CNS such as, cancer-related fatigue, chronic fatigue syndrome, major depressive disorder, narcolepsy, advanced Parkinson's Disease, ADHD, substance-abuse disorders, binge-eating disorder Alzheimer's disease (such as apathy in Alzheimer's disease), or Dopamine Responsive Dystonia.
- the at least one composition or prodrug of the present disclosure can be used in one or more methods of treating a patient having at least one disease, disorder or condition requiring stimulation of the central nervous system of one or more patients, comprising orally administering a pharmaceutically effective amount of the at least one composition or prodrug.
- Certain compounds, compositions and methods provided herein can be used to treat a number of disorders such as those requiring the stimulation of the CNS such as, cancer-related fatigue i.e. fatigue caused due to chemotherapy induced anemia, fatigue caused due to radiation therapy, depression, chronic fatigue syndrome, or major depressive disorder narcolepsy.
- cancer-related fatigue i.e. fatigue caused due to chemotherapy induced anemia
- fatigue caused due to radiation therapy depression, chronic fatigue syndrome, or major depressive disorder narcolepsy.
- certain compounds, compositions and methods provided herein can be used to treat Alzheimer's disease, such as apathy in Alzheimer's disease and cognitive impairment in Alzheimer's disease.
- certain compounds, compositions and methods provided herein can be used to treat dopamine responsive dystonia.
- the prodrug provided herein is mostly (at least 50%, for example, at least 60, at least 70, at least 80, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, at least 100% metabolized by an oral route, over an IV route.
- the prodrug component (the non-active) or any hydrolyzed products are not toxic.
- the product allows for once a day dosing (or is configured in an amount for such dosing).
- the product has an abuse resistant profile (delayed Tmax and/or low Cmax).
- the prodrug has a relatively low IV conversion rate (compared to oral).
- the prodrug moiety is safe for human consumption.
- Table 1 displays a listing of the various chemical names with the names used herein of the actives and prodrugs, as well as the structures.
- the structures in Table 1 do not necessarily depict the absolute configurations of (+)- and (-)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
- any one or more of the prodrugs provided in Table 1 can be part of any composition and/or formulation and/or method provided herein.
- Fencamfamine ((Exo-phenyl,endo-amino)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, PRX-001) was synthesized according to the scheme 1 and modifications of the methods described in Pharmaceutical Chemistry Journal 2011, 45(7), 419-422 , Journal of Organic Chemistry 1961, 26, 5247-5249 , GB 913866 , Organometallics, 2013, 32, 1609 - 1619 , and Organic Letters 2007, 9, 2819 ,
- Dicyclopentadiene 500 g was added to a 1L two-necked round-bottomed flask equipped with thermometer and an upright Friedrich's-type condenser (through which water at 50 °C was circulated).
- the ground-glass outlet of the Friedrich's condenser was connected to the side arm of a simple distilling head fitted with a thermometer and attached to an efficient water-cooled condenser held in a vertical position.
- a receiver was attached which consisted of a weighed 500-ml, two-necked round-bottomed flask immersed in a Dry Ice bath and protected from the air by a calcium chloride drying tube.
- the flask containing dicyclopentadiene was heated by means of oil bath until cyclopentadiene distilled (approximately 160 - 170 °C) into the receiver which was placed in dry ice cooling bath. After two-third of the dicyclopentadiene had been pyrolyzed during the course of 4-5 hours, the residue in the flask may tend to become viscous and a higher temperature for pyrolysis will be required in order to obtain rapid distillation of cyclopentadiene in such case it was desirable to discard the residue while it was still hot and mobile.
- the distilled cyclopentadiene (I-1) (200 g, 40 %) was obtained as a colorless liquid and which was taken for next step immediately to avoid dimerization.
- Racemic PRX-001 (90 g in 200 mg batches) was resolved by chiral preparative HPLC on a Chiralpak AD column (250 X 50 mm) eluted with 0.1% diethylamine in isopropanol (43 mL / min) to afford the two enantiomers, (+)-PRX-002 (37 g), and (-)-PRX-002 (39 g).
- Step 1 To a solution of N-Boc protected amino acids (1.2 eq) in DMF (5 volumes) was added HATU (1.5 eq), Et 3 N (2 eq) and stirred the reaction mixture for 20 min. Then, PRX-002 (+) isomer or (-) isomer (1 eq) in DMF (5 volumes) was added dropwise and the reaction was continued for 12 hour at ambient temperature. After the completion of reaction (TLC eluent: 40% EtOAc in petroleum ether), the reaction product was treated with ice cold water (20 volumes) and product was extracted with ethyl acetate (2 x10 volumes).
- Step 2 To a solution of I-6 (1 eq) in DCM (5 volumes) was added TFA (1 volume) dropwise at 0-5 °C and after complete addition, reaction mixture was stirred for 30 min at ambient temperature. After the completion of reaction (TLC eluent: 80% EtOAc in n- hexane), the solvent was concentrated under reduced pressure. The residue thus obtained was washed with n-hexane (2 x 20 volumes) for removal of impurities. Then it was dissolved in ethyl acetate (2 x 20 volumes), neutralized with saturated NaHCO 3 solution (20 volumes) and washed with brine solution (20 volumes).
- amino acid bonded prodrugs including compounds PRX-P1-005, PRX-P1-006, PRX-P1-012, and PRX-P1-013 .
- Step 1 To a stirred solution of triphosgene (0.5 eq) in THF (5 volumes) at 0 °C, was added dropwise a solution of phenol derivative (1 eq) and DIPEA (1 eq) in THF (5 volumes) and the reaction mixture was kept at ambient temperature for 12 hours. After the completion of reaction (TLC eluent: 10 % EtOAc in hexane), the reaction mixture was treated with water (20 volumes) and product was extracted with EtOAc (2 X 20 volumes). The combined organic layer were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain crude intermediate I-7, which was carried forwarded for the next step.
- TLC eluent 10 % EtOAc in hexane
- Step 2 To a stirred solution of (-)-PRX-002 (1 eq) in dry THF (5 volumes), were added DMAP (0.1 eq) and Et 3 N (2 eq). The mixture was stirred for 10 min at ambient temperature. Then a solution of I-7 (2 eq) in THF (5 volumes) was added dropwise and the reaction mixture was stirred for 12 hours at ambient temperature and monitored TLC (eluent: 5% EtOAc in hexane). Then, the reaction mixture was treated with water (20 volumes), and extracted with EtOAc (2 x 30 volumes). The organic layer was washed with brine (20 volumes), dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- DMAP 0.1 eq
- Et 3 N 2 eq
- Step 1 To a solution of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (PRX-002) (1 eq) in dichloromethane (10 volumes) under argon atmosphere, was added triethylamine (2 eq) dropwise at ambient temperature and the mixture was stirred for 5 min. Then, chloromethyl chloroformate (1.5 eq) was introduced dropwise at 0 - 5 °C and the reaction mixture was further stirred at ambient temperature for 30 min. After the completion of reaction (TLC eluent: 20% EtOAc in petroleum ether), the reaction mixture was quenched in water (20 volumes), extracted with dichloromethane (2 x 20 volumes).
- PRX-002 N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine
- Step 2 To a solution of N-(Chloromethoxycarbonyl)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (also known as ethyl-(3-phenyl-bicyclo[2.2.1]hept-2-yl)-carbamic acid chloromethyl ester) (I-8) (1 eq) in DMF (10 volumes) was added dry Cs 2 CO 3 (2 eq), acid (R-COOH) (2 eq), and KI (0.2 eq) at ambient temperature. The reaction mixture was heated to 100-105 °C and stirred for 4 h.
- Step 1 To a solution of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, PRX-002 (+) isomer or (-) isomer, (1 eq) in DCM (10 volumes) under argon atmosphere, was added triethylamine (2 eq) dropwise at ambient temperature. After stirring for 5 minutes, 1-chloroethyl chloroformate (2) (1.5 eq) was added dropwise at 0 - 5 ° C and the reaction mixture was further stirred at ambient temperature for 30 min. After the completion of reaction (TLC eluent: 20% EtOAc in petroleum ether) the reaction mixture was quenched in water (20 volumes), extracted with DCM (2 x 20 volumes).
- Step 2 To a solution of intermediate I-9 (1 eq) in DMF (10 volumes) was added dry Cs 2 CO 3 (2 eq), a fatty acid (R-COOH) (2 eq), and KI (0.2 eq) at ambient temperature and the reaction mixture was heated at 100 - 105 °C and stirred for 4 hours. After completion of reaction (TLC eluent: 10 % EtOAc in n-Hexane), the reaction mixture was quenched in water (20 volumes), extracted with ethyl acetate (2 x 20 volumes). Combined organic layer was washed with water (2 x 10 volumes) and brine solution (10 volumes), further dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude residue obtained was purified by either flash column chromatography / preparative HPLC to yield 1-Acyloxyethoxycarbonyl pro-drugs, including Compounds PRX-P5-001 to PRX-P5-011.
- PK results of prodrugs of PRX-002 (-) or (+) isomers All doses of prodrugs were administered such that they were equivalent to 5 mg/kg of PRX-002 (-) or (+) for oral studies and 2 mg/kg PRX-002 (-) or (+) for intravenous studies in male Sprague-Dawley (MSD) rats. Higher doses of up to 10 or 15 mg/kg [again equivalent to PRX-002 (-)] were used in some studies (as specified)].
- Formulation preparation, dose administration and time of sample collection was as follows.
- Test item was weighed [5 mg equilvalent dose of PRX-002 for prodrugs] and transferred to a graduated tube. Then 10 ⁇ L of Tween 80 was added and vortexed mixed until the test item was completely mixed. Small volume of 0.5% (w/v) carboxymethylcellulose in water solution was then added dropwise with continuous vortex mixing until a uniform suspension was obtained. The final volume was then made up to 10 mL with 0.5% (w/v) carboxymethylcellulose in water with final strength of 0.5 mg/mL. The obtained formulation was found to be uniform suspension. This formulation was freshly prepared before the administration to animals.
- Oral Dose Administration Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Fasted animals were administered test item by oral route with a dose of 5 mg/kg body weight at dose volume of 10 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K 2 EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4 oC for 10 minutes and plasma were separated and stored at -80 oC until analysis.
- K 2 EDTA-2 mg/mL blood anticoagulant
- Test item was weighed [(to be equivalent to 2 mg/kg of PRX 002 dose] and transferred to a graduated tube. Then 500 ⁇ L of PEG 400 (v/v) was added and vortex mixed thoroughly until the test item was completely dissolved. Then 1500 ⁇ L of Hydroxypropyl- ⁇ -cyclodextrin (HP ⁇ CD, 50% w/v) was added and vortex mixed thoroughly. The final volume was then made up to 5000 ⁇ L with sterile water for injection (SWFI, v/v) with final formulation strength of 0.4 mg/mL. The obtained formulation was found to be clear solution. This formulation was freshly prepared before the administration to animals.
- SWFI sterile water for injection
- Test item PRX-P4-003 was weighed and transferred to a graduated tube. Then 12.42 ⁇ L of Tween 80 was added and vortexed mixed until the test item was completely mixed. Small volume of 0.5% (w/v) Carboxymethylcellulose in water solution was then added dropwise with continuous vortex mixing until a uniform suspension was obtained. The final volume was then made up to 12.42 mL with 0.5% (w/v) Carboxymethylcellulose in water with final strength of 1.0 mgA/mL. The obtained formulation was found to be uniform suspension. This formulation was freshly prepared before the administration to animals.
- Dose Administration Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Animals were administered with a PRX-P4-003 by Intravenous bolus route with a dose of 10 mg/kg body weight at dose volume of 5 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K 2 EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4oC for 10 minutes and plasma were separated and stored at -80oC until analysis.
- K 2 EDTA-2 mg/mL blood anticoagulant
- Test item PRX-P5-006 was weighed and transferred to a graduated tube. Then 10 ⁇ L of Tween 80 was added and vortexed mixed until the test item was completely mixed. Small volume of 0.5% (w/v) Carboxymethylcellulose in water solution was then added dropwise with continuous vortex mixing until a uniform suspension was obtained. The final volume was then made up to 10 mL with 0.5% (w/v) Carboxymethylcellulose in water with final strength of 3.97 mg/ mL. The obtained formulation was found to be uniform suspension. This formulation was freshly prepared before the administration to animals.
- Test item PRX-P5-006 was weighed and transferred to a graduated tube. Then 500 ⁇ L of DMSO (v/v) was added vortex mixed thoroughly until the test item was completely dissolved. Then 4000 ⁇ L of Hydroxypropyl- ⁇ -cyclodextrin (HP ⁇ CD, 50% w/v) was added and vortex mixed thoroughly. Then 2500 ⁇ L of PEG 400 (v/v) was added and vortex mixed thoroughly. The final volume was then made up to 10000 ⁇ L with sterile water for injection (SWFI, v/v) with final formulation strength of 3.97 mg/mL. The obtained formulation was found to be clear solution. This formulation was freshly prepared before the administration to animals.
- DMSO v/v
- HP ⁇ CD Hydroxypropyl- ⁇ -cyclodextrin
- Table 39.3 depicts a set of comparative data of single dose oral and intravenous PK Study of PRX-P4-003. Additional data in this regard is presented in FIG. 1 .
- TABLE 39.3 Single Dose Oral and intravenous PK Study of PRX-P4-003 in Male Sprague Dawley Rats Oral Intravenous PK Parameters Mean Plasma PK Parameters of PRX-P4-003 Dose (mg/kg) 5.00 2.00 C max (ng/mL) 0.0 ⁇ 0.0 171.963 ⁇ 62.6030 T max (hr) 0.0 ⁇ 0.0 0.080 ⁇ 0.0000 AUC last (hr*ng/mL) 0.0 ⁇ 0.0 132.573 ⁇ 32.5110 AUC inf (hr*ng/mL) 0.0 ⁇ 0.0 215.708 ⁇ 83.3890 AUC % extrap (%) 0.0 ⁇ 0.0 32.475 ⁇ 83.3890 Vss (L/kg) 0.0
- FIG. 2 is a graph depicting oral and IV pharmacokinetics for PRX-P4-003 in male Sprague Dawley rats.
- the graph depicts the results for the resulting plasma concentration of PRX-002(-) isomer via oral or IV administration.
- oral administration results in a desired plasma concentration for the active/parent drug (here, PRX-002(-) isomer)
- IV administration results in minimal amounts of any of the PRX-P4-003 being converted from the pro-drug form to the active form.
- the results are outlined above in Table 39.4 and 39.5.
- PRX-002 (-) Isomer IV 10 mg/kg PK data analysis was not carried out because limited exposure in plasma concentration profile TABLE 39.5 Concentration time profile of PRX-002 (-) after oral and IV dose of PRX-P4-003 Single Dose Oral and Intravenous Pharmacokinetics Study of PRX-P4-003 in Male Sprague Dawley Rats Oral PK Intravenous PK Plasma concetration ef PRX-002 (-) Isomer (ng/mL) Time (h) Mean SD Time (h) Mean ⁇ SD 0.00 0.00 ⁇ 0.00 0.00 ⁇ 0.008 0.00 ⁇ 0.00 0.08 30.81 ⁇ 10.08 0.25 35.89 ⁇ 18.38 0.25 15.63 ⁇ 3.90 0.50 97J6 ⁇ 29.02 0.50 9.14 ⁇ 3.39 1.00 149.74 ⁇ 89.23 1.00 7.82 ⁇ 0.92 2.00 56.12 ⁇ 21.49 2.00 0.00 + 0.00 4.00 25.08 ⁇ 11.
- FIG. 3 depicts the results of the comparative data regarding IV PK studies of PRX-P4-003 (2 and 10 mg/kg b.w.) PRX-002(-) isomer (2mg/kg b.w.). As can be observed very limited amount of parent PRX-002 (-) is generated when the prodrug PRX-P4-003 is administered IV even at higher dose of 10 mg/kg. Additional data is summarized in Tables 39.6-39.7.
- FIG. 4 is a graph comparing the oral PK study of PRX-P4-003 to PRX-002(-) isomer, in terms of the amount of resulting PRX-P4-003 or PRX-P4-002(-) isomer present in the plasma.
- PRX-P4-003 the prodrug form of the drug
- PRX-P4-002 the prodrug form of the drug
- a desired amount of the active compound PRX-002 (-) Isomer
- Fig. 5 A and 5B shows comparative Data: Single Dose Oral and Intravenous PK Study of PRX-P5-006. Much higher level of intact PRX-P5-006 was observed when prodrug was administered IV. The data is shown in Table 39.10.
- FIG. 6A is a graph depicting a comparison of oral and IV pharmacokinetics of PRX-P5-006 in Male Sprague Dwaley rats.
- FIG. 6B shows an enlarged view of the IV pharmacokinetics for the amount of resulting active in the plasma depicted in 6A.
- the graph depicts the amount of the active compound found in the plasma over time for the PRX-P5-006 compound.
- the data is shown in Table 39.13, below. Additional data is shown below in Tables 39.14-39.17.
- FIG. 7A and 7B show graph depicting the IV pharmacokinetics for PRX-P5-011 in male Sprague Dawley rats. Even though the only difference between PRX-P5-011 and PRX-P5-006 is that the former has positive isomer PRX-002 (+) while the latter has PRX-002 (-) the oral plasma profile is remarkably different. The active compound PRX-002 (+) was not detected in plasma after oral administration.
- Plasma concentration of PRX-P5-011 (ng/mL) Time (h) R010 R011 R012 Mean SD 0.00 0.00 0.00 0.00 0.000 0.08 0.00 0.00 0.00 0.000 0.25 0.00 0.00 0.000 0.50 0.00 0.00 0.00 0.000 1.00 0.00 0.00 0.00 0.000 2.00 0.00 0.00 0.000 4.00 0.00 0.00 0.00 0.000 6.00 0.00 0.00 0.000 24.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-P5-011 in plasma-3.373 ng/mL TABLE 39.19: SINGLE DOSE ORAL PHARMACOKINETIC STUDY OF PRX-P5-011 PLASMA CONCENTRATIONS OF PRX-002 (+) ISOMER IN MALE SPRAGUE DAWLEY RATS.
- Plasma concentration of PRX-002 (+) Isomer (ng/mL) Time (h) R010 R011 R012 Mean SD 0.00 0.00 0.00 0.00 0.000 0.08 0.00 0.00 0.00 0.000 0.25 0.00 0.00 0.000 0.50 0.00 0.00 0.00 0.000 1.00 0.00 0.00 0.00 0.000 2.00 0.00 0.00 0.000 4.00 0.00 0.00 0.00 0.000 6.00 0.00 0.00 0.000 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-002 (+) Isomer In plasma-1.779 ng/mL TABLE 39.20 Single Dose Intravenous Pharmacokinetics Study of PRX-P5-011 in Male Sprague Dawley Rats (2 mg/kg b.w.) Plasma concentration of PRX-P5-011 (ng/mL) Group No.
- FIG. 8A is a graph depicting the IV pharmacokinietics of PRX-P6-011 in male Sprague Dawley rats.
- Fig. 8B is a more closely visualized graph (from 8A) consisting of PRX-P6-011, PRX-002 (+) [compared to the level of PRX-002 (-) after direct administration]. The results are summarized in tables 39.22-39.25.
- Tables 39.22-39.25 provide comparative oral pharmacokinetics study results for PRX-P6-011 and PRX-002(+), including mean plasma PK parameters of PRX-P6-011, PRX-P1-006, PRX-002(+) .
- Fig. 9 A , B , and C show graph of PRX-002 (+) administered to the rats at a dose of 5 mg kg orally or 2 mg/kg intravenously.
- Tables 39.26 and 39.27 show the detailed oral and IV PK parameters.
- Fig. 10 A , B , and C show graph of PRX-002 (-) administered to the rats at a dose of 5 mg kg orally or 2 mg/kg intravenously.
- Tables 39.28 and 39.29 show the detailed oral/IV PK parameters.
- FIGS. 1-10 demonstrate the different PK curves achieved by the different fencamfamine prodrugs as compared with unconjugated forms and the specific pharmacokinetic parameter data is presented in the Tables above and noted figures.
- the release of fencamfamine from the prodrugs varied depending on the chain length of the fatty acid linkers attached to fencamfamine. Changes in the amount of fencamfamine released from the prodrugs was measured by the area under the curve and compared to unconjugated fencamfamine.
- prodrug compositions unexpectedly provided an amount sufficient to provide an extended T max when compared to unconjugated fencamfamine when administered at equimolar doses.
- the prodrug composition showed an extended or controlled release profile as measured by plasma concentrations of released fencamfamine when compared to unconjugated fencamfamine when administered orally at equimolar doses.
- not all of the compounds displayed all or similar such properties.
- the plasma concentration of fencamfamine released from the prodrug increased more slowly and over a longer period of time after oral administration, resulting in a delay in peak plasma concentration of released fencamfamine and in a longer duration of action when compared to unconjugated fencamfamine.
- the form of the isomer would also alter the pharmacokinetic profile in unexpected ways.
- the type of blocking moiety associated with the drug e.g., fatty acid or amino acid, etc.
- the particular isomer of fencamfamine used each resulted in varied properties and for the provision of the drug in question.
- EXAMPLE 40A PHARMACODYNAMIC RESPONSE (SPONTANEOUS LOCOMOTOR ACTIVITY) TO PRX-P4-003 BY ORAL ADMINISTRATION
- mice Male Sprague-Dawley (SD) were housed in groups of three under controlled conditions. Water and food were available ad libitum. The rats were kept for 1 week under these conditions before behavioral test. On the day of test rats were allowed to acclimate to the testing room for at least 30 min before test compound administration. Rats were randomly assigned into 4 groups.
- Vehicle was 0.1% Tween-80 and 0.5% carboxymethylcellulose to which respective amount of PRX-P4-003 was added to obtain a clear solution.
- the rat was placed at the center of test chamber for the 60 min sLMA video recording. 60 min of spontaneous locomotion activity was video recorded and off line analyzed with Animal Behavior Video Tracking Analysis System (Ji Liang Software Technology Co., Ltd., Shanghai, China). Total traveling distance (cm) and duration (sec) of locomotor activity of every 15 min is presented FIGs. 11A and 11B .
- PRX-P4-003 showed a dose dependent increase in sLMA when given orally.
- EXAMPLE 40B PHARMACODYNAMIC RESPONSE (SPONTANEOUS LOCOMOTOR ACTIVITY) TO PRX-P4-003 BY INTRAVENOUS ADMINISTRATION
- Vehicle 10% PEG 400 (v/v) + 30% (v/v) of (50% w/v) Hydroxypropyl- ⁇ -cyclodextrin in water + 60% (v/v) sterile water for injection (SWFI): 1 ml/kg volume.
- PRX-P4-003 solution was: 25.8 mg/ml PRX-P4-003 (25.8 mg/kg: equivalent to 10 mg/ml active drug, i.v. @volume of 1 ml/kg). 42.3 mg PRX-P4-003 was added to vehicle 1.639 ml, vortexed for 30 min under room temperature to get a uniform suspension solution, suspension solution was continuously stirred during dosage.
- the PRX-P4-002(-) solution was: 2 mg/ml PRX-P4-002(-) (2 mg/kg, i.v.@ volume of 1 ml/kg). 4.5 mg PRX-002(-) was added to 2.25 ml Vehicle, vortexed for 30 min under room temperature to get a clear solution, the solution was continuously stirred during dosage.
- FIGs. 12A and 12B Total traveling distance (cm) and duration (sec) of locomotor activity of every 15 min is presented in FIGs. 12A and 12B . Consistent with the the present disclosures, intravenous PRX-002 (-) significantly increased sLMA but prodrug PRX-P4-003 showed no increase in sLMA (even at a 5 times equivalent dose of active) compared to vehicle, even when given intravenously.
- the prodrug PRX-P4-003 resulted in higher levels of sLMA activity when administered orally than intravenously. Indeed, while both traveling distance and locomotion duration increased following the oral administration of the prodrug ( FIG. 11A and 11B ), intravenous administration resulted in practically no change (in comparison to the administration of the active ingredient itself (PRX-002(-)). Thus, the active drug's availability and impact upon the subject is dependent upon its route of administration of the prodrug.
- a group of items linked with the conjunction 'and' should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as 'and/or' unless expressly stated otherwise.
- a group of items linked with the conjunction 'or' should not be read as requiring mutual exclusivity among that group, but rather should be read as 'and/or' unless expressly stated otherwise.
Description
- This application claims priority to
U.S. Provisional Applications Ser.62/219052, filed Sept. 15, 2015 Ser. No.62/298267, filed Feb. 22, 2016 Ser No. 62/308078, filed March 14, 2016 - The present disclosure relates to prodrug derivatives of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine or any of its stereoisomers. More particularly disclosed herein are pharmaceutical prodrug compositions of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, and methods of synthesizing the same.
- Fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as a treatment for reduced performance and rehabilitation from prolonged and debilitating diseases; treatment of depressive day-time fatigue, lack of concentration and lethargy (Brazil, European countries, South Africa, etc.).
- In one aspect, a fencamfamine prodrug is disclosed. The fencamfamine prodrug comprises fencamfamine, a linker conjugated to the fencamfamine, and a fatty acid or at least one amino acid conjugated to the linker.
-
- In some embodiments,
the prodrug composition is for use in a method for treating cancer-related fatigue
. Other targeted therapeutic applications include apathy in Alzheimer's Disease, major depression, attention deficit-hyperactivity disorder, etc. The use comprises administering to the subject an effective amount of any one or more of the compounds provided herein to a subject in need thereof. -
-
FIG. 1 depicts a set of comparative data of single dose oral and intravenous PK Study of PRX-P4-003. -
FIG. 2 is a graph depicting oral and IV pharmacokinetics for PRX-P4-003 in male Sprague Dawley rats. -
FIG. 3 depicts the results of the comparative data regarding IV PK studies of PRX-P4-003 (2 and 10 mg/kg b.w.) PRX-002(-) isomer (2mg/kg b.w.). -
FIG. 4 is a graph comparing the oral PK study of PRX-P4-003 to PRX-002(-) isomer, in terms of the amount of resulting PRX-P4-003 or PRX-P4-002(-) isomer present in the plasma. -
FIGS. 5A and5B show comparative Data: Single Dose Oral and Intravenous PK Study of PRX-P5-006. -
FIG. 6A is a graph depicting a comparison of oral and IV pharmacokinetics of PRX-P5-006 in Male Sprague Dawley rats. -
FIG. 6B shows an enlarged view of the IV pharmacokinetics for the amount of resulting active in the plasma depicted inFIG. 6A . -
FIGS. 7A and7B show graph depicting the IV pharmacokinetics for PRX-P5-011 in male Sprague Dawley rats. -
FIG. 8A is a graph depicting the IV pharmacokinietics of PRX-P6-011 in male Sprague Dawley rats. -
Fig. 8B is a more closely visualized graph (from 8A) consisting of PRX-P6-011, PRX-002 (+) [compared to the level of PRX-002 (-) after direct administration]. -
FIG. 9A ,9B , and9C show graph of PRX-002 (+) administered to the rats at a dose of 5 mg kg orally or 2 mg/kg intravenously. -
FIG. 10A ,10B , and10C show graph of PRX-002 (-) administered to the rats at a dose of 5 mg kg orally or 2 mg/kg intravenously. -
FIGs. 11A and11B : Total traveling distance (cm,FIG. 11A ) and duration (sec,FIG. 11B ) of locomotor activity of every 15 min. Data were expressed as Mean±S.E.M. and analyzed with Repeated measures ANOVA followed by Bonferroni test compared to vehicle group. * P<0.05, ** P<0.01, *** P<0.001: vs. Veh group. -
FIGs. 12A and12B : Total traveling distance (cm,FIG. 12A ) and duration (sec,FIG. 12B ) of locomotor activity of every 15 min. Data were expressed as Mean±S.E.M. and analyzed with Repeated measures ANOVA followed by Bonferroni test compared to vehicle group. * P<0.05, ** P<0.01, *** P<0.001: vs. Veh group. - The following description and examples illustrate various embodiments of the present disclosure in detail. The description of the disclosed embodiment should not be deemed to limit the scope of the present disclosure.
- Cancer-related fatigue (CRF) is a widespread adverse symptom related to cancer and cancer therapy. In a recent study, cancer patients reported that fatigue is the most distressing symptom associated with their cancer and cancer treatment (Richardson et al, 1995). CRF is a multicausal, multidimensional, and complex disturbance and hence is difficult to describe for patients, their families and even for health care providers (Portenoy et al, 1999). CRF can be best defined as an unusual and persistent sense of tiredness that can occur with cancer and cancer therapy (Atkinson et al, 2000). CRF may affect both physical and mental capacity and is unrelieved by rest. It is more severe, more energy draining, longer lasting and more unrelenting than other forms of fatigue (Glaus et al, 1996). CRF interferes with usual functioning and has a devastating effect on almost all aspects of patients' lives. It has a pervasive effect on motivation. Additionally, attending and completing a task becomes difficult. The most unusual characteristic of CRF is that it is unrelieved by rest or additional sleep (Holly, 2000). Most of the current pharmacological and non-pharmacological treatments offered by health care professionals are based on anecdotal evidence.
- As noted above, fencamfamine (Glucoenergan, Reactivan) is a stimulant which was developed by E Merck in the 1960s. Until recently there have been reports that fencamfamine was still rarely used for treating depressive day-time fatigue, lack of concentration and lethargy, particularly in individuals who have chronic medical conditions, although its favorable safety profile makes it the most suitable drug in some cases. Fencamfamine increases drive and mental alertness and an elevation of mood and a general feeling of well-being.
- Fencamfamine acts as an indirect dopamine agonist. The drug seems to inhibit the dopamine transporter (DAT) that removes dopamine from the synapses. This inhibition of DAT blocks the reuptake of dopamine and norepinephrine into the presynaptic neuron, increasing the amount of dopamine in the synapse. Also unlike amphetamines, fencamfamine does not appear to inhibit the action of monoamine oxidase enzymes and so is somewhat safer.
- Due to its efficacy and extensive use in treating fatigue-related conditions fencamfamine could provide a pharmacological approach to treat CRF. In some embodiments provided herein, prodrug compositions of fencamfamine can provide a treatment for CRF while avoiding and/or reducing the drug-abuse profile but still providing the abilty to dose via routine administration routes, e.g. oral.
- In some embodiments, prodrug versions of fencamfamine allow for greater amounts of fencamfamine to be present in the plasma of the subject. In some embodiments, it allows for greater amounts of fencamfamine to be present in the plasma of the subject from oral administration of the prodrug to the subject.
- In some embodiments, prodrug versions of fencamfamine allow for a particular isomer of fencamfamine to be provided to the subject.
- The present disclosure provides derivatives and/or combinations thereof of fencamfamine (or N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine) in prodrug form (including particular isomers thereof). In some embodiments, the fencamfamine is conjugated to at least one acyloxyalkoxycarbonyl moiety (group Y)
- In some embodiments, the prodrugs provided herein allow for a reduced risk of abuse or addiction by a user or patient. In some embodiments, this can be achieved by providing a release profile such that there is only an adequate amount of the active compound if the prodrug is taken orally. However, when the prodrug is taken by IV, it is not broken down into its active form in a substantial amount in the subject. With this release aspect, a subject's ability to receive, via IV, a large amount of the active form of the molecule is reduced (as taking a large amount of the prodrug via IV does not necessarily result in an increase of the active in the plasma levels, for various embodiments). Some exemplary embodiments of such prodrugs include PRX-P5-006 and PRX-P4-003 (which include a (-) isomer of fencamfamine).
- In some embodiments, the prodrug composition provided herein allows for an increase in a total amount of exposure of an active form of the drug in the subject's plasma. Thus, in some embodiments, the prodrug described herein as PRX-P6-011 (which includes the (+) isomer of fencamfamine) can be used to provide a higher level of the active form of the drug over a desired time period. Such embodiments need not have the above noted IV vs oral selective activation aspects.
- In some embodiments, the prodrug can have the (+) or (-) isomer of fencamfamine; however, as shown by the data provided herein, the type of Y group employed for the (+) or (-) isomers can vary and change the properties of the prodrug. Thus, various fencamfamine isomer prodrugs can have further unique characteristics and/or components, as outlined herein.
- Thus, in some embodiments, prodrugs are provided that delay the time in which the active drug (fencamfamine) is made available to the brain (or within the plasma). In some embodiments, prodrugs are provided that allow for higher levels of the active drug to be present in the plasma.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
- The use of the term "N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine" herein is meant to include any of the stereoisomer forms of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, including the four stereoisomers: (1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2R,3S,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2S,3R,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and (1S,2R,3S,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and the salts and derivatives thereof. The term "N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine" includes all salt forms. N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine is also known by its trade name Fencamfamine®, Glucoenergan®, and Reactivan® (E Merck, Germany). The N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine used in the present disclosure can be any stereoisomer of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, including, but not limited to, (1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2R,3S,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, (1R,2S,3R,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and (1S,2R,3S,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine. In some embodiments, the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine can be a mixture of two or more racemates. Depending on the chemical structure of the Y group, the resulting prodrug conjugates can be optically active mixtures of isomers, racemic mixtures, single isomers or combinations thereof. The various isomers of fencamfamine are depicted below.
- RX-002 consists of racemic fencamfamine. The (+)- and (-)-isomers designate the optical rotation of the resolved fencamfamine enantiomers. As used herein, the two Exo-phenyl,endo-amino isomers are PRX 002 (+) and (-). One of skill in the art can obtain the desired (+) or (-) enantiomers by chromatography on a chiral column (as outlined in the examples below). The (+)-enantiomer of fencamfamine is (1S,2S,3R,4R)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine. The (-)-enantiomer of fencamfamine is (1R,2R,3S,4S)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine. In some embodiments, the (1R,2R,3S,4S)-compound can be used as any of the prodrug compounds provided herein (including any of the methods). In some embodiments, the (1S,2S,3R,4R)-compound can be used as any of the prodrug compounds provided herein (including any of the methods). In some embodiments, the (1R,2R,3S,4S)-compound can be used as any of the prodrug compounds provided herein (including any of the methods). In some embodiments, the (1S,2S,3R,4R)-compound can be used as any of the prodrug compounds provided herein (including any of the methods). Thus, any one of the above isomers can be used as the active in any one of the prodrug arrangements provided herein. In some embodiments, it is one or more of the Exo isomers noted above. In some embodiments, it is one or more of the Endo isomers noted above.
- The term "pharmaceutically acceptable salt" refers to a salt of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, the salt is an acid addition salt of the compound. Pharmaceutical salts can be obtained by reacting a compound with inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or hydrobromic acid), sulfuric acid, nitric acid and phosphoric acid. Pharmaceutical salts can also be obtained by reacting a compound with an organic acid such as aliphatic or aromatic carboxylic or sulfonic acids, for example formic, acetic, succinic, lactic, malic, tartaric, citric, ascorbic, nicotinic, methanesulfonic, ethanesulfonic, p-toluensulfonic, salicylic or naphthalenesulfonic acid. Pharmaceutical salts can also be obtained by reacting a compound with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, C1-C7 alkylamine, cyclohexylamine, triethanolamine, ethylenediamine, and salts with amino acids such as arginine and lysine.
- It is understood that, in any compound described herein having one or more chiral centers, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S-configuration or a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture. In addition it is understood that, in any compound described herein having one or more double bond(s) generating geometrical isomers that can be defined as E or Z, each double bond may independently be E or Z a mixture thereof.
- Where the compounds disclosed herein have at least one chiral center, they may exist as individual enantiomers and diastereomers or as mixtures of such isomers, including racemates. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included in the scope of the compounds disclosed herein. Furthermore, compounds disclosed herein may exist in one or more crystalline or amorphous forms. Unless otherwise indicated, all such forms are included in the scope of the compounds disclosed herein including any polymorphic forms. In addition, some of the compounds disclosed herein may form solvates with water (i.e., hydrates) or common organic solvents. Unless otherwise indicated, such solvates are included in the scope of the compounds disclosed herein.
- It is understood that the compounds described herein can be labeled isotopically. Substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements. Each chemical element as represented in a compound structure may include any isotope of said element. For example, in a compound structure a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position of the compound that a hydrogen atom may be present, the hydrogen atom can be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium). Thus, reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
- As used herein, the term "prodrug" generally refers to a compound, which is pharmaceutically acceptable and upon administration is converted to a desired active compound, here fencamfamine. In some embodiments, the prodrug can be therapeutically inactive until cleaved to release the active compound. The prodrug will contain an "active" component, in this case fencamfamine, and a Y moiety as defined. Removal of some or all of the Y moiety will convert the prodrug from an inactive form to an active drug. This is done in the body by a chemical or biological reaction.
- In the present disclosure, the prodrug is a conjugate of at least one drug, N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, and an additional Y moiety that can be removed and/or altered within the body. Thus, the conjugates of the present disclosure are prodrugs and the prodrugs of the present disclosure are conjugates.
- While not a necessary term for describing various embodiments provided here (such as when explicit structures are shown for the Y moiety, etc.), the term "blocking moiety" denotes a chemical moiety, which may be removed from a larger prodrug, but when present, reduces and/or alters a property of the active component of the prodrug.
- While not a necessary term for describing various embodiments provided here (such as when explicit structures are shown for the Y moiety, etc.), the term "linker" denotes a chemical moiety, which may link the blocking moiety to the active in a prodrug.
- The Y moiety itself may be removable from the prodrug, or the Y moiety (or a part thereof) can remain associated with the active, after the removal of at least part of the prodrug.
- The term "active" is used herein to refer to fencamfamine, and/or N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (or a particular isomer or collection thereof) to distinguish it from the prodrug form. Thus, it does not necessarily denote any other metabolite or derivative from fencamfamine (such as whether or not the fencamfamine is altered further when administered to a subject). The term "active" also encompasses the prodrug compounds that have been activated by proper exposure in vivo and/or in vitro. Thus, the active form of a prodrug may include fencamfamine that is still bonded to some subpart of the prodrug form (for example, whatever remains after the body has removed an adequate section of the Y moiety). The "activated prodrug" denotes the form of the molecule after it has been processed by the body and is in an active form of fencamfamine. In some embodiments, any of the four isomers of fencamfamine noted above can be used in the prodrug, and thus, result in the isomer for the activated prodrug.
- In some embodiments, the prodrug can be easier to administer or process than the parent or active form of the drug. They may, for instance, be more bioavailable by oral administration whereas the active drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the active drug. In some embodiments, a prodrug is an N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine conjugate that is metabolized to reveal the active moiety. In some embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically more active form of the compound. In some embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound. In some embodiments, to produce a prodrug, a pharmaceutically active compound is modified such that the active compound will be regenerated upon in vivo administration. In some embodiments, the prodrug is designed to alter the metabolism or the transport characteristics of a drug in certain embodiments, to mask side-effects or toxicity, to improve bioavailability and/or water solubility, to improve the flavor of a drug, to reduce the risk of abuse, or to alter other characteristics or properties of a drug in other discrete embodiments.
- The term "cancer-related fatigue" encompasses any unusual and persistent sense of tiredness that can occur with cancer and cancer therapy.
- The term "supportive oncology" encompasses the treatment of a subject receiving or a subject that has received a cancer therapy.
- As used herein, phrases such as "decreased," "reduced," "diminished" or "lowered" is meant to include at least a 10% change in pharmacological activity with greater percentage changes being preferred for reduction in abuse potential and overdose potential. For instance, the change may also be greater than 25%, 35%, 45%, 55%, 65%, 75%, 85%, 95%, 96%, 97%, 98%, 99%, or increments therein.
- Unless otherwise specified, the term "naturally occurring" refers to occurring in nature, for example, in bacteria or in a mammal (e.g., a human).
- The term "abuse" encompasses uses that are inconsistent with a doctor's or manufacturer's instructions.
- As used herein, "in a manner inconsistent with the manufacturer's instructions" or similar expression is meant to include, but is not limited to, consuming amounts greater than amounts described on the drug label or ordered by a licensed physician, and/or altering by any means (e.g., crushing, breaking, melting, or separating) the dosage form such that the composition may be injected, inhaled or smoked instead of being taken orally (or according to the instructions).
- Depending on the blocking moiety and the alcohol, amine, acyl group from a carboxylic acid conjugated to N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine or derivative thereof, the at least one prodrug formed can be either a neutral (uncharged), a free acid, a free base or a pharmaceutically acceptable anionic or cationic salt form or salt mixtures with any ratio between positive and negative components. These anionic salt forms can include, but are not limited to, for example, acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, l-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, l-tartrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsufate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate (mucate), galacturonate, gallate, gentisate, glutamate, glutamate, glutarate, glycerophosphate, heptanoate (enanthate), hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, or undecylenate. The cationic salt forms can include, but are not limited to, for example, sodium, potassium, calcium, magnesium, zinc, aluminum, lithium, cholinate, lysinium, ammonium, or tromethamine.
- The term "pharmaceutically acceptable carriers" includes, but is not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer, or in another embodiment 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be in another embodiment aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. In some embodiments, the carrier can be a) 10% PEG 400 (v/v) + 30% (v/v) HPβCD, 50% w/v + 60% (v/v) Sterile Water for Injection or b) 0.1% (v/v)
Tween 80 + 0.5% (w/v) Carboxymethylcellulose in water. - The term "subject" refers to a mammal, such as humans, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, and cats, avian species, such as chickens, turkeys, and songbirds. The subject can be, for example, a child, such as an adolescent, or an adult.
- The term "treatment" refers to any treatment of a pathologic condition in a subject, such as a mammal, particularly a human, and includes: (i) preventing and/or reducing the risk of a pathologic condition from occurring in a subject which may be predisposed to the condition but has not yet been diagnosed with the condition and, accordingly, the treatment constitutes prophylactic treatment for the disease condition; (ii) inhibiting and/or reducing the speed of development of the pathologic condition, e.g., arresting its development; (iii) relieving the pathologic condition, e.g., causing regression of the pathologic condition; or (iv) relieving the conditions mediated by the pathologic condition and/or symptoms of the pathologic condition. Treatment to subjects who have previously and/or are currently, and/or are about to receive a cancer therapy are contemplated herein.
- The term "therapeutically effective amount" refers to that amount of a compound of the invention that is sufficient to effect treatment, when administered to a subject in need of such treatment. The therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- Without being limited to the following theory, some of the embodiments of the prodrugs/conjugates provided herein undergo enzyme hydrolysis of the ester bond in vivo, which subsequently leads to a cascade reaction resulting in provision of of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and the respective, metabolites thereof and/or derivatives and/or components thereof. The blocking moieties of the present disclosure are non-toxic or have very low toxicity at the given dose levels and are preferably known drugs, natural products, metabolites, or GRAS (Generally Recognized As Safe) compounds (e.g., preservatives, dyes, flavors, etc.) or non-toxic mimetics or derivatives thereof.
- It is understood that the methods and combinations described herein include crystalline forms (also known as polymorphs, which include the different crystal packing arrangements of the same elemental composition of a compound), amorphous phases, salts, solvates, and hydrates. In some embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, or the like. In other embodiments, the compounds described herein exist in unsolvated form. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, or the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.
- In some embodiments, a fencamfamine prodrug is provided. In some embodiments, the prodrug comprises fencamfamine, a Y group conjugated to the fencamfamine, such as the Y moiety comprises 1-Acyloxyethoxycarbonyl, (R3C(O)OCH(Me)OCO-). According to the invention, this fencamfamine prodrug comprises a linear saturated C18 fatty acid. In some embodiments, the fencamfamine is the 002(-) isomer.
- In some embodiments, the Y group comprises acyloxymethoxycarbonyl , (R3C(O)OCH2OCO-). According to the invention, this prodrug comprises a linear saturated C18 fatty acid and the fencamfamine is the PRX-002 (-) isomer or PRX-002 (+) isomer.
- In some embodiments, the fencamfamine component within the prodrug comprises any one or more of the isomers of fencamfamine as provided herein. In some embodiments, the fencamfamine comprises 1, 2, 3, or 4 of the isomers of fencamfamine. In some embodiments, the fencamfamine is only one of the isomers
-
- In some embodiments, a pharmaceutical composition comprising the compound of any embodiment provided herein regarding fencamfamine and a pharmaceutically acceptable carrier is provided.
- In some embodiments, one or more prodrug compositions of the present disclosure will surprisingly exhibit a slower rate of release over time as compared to unmodified fencamfamine.
- In some embodiments, one or more prodrug compositions of the present disclosure provides reduced side effects as compared to unconjugated fencamfamine when administered at equimolar doses, and also provide reduced abuse potential as compared to unconjugated fencamfamine. In some embodiments, after administration of the prodrug of fencamfamine via IV, the amount of fencamfamine present in the subject's plasma is at least 5% less than if fencamfamine had been administered to the subject orally, for example, at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9% or less, or 100%, including any range above any one of the preceding values and any range between any two of the preceding values.
- In some embodiments one or more fencamfamine prodrug compositions of the present disclosure provides an amount sufficient to provide an extended Tmax when compared to unconjugated fencamfamine when administered at equimolar doses, and/or provides an equivalent Tmax when compared to unconjugated fencamfamine when administered at equimolar doses.
- In some embodiments, one or more fencamfamine prodrug compositions of the present disclosure provides an increased level of the active drug (fencamfamine) in the plasma, when the prodrug compound is administered orally, in comparison to the amount of active present in the plasma when fencamfamine itself is administered (not as a prodrug). Thus, in some embodiments, the composition results in a higher level of active in the plasma, than would be present if the active itself had been administered. In some embodiments, the increase is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 400% or more at any given point in time.
-
- Compounds described herein can be prepared in various ways. General synthetic routes are shown and described herein. The routes shown and described herein are illustrative only and are not intended, nor are they to be construed, to limit the scope of the claims in any manner whatsoever. Those skilled in the art will be able to recognize modifications of the disclosed syntheses and to devise alternate routes based on the disclosures herein; all such modifications and alternate routes are within the scope of the claims. In some embodiments, the fatty acid bonded prodrug is prepared by the reaction of PRX-002 with chloromethyl chloroformate or 1-chloroethyl chloroformate, followed by the reaction with various carboxylic acids in the presence of cesium cartbonate and potassium iodide in DMF, as illustrated in the scheme 4.2.
- Depending upon the substituents present, the compounds can be in a form of a pharmaceutically acceptable salt. The terms "pharmaceutically acceptable salt" as used herein are broad terms, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to salts prepared from pharmaceutically acceptable, non-toxic acids or bases. Suitable pharmaceutically acceptable salts include metallic salts, e.g., salts of aluminum, zinc, alkali metal salts such as lithium, sodium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts; organic salts, e.g., salts of lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine, and tris; salts of free acids and bases; inorganic salts, e.g., sulfate, hydrochloride, and hydrobromide; and other salts which are currently in widespread pharmaceutical use and are listed in sources well known to those of skill in the art, such as, for example, The Merck Index. Any suitable constituent can be selected to make a salt of the therapeutic agents discussed herein, provided that it is non-toxic and does not substantially interfere with the desired activity.
- The compounds of preferred embodiments can include isomers, racemates, optical isomers, exo-isomers, endo-isomers, enantiomers, diastereomers, tautomers, and cis/trans conformers. All such isomeric forms are included within preferred embodiments, including mixtures thereof. As discussed above, the compounds of preferred embodiments may have chiral centers, for example, they may contain asymmetric carbon atoms and may thus exist in the form of enantiomers or diastereoisomers and mixtures thereof, e.g., racemates. Asymmetric carbon atom(s) can be present in the (R)- or (S)-configuration, or can be present as mixtures of the (R)- and (S)- forms. N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine can exist as the Exo-phenyl,endo-amino and endophenyl,exo-amino substituted diastereomers. Each diastereomer is a pair of enantiomers. For e.g. the Exo-phenyl,endo-amino diastereomer is a mixture of the following two enantiomers, namely, (1S,2S,3R,4R)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine and (1R,2R,3S,4S)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine. The following are enantiomeric forms of the Exo-phenyl,endo-amino isomer of the compounds of Formula (I):
- The compounds can be in amorphous form, or in crystalline forms. The crystalline forms of the compounds of preferred embodiments can exist as polymorphs, which are included in preferred embodiments. In addition, some of the compounds of preferred embodiments may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of the preferred embodiments.
- In some embodiments, one can administer the prodrugs in an oral unit dosage form; however, other routes of administration are also possible. For various embodiments, contemplated routes of administration include but are not limited to oral, parenteral, intravenous, and subcutaneous. The prodrugs can be formulated into liquid preparations for, e.g., oral administration. Suitable forms include suspensions, syrups, elixirs, and the like. Particularly preferred unit dosage forms for oral administration include tablets and capsules. Unit dosage forms configured for administration once a day can be employed; however, in some embodiments it can be desirable to configure the unit dosage form for administration twice a day, or more.
- For oral administration, the pharmaceutical compositions can be provided as a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup or elixir. Compositions intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and can include one or more of the following agents: sweeteners, flavoring agents, coloring agents and preservatives. Aqueous suspensions can contain the prodrug in admixture with excipients suitable for the manufacture of aqueous suspensions.
- Formulations for oral use can also be provided as hard gelatin capsules, wherein the prodrug(s) are mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules. In soft capsules, the prodrugs can be dissolved or suspended in suitable liquids, such as water or an oil medium, such as peanut oil, olive oil, fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers and microspheres formulated for oral administration can also be used. Capsules can include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredient in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- Tablets can be uncoated or coated by known methods to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period of time. For example, a time delay material such as glyceryl monostearate can be used. When administered in solid form, such as tablet form, the solid form typically comprises from about 0.001 wt. % or less to about 50 wt. % or more of active ingredient(s), preferably from about 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1 wt. % to about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 45 wt. %.
- Tablets can contain the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients including inert materials. For example, a tablet can be prepared by compression or molding, optionally, with one or more additional ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, antiadherents, coatings, disintegrants, fillers, flavors and colors, preservatives, sorbens, sweeteners, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered prodrug moistened with an inert liquid diluent.
- In some embodiments, each tablet or capsule contains from about 1 mg or less to about 1,000 mg or more of an prodrug of the preferred embodiments, more preferably from about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg to about 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, or 900 mg. Most preferably, tablets or capsules are provided in a range of dosages to permit divided dosages to be administered. A dosage appropriate to the patient and the number of doses to be administered daily can thus be conveniently selected. In certain embodiments it can be preferred to incorporate two or more of the therapeutic agents to be administered into a single tablet or other dosage form (e.g., in a combination therapy); however, in other embodiments it can be preferred to provide the therapeutic agents in separate dosage forms.
- Suitable inert materials include diluents, such as carbohydrates, mannitol, lactose, anhydrous lactose, cellulose, sucrose, modified dextrans, starch, and the like, or inorganic salts such as calcium triphosphate, calcium phosphate, sodium phosphate, calcium carbonate, sodium carbonate, magnesium carbonate, and sodium chloride. Disintegrants or granulating agents can be included in the formulation, for example, starches such as corn starch, alginic acid, sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, ultramylopectin, sodium alginate, gelatin, orange peel, acid carboxymethyl cellulose, natural sponge and bentonite, insoluble cationic exchange resins, powdered gums such as agar, karaya or tragacanth, or alginic acid or salts thereof.
- Binders can be used to form a hard tablet. Binders include materials from natural products such as acacia, tragacanth, starch and gelatin, methyl cellulose, ethyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, and the like.
- Lubricants, such as octadecanoic acid or magnesium or calcium salts thereof, polytetrafluoroethylene, liquid paraffin, vegetable oils and waxes, sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol, starch, talc, pyrogenic silica, hydrated silicoaluminate, and the like, can be included in tablet formulations.
- Surfactants can also be employed, for example, anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate and dioctyl sodium sulfonate, cationic such as benzalkonium chloride or benzethonium chloride, or nonionic detergents such as polyoxyethylene hydrogenated castor oil, glycerol monostearate, polysorbates, sucrose fatty acid ester, methyl cellulose, or carboxymethyl cellulose.
- Controlled release formulations can be employed wherein prodrug is incorporated into an inert matrix that permits release by either diffusion or leaching mechanisms. Slowly degenerating matrices can also be incorporated into the formulation. Other delivery systems can include timed release, delayed release, or sustained release delivery systems.
- Coatings can be used, for example, nonenteric materials such as methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, methylhydroxy-ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxy-methyl cellulose, providone and the polyethylene glycols, or enteric materials such as phthalic acid esters. Dyestuffs or pigments can be added for identification or to characterize different combinations of prodrug doses.
- In some embodiments, the pharmaceutical compositions of the prodrugs can be isotonic with the blood or other body fluid of the recipient. The isotonicity of the compositions can be attained using sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is particularly preferred. Buffering agents can be employed, such as acetic acid and salts, citric acid and salts, boric acid and salts, and phosphoric acid and salts. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like.
- Viscosity of the pharmaceutical compositions can be maintained at the selected level using a pharmaceutically acceptable thickening agent. In some embodiments, methylcellulose can be used. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The preferred concentration of the thickener will depend upon the thickening agent selected. An amount is preferably used that will achieve the selected viscosity. Viscous compositions are normally prepared from solutions by the addition of such thickening agents.
- In some embodiments, a pharmaceutically acceptable preservative can be employed to increase the shelf life of the pharmaceutical compositions. Benzyl alcohol can be suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, or benzalkonium chloride can also be employed. A suitable concentration of the preservative is typically from about 0.02% to about 2% based on the total weight of the composition, although larger or smaller amounts can be desirable depending upon the agent selected. Reducing agents, as described above, can be advantageously used to maintain good shelf life of the formulation.
- The prodrugs can be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, or the like, and can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors, and the like, depending upon the route of administration and the preparation desired. See, e.g., "Remington: The Science and Practice of Pharmacy", Lippincott Williams & Wilkins; 20th edition (June 1, 2003) and "Remington's Pharmaceutical Sciences," Mack Pub. Co.; 18th and 19th editions (December 1985, and June 1990, respectively). Such preparations can include complexing agents, metal ions, polymeric compounds such as polyacetic acid, polyglycolic acid, hydrogels, dextran, and the like, liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. The presence of such additional components can influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application, such that the characteristics of the carrier are tailored to the selected route of administration.
- When administered orally in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils can be added to the active ingredient(s). Physiological saline solution, dextrose, or other saccharide solution, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol are also suitable liquid carriers. The pharmaceutical compositions can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive or arachis oil, a mineral oil such as liquid paraffin, or a mixture thereof. Suitable emulsifying agents include naturally-occurring gums such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsions can also contain sweetening and flavoring agents.
- Pulmonary delivery can also be employed. The compound is delivered to the lungs while inhaling and traverses across the lung epithelial lining to the blood stream. A wide range of mechanical devices designed for pulmonary delivery of therapeutic products can be employed, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. These devices employ formulations suitable for the dispensing of compound. Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants, and/or carriers useful in therapy.
- The compound and/or other optional active ingredients can be prepared for pulmonary delivery in particulate form with an average particle size of from 0.1 µm or less to 10 µm or more, more preferably from about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 µm to about 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, or 9.5 µm. Pharmaceutically acceptable carriers for pulmonary delivery of prodrug include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and sorbitol. Other ingredients for use in formulations can include DPPC, DOPE, DSPC, and DOPC. Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran. Bile salts and other related enhancers, as well as cellulose and cellulose derivatives, and amino acids can also be used. Liposomes, microcapsules, microspheres, inclusion complexes, and other types of carriers can also be employed.
- Pharmaceutical formulations suitable for use with a nebulizer, either jet or ultrasonic, typically comprise the prodrug dissolved or suspended in water at a concentration of about 0.01 or less to 100 mg or more of prodrug per mL of solution, preferably from about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg to about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 mg per mL of solution. The formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the prodrug caused by atomization of the solution in forming the aerosol.
- Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the active ingredients suspended in a propellant with the aid of a surfactant. The propellant can include conventional propellants, such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, and hydrocarbons. Preferred propellants include trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, 1,1,1,2-tetrafluoroethane, and combinations thereof. Suitable surfactants include sorbitan trioleate, soya lecithin, and oleic acid.
- Formulations for dispensing from a powder inhaler device typically comprise a finely divided dry powder containing prodrug, optionally including a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in an amount that facilitates dispersal of the powder from the device, typically from about 1 wt. % or less to 99 wt. % or more of the formulation, preferably from about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt. % to about 55, 60, 65, 70, 75, 80, 85, or 90 wt. % of the formulation.
- When a compound is administered by intravenous, parenteral, or other injection, it is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution or oleaginous suspension. Suspensions can be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The preparation of acceptable aqueous solutions with suitable pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for injection preferably contains an isotonic vehicle such as 1,3-butanediol, water, isotonic sodium chloride solution, Ringer's solution, dextrose solution, dextrose and sodium chloride solution, lactated Ringer's solution, or other vehicles as are known in the art. In addition, sterile fixed oils can be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the formation of injectable preparations. The pharmaceutical compositions can also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
- The duration of the injection can be adjusted depending upon various factors, and can comprise a single injection administered over the course of a few seconds or less, to 0.5, 0.1, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 hours or more of continuous intravenous administration.
- In on aspect of the disclosure, the prodrugs can be provided to an administering physician, other health care professional, or subject in the form of a kit. The kit is a package which houses a container which contains the compound in a suitable pharmaceutical composition, and instructions for administering the pharmaceutical composition to a subject. The kit can optionally also contain one or more additional therapeutic agents, e.g., chemotherapeutics currently employed for treating a cancer as described herein. For example, a kit containing one or more compositions comprising one or more prodrug in combination with one or more additional chemotherapeutic agents can be provided, or separate pharmaceutical compositions containing a prodrug of the preferred embodiments and additional therapeutic agents can be provided. The kit can also contain separate doses of a prodrug for serial or sequential administration. The kit can optionally contain one or more diagnostic tools and instructions for use. The kit can contain suitable delivery devices along with instructions for administering the prodrug(s) and any other therapeutic agent. The kit can optionally contain instructions for storage, reconstitution (if applicable), and administration of any or all therapeutic agents included. The kits can include a plurality of containers reflecting the number of administrations to be given to a subject. The kit can also include different types of fencamfamine prodrugs, as described herein. In some embodiments, the instructions can be inline with one or more of the methods outlined herein.
Methods of Use and Treatment All references to methods of treatment by therapy or surgery or in vivo diagnosis methods in this description are to be interpreted as references to compounds, pharmaceutical compositions and medicaments of the present invention for use in those methods. - In some embodiments one or more prodrug compositions can be used for treating cancer-related fatigue by administering an effective amount of the composition to a subject in need thereof. In some embodiments, any of the prodrugs provided herein can be used. In some embodiments, the subject is human. In some embodiments, the subject has or had cancer. In some embodiments, the subject has gone through one or more rounds of a cancer therapy. In some embodiments, the subject has or has been diagnosed with cancer related fatigue.
- In some embodiments, such as cancer-related fatigue, chronic fatigue syndrome, major depressive disorder, narcolepsy, advanced Parkinson's Disease, attention deficit-hyperactivity disorder (ADHD), substance-abuse disorders or Binge-eating disorder, the subject to be treated is in need of one or more of the benefits or properties of fencamfamine. In some embodiments, such as Alzheimer's disease, such as apathy in Alzheimer's disease and cognitive impairment in Alzheimer's disease and dopamine responsive dystonia the subject to be treated is in need of one or more of the benefits or properties of fencamfamine.
- In some embodiments, the subject to be treated is at risk of abusing fencamfamine. In some embodiments, the risk is that the subject will or has taken fencamfamine via IV or injection. In some embodiments, some of the embodiments provided herein allow for a reduced risk that the subject will, or will repeat an IV administration of the prodrug.
- In some embodiments, via the use of one or more of the prodrug compositions provided herein, one can provide to a subject a sufficient level of fencamfamine via oral administration, but not via IV administration (at least the amount of actived compound in the subject's plasma will be lower if given via IV than if given orally).
- In some embodiments one or more prodrug compositions can be used for treating neurological disorders such as Parkinson's disease, Alzheimer's disease, and/or dopamine responsive dystonia by administering an effective amount of the composition to a subject in need thereof.
- In some embodiment, the present disclosure provides at least one prodrug composition having an extended or controlled release profile as measured by plasma concentrations of released fencamfamine when compared to unconjugated fencamfamine when administered orally at equimolar doses. In some embodiments, the plasma concentration of fencamfamine released from the prodrug increases more slowly and over a longer period of time after oral administration, resulting in a delay in peak plasma concentration of released fencamfamine and in a longer duration of action when compared to unconjugated fencamfamine. In some embodiments, this can be the PRX-P6-011 using the + isomer) and/or PRX-P5-006 (using the - isomer) and/or PRX-P4-003 (using the - isomer).
- In some embodiments, the subject is mammalian. In some embodiment, the subject is human.
- In some embodiments, one or more of the fencamfamine produgs provides for an increase in an amount of fencamfamine present in a subject, compared to the administration of fencamfamine to the subject. Thus, in some embodiments, a method is provided for providing to a subject greater levels of fencamfamine by administering a prodrug of fencamfamine as described herein. In some embodiments, this can be a prodrug with a valine-valine Y moiety. In some embodiments, this can be the PRX-P6-011 compound.
- In some embodiments, two or more of the fencamfamine prodrugs provided herein are combined into a compostition of two or more of the fencamfamine prodrugs provided herein are administered to a subject. The two or more fencamfamine prodrugs can be administered serially or in parallel (either at overlapping volumes or over the same period of time). In some embodiments, this combination can be a first prodrug that provides delayed release and/or effects, while a second produg and provide a greater level of availability of the active than would be present if fencamfamine were given directly. For example, this can be achieved by having PRX-P5-006 as the first prodrug, to provide a delayed onset and/or abuse-resistance, while having PRX-P6-011 as the second prodrug so as to provide a greater initial and/or sustained level of fencamfamine isomer compared to parent.
- In some embodiments, the prodrugs or conjugate compositions of the present disclosure can be administered orally and, upon administration, release N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof (which would include some part of the Y moiety from the prodrug) or combinations thereof, after being hydrolyzed in the body. Without being bound by any particular theory, in some embodiments, the acyloxyalkoxycarbonyl bonded fatty acids that are conjugated to the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, of the present disclosure are naturally occurring metabolites, pharmaceutically active compounds or mimetics thereof or derivatives thereof. The prodrugs or conjugates of the present disclosure can be recognized by physiological systems resulting in hydrolysis and release of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (or a derivative thereof), when taken orally, but not when taken via IV injection.
- Some embodiments of the prodrugs are believed to have no or limited pharmacological activity themselves and consequently may follow a metabolic pathway that differs from the parent drug (i.e., N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine). Without being bound by any theory, by choosing a suitable blocking moiety, such as an acyl group from a carboxylic acid, the release of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine into the systemic circulation can be controlled even when the prodrug is administered via routes other than oral administration.
- In some embodiments, the prodrugs of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, of the present disclosure surprisingly release N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, similar to free or unmodified N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine. That is, the activated prodrug is identical or similar in its properties to the original form of the drug (fencamfamine).
- In some embodiments, the at least one conjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, of the present disclosure are believed to be released in a controlled or sustained form.
- In some embodiments, the at least one prodrug or conjugate generates a Tmax value of released N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine that is longer than the Tmax value produced by "unconjugated" N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (i.e., the active) when administered at equimolar doses. In another embodiment, the at least one prodrug or conjugate generates a Tmax value of released N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine that is similar to the Tmax value produced by unconjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, when administered at equimolar doses.
- In some embodiments, the AUC is about 50% or smaller of the AUC of unconjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, when administered intranasally or intravenously at equimolar doses, for example about 50% to about 0.1%, alternatively from about 25% to about 0.1%, alternatively from about 50% to about 1%, including, but not limited to, about 50%, about 40%, about 30%, about 20%, about 10%, about 1% or any amounts in between, in increments of about 0.5%, about 1%, about 2%, about 2.5%, about 5% or about 10%.
- In some embodiments, the compounds, prodrugs, compositions and/or methods of the present disclosure provide reduced potential for overdose, reduced potential for abuse and/or improve the characteristics of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof with regard to toxicities or suboptimal release profiles.
- In some embodiments, some compositions may have no or a substantially decreased pharmacological activity when administered through intravenous injection or intranasal routes of administration. However, they remain orally bioavailable. Without being limited to the below theory, overdose protection may occur due to the conjugates being exposed to different enzymes and/or metabolic pathways after oral administration whereby the conjugate of the present disclosure is exposed to the gut and first-pass metabolism as opposed to exposure to enzymes in the circulation or mucosal membranes in the nose which limits the ability of the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, from being released from the conjugate. Therefore, in some embodiments, abuse resistance is provided by limiting the effectiveness of alternative routes of administration. Again, not being bound by any particular theory, the bioavailability can be a result of the hydrolysis of the chemical linkage (such as a covalent linkage) following oral administration. In at least one alternative embodiment, the prodrugs of the present disclosure are envisioned to not hydrolyze or to hydrolyze at a reduced rate or to a limited extent via non-oral routes. As a result, they are believed to not generate high plasma or blood concentrations of released N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine when injected or snorted compared to free N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine administered through these routes.
- In some embodiments, at least some compositions of the present disclosure comprising the prodrugs of one or more N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, are resistant to abuse by parenteral routes of administration, such as intravenous "shooting," or intranasal "snorting," that are often employed during illicit use. In at least some contemplated alternative embodiments, release of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, is reduced when the composition of the present disclosure is delivered by parenteral routes. In some embodiments, the conjugates, since they are believed to include covalently bound N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, are not able to be physically manipulated to release the N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, from the conjugated N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, derivatives thereof or combinations thereof, by methods, for example, of grinding up or crushing of solid forms. In some embodiments, some compositions containing prodrugs or conjugates of the present disclosure preferably have no or a substantially decreased pharmacological activity when administered through injection or intranasal routes of administration. However, they remain orally bioavailable.
- In some embodiments, the present disclosure provides a stimulant based treatment modality and dosage form for certain disorders requiring the stimulation of the CNS such as, cancer-related fatigue, chronic fatigue syndrome, major depressive disorder, narcolepsy, advanced Parkinson's Disease, ADHD, substance-abuse disorders, binge-eating disorder Alzheimer's disease (such as apathy in Alzheimer's disease), or Dopamine Responsive Dystonia.
- In some embodiments, the at least one composition or prodrug of the present disclosure can be used in one or more methods of treating a patient having at least one disease, disorder or condition requiring stimulation of the central nervous system of one or more patients, comprising orally administering a pharmaceutically effective amount of the at least one composition or prodrug.
- Certain compounds, compositions and methods provided herein can be used to treat a number of disorders such as those requiring the stimulation of the CNS such as, cancer-related fatigue i.e. fatigue caused due to chemotherapy induced anemia, fatigue caused due to radiation therapy, depression, chronic fatigue syndrome, or major depressive disorder narcolepsy. In some embodiments, certain compounds, compositions and methods provided herein can be used to treat Alzheimer's disease, such as apathy in Alzheimer's disease and cognitive impairment in Alzheimer's disease. In some embodiments, certain compounds, compositions and methods provided herein can be used to treat dopamine responsive dystonia.
- In some embodiments, the prodrug provided herein is mostly (at least 50%, for example, at least 60, at least 70, at least 80, at least 90, at least 91, at least 92, at least 93, at least 94, at least 95, at least 96, at least 97, at least 98, at least 99, at least 100% metabolized by an oral route, over an IV route. In some embodiments, the prodrug component (the non-active) or any hydrolyzed products, are not toxic. In some embodiments, there is a good AUC (at least about 50% compared to the active). In some embodiments, the product allows for once a day dosing (or is configured in an amount for such dosing). In some embodiments, the product has an abuse resistant profile (delayed Tmax and/or low Cmax). In some embodiments, the prodrug, has a relatively low IV conversion rate (compared to oral). In some embodiments, the prodrug moiety is safe for human consumption.
- For convenience, Table 1 displays a listing of the various chemical names with the names used herein of the actives and prodrugs, as well as the structures. The structures in Table 1 do not necessarily depict the absolute configurations of (+)- and (-)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
- In some embodiments, any one or more of the prodrugs provided in Table 1 can be part of any composition and/or formulation and/or method provided herein.
- With the exception of PRX-P4-003 and PRX-P4-006 all compounds are reference compound falling outside the scope of the claimed invention.
TABLE 1: COMPOUNDS Compound Identification Fencamfamne Isomer Chemical Name Structure PRX-001 (±) N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (Racemic mixture) PRX-002 (+) N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine ((+)- isomer) PRX-002 (-) N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine ((-)- isomer) PRX-P1-001 (±) N-Succinyl-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P1-005 (-) N-Lysyl-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P1-006 (±) N-Valyl-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P1-011 (-) N-Acetyl-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P1-012 (-) N-Glycyl-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P1-013 (-) N-Phenylalanyl-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P2-001 (±) N-Ethoxycarbonyl-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P3-002 (-) N-(5-lsopropyl-2-methylphenoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P3-004 (-) N-(2-lsopropyl-5-methylphenoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P4-001 (-) N-(Acetoxymethoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P4-002 (-) N-(Decanoyloxymethoxycarbon yl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P4-003 (-) N-(Octadecanoyloxymethoxyca rbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P4-004 (-) N-((Z)-Octadec-9-enoyloxymethoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-001 (-) N-(1-Acetoxyethoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-002 (-) N-(1-Decanoyloxyethoxycarbonyl) -(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-003 (-) N-(1-Butanoyloxyethoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-004 (-) N-(1-Octanoyloxyethoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-005 (-) N-(1-Dodecanoyloxyethoxycarbon yl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-006 (-) N-(1-Octadecanoyloxyethoxycarb onyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-007 (-) N-(1-(2,2-Dimethylpropionyloxy)ethoxy carbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-008 (-) N-(1-(Z)-Octadec-9-enoyloxy)ethoxycarbonyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-009 (-) N-(1-Tetradecanoyloxyethoxycarb onyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-010 (-) N-(1-Hexadecanoyloxyethoxycarb onyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P5-011 (+) N-(1-Octadecanoyloxyethoxycarb onyl)-(+)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-001 (-) N-(Glycyl-glycyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-002 (-) N-(Valyl-D-valyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-003 (-) N-(Glycyl-Alanyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-004 (-) N-(Valyl-valyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-005 (-) N-(Phenylalanyl-phenylalanyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-006 (-) N-(Alanyl-glycyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-007 (-) N-(N6-Lysyl-lysyl)-(-)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine PRX-P6-011 (+) N-(Valyl-valyl)-(+)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine - Fencamfamine ((Exo-phenyl,endo-amino)-N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, PRX-001) was synthesized according to the
scheme 1 and modifications of the methods described in Pharmaceutical Chemistry Journal 2011, 45(7), 419-422, Journal of Organic Chemistry 1961, 26, 5247-5249,GB 913866 - The synthesis of the intermediate was performed as described in Organic Syntheses, Coll. Vol. 4, p.238 (1963 ); Vol. 32, p.41 (1952).
- Dicyclopentadiene (500 g) was added to a 1L two-necked round-bottomed flask equipped with thermometer and an upright Friedrich's-type condenser (through which water at 50 °C was circulated). The ground-glass outlet of the Friedrich's condenser was connected to the side arm of a simple distilling head fitted with a thermometer and attached to an efficient water-cooled condenser held in a vertical position. At the lower end of this condenser, a receiver was attached which consisted of a weighed 500-ml, two-necked round-bottomed flask immersed in a Dry Ice bath and protected from the air by a calcium chloride drying tube.
- The flask containing dicyclopentadiene was heated by means of oil bath until cyclopentadiene distilled (approximately 160 - 170 °C) into the receiver which was placed in dry ice cooling bath. After two-third of the dicyclopentadiene had been pyrolyzed during the course of 4-5 hours, the residue in the flask may tend to become viscous and a higher temperature for pyrolysis will be required in order to obtain rapid distillation of cyclopentadiene in such case it was desirable to discard the residue while it was still hot and mobile. The distilled cyclopentadiene (I-1) (200 g, 40 %) was obtained as a colorless liquid and which was taken for next step immediately to avoid dimerization.
- To a stirred solution of β-Nitro styrene (500 g, 3.352 mol) in dichloroethane (1L) was added freshly distilled cyclopentadiene (I-1) (800 mL) and pale yellow colored reaction mixture was stirred for 12 h under argon atmosphere at 70°C. After the completion of reaction (TLC eluent: 5 % EtOAc in petroleum ether), the reaction mixture was concentrated under reduced pressure. The residue thus obtained was purified by column chromatography over 60-120 silica gel (4.5 Kg) using 1 % EtOAc in petroleum ether to afford the mixture of intermediates I-2a and I-2b as a thick pale yellow colored liquid (680 g, 94 %).
1H-NMR (CDCl3, 400 MHz) δ 7.39 - 7.19 (m ,5H), 6.63 - 6.61 (dd, J = 3.2 Hz & 5.6 Hz, 1H), 6.15 - 6.13 (m, 1H), 5.03 - 5.01 ( t, J = 4 Hz, 1H), 3.63 - 3.62 (m, 1H), 3.50 - 3.46 (d, J = 4 Hz, 1H), 3.20 - 3.19 (d, J = 1.6 Hz, 1H), 1.92 -1.89 (m, 1H ), 1.78 - 1.74 (m, 1H). - In an autoclave hydrogenation apparatus, to the solution of the mixture of I-2a and I-2b (600g, 2.787 mol) in methanol (6 L) was added 10 % Pd/C (120 g) and the reaction mixture was stirred for 32 hours under H2 pressure of 5 Kg/m2. The reaction was monitored by TLC (TLC eluent: 5 % MeOH in CH2Cl2). After the completion of reaction, the reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to give an 80:20 mixture of the (Exo-phenyl,endo-amino) and (Endophenyl,exo-amino) isomers with Rf values of 0.35 and 0.2, respectively (CH2Cl2-MeOH, 90:10, eluted twice) . The crude residue obtained was purified by chromatography on silica gel (15 X 60 cm, 230 - 400 mesh) using 1.5% methanolic ammonia in dichloromethane as eluent and rechromatographed on the same column to give intermediate I-3a as a thick pale yellow colored liquid (280 g, 54% yield).
- 1H-NMR (DMSO, 400 MHz) δ 7.26-7.23 (m, 4H), 7.16 -7.12 (m, 1H), 3.05-3.02 (m, 1H), 2.22 - 2.21 (d, J = 3.6 Hz, 1H), 2.06 - 2.05 (m, 1H), 1.98 -1.96 (dd, J = 2 Hz & 5.6 Hz, 1H), 1.89 -1.83 (m, 1H), 1.65 -1.51 (m, 4H), 1.37 -1.26 (m, 3H).
- [M+ H]+ = 188.1; HPLC Purity: 94.6%.
- To a solution of I-3a (50g, 0.266 mol) in CH2Cl2 (350 mL) was added triethylamine (75 mL, 0.533 mol) at ambient temperature. After 10 min stirring, acetyl chloride (23 mL, 0.320 mol) was added dropwise at 0°C and stirring was continued further for a period of 1 h. After the completion of reaction, reaction mixture was quenched with water (500 mL) and the product was extracted with DCM (2 × 200 mL). The organic layer was treated with 1.5N HCl (2 × 100 mL), sat.NaHCO3 (2 × 100 mL), brine (2 × 100 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford yellow crude semi solid intermediate 6. Further it was triturated with diethyl ether (10 × 500 mL) to obtain l-4 as a pure off white solid (47g, 82% yield), mp 159 - 161°C..
- 1H NMR (CDCl3, 400 MHz) δ 7.31-7.24 (m, 4H), 7.21-7.18 (m, 1H), 5.68 (s, 1H), 4.35-4.32 (m, 1H), 2.61 (s, 1H), 2.40-2.39 (d, J = 3.2 Hz, 1H), 2.22-2.21 (d, J = 4.8 Hz, 1H), 2.0 (s, 3H), 1.87 -1.64 (m, 2H), 1.57 -1.51 (m, 2H), 1.45 -1.35 (m, 2H).
- [M+ H]+ = 230.3, HPLC purity: 98.5%
- To a stirred suspension of lithium aluminum hydride (30g, 0.348 mol) in dry THF (200 mL) was added dropwise a solution of I-4 (40g, 0.174mol) dry THF (200 mL) at 0 °C. After addition, the reaction mixture was refluxed at 70 °C for 16 h under argon atmosphere. After the completion of the reaction (TLC eluent: 70 % EtOAc in petroleum ether), the reaction mixture was added dropwise to an ice cold solution of 4N NaOH (2 L) solution with stirring. After complete quenching, it was filtered through Celite. The filtrate was extracted with EtOAc (3 × 400 mL) and washed with brine (2 × 200 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain crude PRX-001, (33g) as a pale yellow liquid.
- To a solution of crude PRX-001 (33 g) in diethyl ether (66 mL) was added ethereal HCl (130 mL) at 0 °C. After 1 h, the off-white precipitate, was collected, washed with excess of diethyl ether and dried under vacuum. The obtained solid was dissolved in EtOAc (200 mL), basified with 2N NaOH solution. The separated organic layer was treated with brine (2 x 100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain PRX-001 as a pure pale yellow liquid (30 g, 81% yield).
- 1H-NMR (CDCl3, 400 MHz) δ 7.30-7.28 (m, 4H), 7.21-7.17 (m, 1H), 3.17-3.14 (m, 1H), 2.59-2.49 (q, 2H), 2.42 (s, 1H), 2.26-2.25 (d, J = 4 Hz, 1H), 2.16-2.15 (m, 1H), 1.79-1.74 (m, 2H), 1.68 - 1.59 (m, 3H), 1.47 - 1.38 (m, 2H), 1.09 (t, 3H).
- [M+ H]+ = 216.0; HPLC purity: 94.3%
- Racemic PRX-001 (90 g in 200 mg batches) was resolved by chiral preparative HPLC on a Chiralpak AD column (250 X 50 mm) eluted with 0.1% diethylamine in isopropanol (43 mL / min) to afford the two enantiomers, (+)-PRX-002 (37 g), and (-)-PRX-002 (39 g).
- PRX-002 (+ isomer): 1H-NMR (CDCl3, 400 MHz) δ 7.30-7.27 (m, 4H), 7.21-7.17 (m, 1H), 3.17 -3.15 (m, 1H), 2.59 (q, 2 H), 2.42 (s, 1H), 2.27 - 2.26 (d, J = 4 Hz, 1H), 2.16-2.15 (dd, J = 2 Hz & 5.6 Hz, 1H), 1.77 - 1.74 (m, 2H), 1.65 - 1.61 (m, 1H), 1.48 - 1.41 (m, 3H), 1.36 -1.32 (m, 1H), 1.06 (t, 3H).
- [M+ H]+ = 216.3;
- HPLC Retention Time (min) = 4.42, purity 97.7%
- Chiral HPLC Retention Time (min) 12.63, purity 99.6%
- [α]20 D : +52.76° (sample concentration: 0.16% in MeOH)
- PRX-002 (- isomer): 1H-NMR (CDCl3, 400 MHz) δ 7.30-7.27 (m, 4H), 7.21-7.17 (m, 1H), 3.17-3.15 (m, 1H), 2.59 (q, 2 H), 2.42 (s, 1H), 2.27 - 2.26 (d, J = 4 Hz, 1H), 2.16 - 2.15 (dd, J = 2 Hz & 5.6 Hz, 1H), 1.77 - 1.74 (m, 2H), 1.65 - 1.61 (m, 1H), 1.48 - 1.41 (m, 3H), 1.36 -1.32 (m, 1H), 1.06 (t, 3H).
- [M+ H]+ = 216.3
- HPLC Ret. Time (min) 4.426, purity 95.5%
- Chiral HPLC Ret. Time (min) 14.437, purity 97.3%
- [α]20D : - 49.70 ° (sample concentration: 0.17% in MeOH)
- The HCl salt of (+)-PRX-002 (120 mg) was dissolved in warm methanol (0.1 mL) and water (0.2 mL), then allowed to cool to room temperature. A resulting rectangular crystal was analyzed by X-ray crystallography which indicated the absolute configuration indicated in
Scheme 1 for (+)-fencamfamine. The structures presented herein are from the same compounds as initially tested in the examples, updated after X-ray crystallography was performed. -
- To a stirred solution of mono methyl succinate (0.92 g, 6.96 mmol) in DMF (10 mL, 10 volumes) was added EDC.HCl (1.33 g, 6.96 mmol), HOBT (0.94 g, 6.96 mmol) and triethylamine (1.29 mL, 9.28 mmol) at ambient temperature. After 10 min, N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (PRX-001) (1 g, 4.64 mmol) dissolved in DMF (2 mL, 2 volumes) was added dropwise and reaction mixture was further stirred for 12 h at ambient temperature. After the completion of reaction (TLC eluent: 70 % EtOAc in petroleum ether), the reaction mixture was quenched with water (200 mL) and product was extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with brine solution (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue thus obtained was purified by flash column chromatography with silica gel 60-120 mesh (12% EtOAc in petroleum ether) to obtain l-5 (1.14 g, 75%).
- To a stirred solution of l-5 (0.85 g, 2.60 mmol) in a mixture of THF and MeOH (1:1, 20 mL) was added LiOH (0.32 g, 7.80 mmol) in water at 0 °C and reaction mixture was stirred for 1 hour. After the completion of reaction (70% EtOAc in petroleum ether), the reaction mixture was treated with 10 % aqueous ammonium chloride solution (100 mL), extracted with EtOAc (2 X 50 mL). The combined organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue thus obtained was purified by flash column chromatography over silica gel 60-120 mesh using 2% of MeOH in dichloromethane to obtain (PRX-P1-001) as a sticky off white solid (0.57 g, 70%).
- 1H-NMR (CDCl3, 400 MHz) δ 7.31-7.19 (m, 5H), 4.74 (s, 1H), 4.15 (s, 1H), 3.99-3.96 (m, 1H), 3.63 - 3.55 (m, 1H), 3.39 - 3.37 (m, 1H), 3.18 - 3.13 (m, 1H), 2.90 - 2.42 (m, 4H), 1.84 - 1.67 (m, 4H), 1.54 - 1.50 (m, 2H), 1.37 (t, J = 6.7 Hz, 3H).
- [M-H]- = 314.0
-
- Step 1: To a solution of N-Boc protected amino acids (1.2 eq) in DMF (5 volumes) was added HATU (1.5 eq), Et3N (2 eq) and stirred the reaction mixture for 20 min. Then, PRX-002 (+) isomer or (-) isomer (1 eq) in DMF (5 volumes) was added dropwise and the reaction was continued for 12 hour at ambient temperature. After the completion of reaction (TLC eluent: 40% EtOAc in petroleum ether), the reaction product was treated with ice cold water (20 volumes) and product was extracted with ethyl acetate (2 x10 volumes). The combined organic layer was washed with 3% citric acid solution (2 x10 volumes), saturated NaHCO3 solution (2 x10 volumes) and brine solution (1 volume). The obtained organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure. The crude product thus obtained was purified by using flash column chromatography to obtain intermediate I-6.
- Step 2: To a solution of I-6 (1 eq) in DCM (5 volumes) was added TFA (1 volume) dropwise at 0-5 °C and after complete addition, reaction mixture was stirred for 30 min at ambient temperature. After the completion of reaction (TLC eluent: 80% EtOAc in n-hexane), the solvent was concentrated under reduced pressure. The residue thus obtained was washed with n-hexane (2 x 20 volumes) for removal of impurities. Then it was dissolved in ethyl acetate (2 x 20 volumes), neutralized with saturated NaHCO3 solution (20 volumes) and washed with brine solution (20 volumes). After separation, the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford amino acid bonded prodrugs, including compounds PRX-P1-005, PRX-P1-006, PRX-P1-012, and PRX-P1-013.
-
- Using the general procedure described in Example 4 above employing PRX-001 (±) isomers, (500 mg, 2.32 mmol) and (S)-2-(Boc-amino)-3-methylbutyric acid (504 mg, 2.32 mmol), provided the product (PRX-P1-006) (460 mg, 64% yield) as a brownish liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 -7.18 (m, 5H), 4.80- 4.78 (m, 1H), 4.51(s, 1H), 4.14 (s, 1H), 3.61- 3.31 (m, 1H), 3.09 - 3.08 (m, 1H), 2.97 - 2.91 (m, 1H), 2.50 - 2.41 (m, 2H), 3.00 - 2.90 (m, 2H), 2.71 - 2.66 (m, 1H), 2.44 - 2.28 (m, 2H), 1.66 - 1.61 (m, 2H), 1.42 -1.36 (m, 1H), 1.26 - 1.19 (m, 6H), 1.01 (t, J =. 5.6 Hz, 3H)
- [M+H]+ = 315.4
-
- Using the general procedure described in Example 4 above employing PRX-002 (-) isomer, (200 mg,0.92 mmol) and (S)-2,6-bis-tert-butoxycarbonylamino-hexanoic acid (386 mg,1.11 mmol), provided the product (PRX-P1-005) (160 mg, 160 mg % yield) as a pale yellow liquid.
- 1H-NMR (DMSO, 400 MHz) δ 8.34 (s, 2H), 7.33 - 7.18 (m, 5H), 4.60 (s, 1H), 4.38 (s, 1H), 4.06 (s, 1H), 3.82 - 3.78 (m, 1H), 3.64 - 3.35 (m, 4H), 3.33 - 3.29 (m, 2H), 3.00 - 2.90 (m, 2H), 2.71 - 2.66 (m, 1H), 2.44 - 2.28 (m, 2H), 1.66 -1.61 (m, 2H), 1.50 - 1.45 (m, 2H), 1.42 -1.36 (m, 2H), 1.26 - 1.19 (m, 2H), 1.01 (t, J = 5.6 Hz, 3H)
- [M+H]+ = 344.5
-
- Using the general procedure described in Example 4 above employing PRX-002 (-) isomer, (500 mg, 2.32 mmol) and N-(tert-butoxycarbonyl)glycine (487 mg, 2.78 mmol), provided the product (PRX-P1-012) (420 mg, 68% yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.38 -7.25 (m, 4H), 7.23 -7.11 (m, 1H), 4.58 -4.57 (m, 1H), 4.42 - 4.40 (m, 1H), 3.32 - 3.21 (m, 1H), 2.93 - 2.92 (m, 1H), 2.32 - 2.31(m, 1H), 1.66 - 1.57 (m, 5H), 1.48 - 1.40 (m, 2H), 1.23 - 1.18 (m, 2H), 1.00 (t, J = 5.6 Hz, 3H)
- [M+H]+ = 273.3
-
- Using the general procedure described in Example 4 above employing PRX-002 (-) isomer, (0.7g, 3.25 mmol) and N-(tert-butoxycarbonyl)-L-phenylalanine (1 g, 3.90 mmol), provided the product (PRX-P1-013), (0.73 g, 62% yield as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.26 - 6.99 (m, 10 H), 4.80 - 4.78 (m, 1H), 4.67 -4.56 (m, 1H), 4.05 -4.00 (m, 1H), 3.61 - 3.11 (m, 2H), 3.09 - 2.80 (m, 5H), 2.50 - 2.41 (m, 2H), 1.66 -1.61 (m, 1H), 1.42 - 1.36 (m, 1H), 1.26 - 1.19 (m, 1H), 1.01 (t, J =. 5.6 Hz, 3H)
- [M+H]+ = 363.1
-
- To a solution of PRX-001 (200 mg, 0.93 mmol) in DCM (2 mL, 10 volumes) was added Et3N (0.25 mL, 1.86 mmol) and reaction mixture was cooled to 0 °c. After 5 minutes stirring, ethyl chloroformate (0.1 mL, 1.11 mmol) was added dropwise and then the reaction mixture was stirred at ambient temperature for 16 hours. After the completion of reaction (TLC eluent: 60 % EtOAc in petroleum ether), the reaction mixture was concentrated to dryness and then dissolved in ethyl acetate (50 mL), washed with water (2 x 20 mL) and brine solution (20 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure. The crude product obtained was purified by flash column chromatography with silica (60-120) mesh using 10-12% EtOAc in hexane as eluent to obtain the product (PRX-P2-001) as pale yellow liquid (106 mg, 40%).
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 -7.27 (m, 4H), 7.22 -7.17 (m, 1H), 4.39 - 4.37 (m, 1H), 4.19 - 4.09 (m, 2H), 3.69 - 3.56 (m, 1H), 3.25 - 3.17 (m, 1H), 2.86 - 2.85 (d, J = 6 Hz ,1H), 2.60 (s, 1H), 2.44 - 2.43 (d, J = 3.2 Hz, 1H), 1.77 - 1.63 (m, 2H), 1.54 - 1.43 (m, 3H) 1.29 - 1.23 (m, 4H), 1.10 (t, J = 7.2 Hz, 3H)
- [M+ H]+ = 288.4
-
- Step 1: To a stirred solution of triphosgene (0.5 eq) in THF (5 volumes) at 0 °C, was added dropwise a solution of phenol derivative (1 eq) and DIPEA (1 eq) in THF (5 volumes) and the reaction mixture was kept at ambient temperature for 12 hours. After the completion of reaction (TLC eluent: 10 % EtOAc in hexane), the reaction mixture was treated with water (20 volumes) and product was extracted with EtOAc (2
X 20 volumes). The combined organic layer were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain crude intermediate I-7, which was carried forwarded for the next step. - Step 2: To a stirred solution of (-)-PRX-002 (1 eq) in dry THF (5 volumes), were added DMAP (0.1 eq) and Et3N (2 eq). The mixture was stirred for 10 min at ambient temperature. Then a solution of I-7 (2 eq) in THF (5 volumes) was added dropwise and the reaction mixture was stirred for 12 hours at ambient temperature and monitored TLC (eluent: 5% EtOAc in hexane). Then, the reaction mixture was treated with water (20 volumes), and extracted with EtOAc (2 x 30 volumes). The organic layer was washed with brine (20 volumes), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue thus obtained was purified by preparative HPLC method to afford aryl carbamate linked prodrug, including Compounds PRX-P3-002 and PRX-P3-004. For the present example, R denotes the atoms for the noted compounds PRX-P3-002 and PRX-P3-004.
-
- Using the general procedure described in Example 10 above employing PRX-002 (-) isomer, (250 mg, 1.17 mmol) and carvacrol (400 mg,2.66 mmol), provided the product (PRX-P3-002) (337 mg, 75% yield) as a colorless liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.34 -7.30 (m, 4H), 7.24-7.21 (m, 1H), 7.13 -7.11 (d,, J = 8 Hz, 1H), 6.99 - 6.96 (m, 1H), 6.91 (s, 1H), 4.49 (s, 1H), 3.76 - 3.71 (m, 1H), 3.40- 3.35 (m, 1H), 2.99 (s, 1H), 2.90 - 2.84 (m, 1H), 2.74 (s, 1H), 2.48 (s, 1H), 2.14 (s, 3H), 1.81 - 1.70 (m, 3H), 1.60 -1.52 (m, 2H), 1.31-1.19 (m, 10H).
- [M+ H]+ = 392.2
-
- Using the general procedure described in Example 10 above employing PRX-002 (-) isomer, (250 mg, 1.17 mmol) and thymol (400 mg, 2.66 mmol), provided the product (PRX-P3-004) (351 mg, 78% yield) as a transparent liquid.
- 1H NMR (CDCl3, 400 MHz) δ 7.34 -7.33 (m, 4H), 7.23 -7.22 (m, 1H), 7.17 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.87 (s, 1H), 4.49 (s, 1H), 3.75 - 3.70 (m, 1H), 3.38 (s, 2H), 3.00 (s, 2H), 2.71 (s, 1H), 2.49 (s, 1H), 2.31 (s, 3H), 1.81 - 1.70 (m, 3H), 1.56 - 1.55 (m, 1H), 1.31 - 1.17 (m, 10H).
- [M+ H]+ = 392.2
-
- Step 1: To a solution of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (PRX-002) (1 eq) in dichloromethane (10 volumes) under argon atmosphere, was added triethylamine (2 eq) dropwise at ambient temperature and the mixture was stirred for 5 min. Then, chloromethyl chloroformate (1.5 eq) was introduced dropwise at 0 - 5 °C and the reaction mixture was further stirred at ambient temperature for 30 min. After the completion of reaction (TLC eluent: 20% EtOAc in petroleum ether), the reaction mixture was quenched in water (20 volumes), extracted with dichloromethane (2 x 20 volumes). The combined organic layer was washed with water (2 x 20 volumes), brine (20 x1 volumes) solution, filtered, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain N-(Chloromethoxycarbonyl)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (I-8) as a thick brown liquid, which was used in the next step without further purification.
- Step 2: To a solution of N-(Chloromethoxycarbonyl)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (also known as ethyl-(3-phenyl-bicyclo[2.2.1]hept-2-yl)-carbamic acid chloromethyl ester) (I-8) (1 eq) in DMF (10 volumes) was added dry Cs2CO3 (2 eq), acid (R-COOH) (2 eq), and KI (0.2 eq) at ambient temperature. The reaction mixture was heated to 100-105 °C and stirred for 4 h. After completion of reaction (TLC eluent: 10 % EtOAc in n-hexane), the reaction mixture was quenched in water (20 volumes), extracted with ethyl acetate (2 x 20 volumes). Combined organic layer was washed with water (2 x 10 volumes), brine solution (10 volumes), filtered, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude residue obtained was purified by flash column chromatography or preparative HPLC to yield acyloxymethoxycarbonyl pro-drugs of PRX-002, including PRX-P4-002, PRX-P4-005, and PRX-P4-004. For the present example, R denotes the atoms for the noted compounds PRX-P4-002, PRX-P4-005, and PRX-P4-004.
-
- Using the general procedure described in Example 14 above employing PRX-002 (-) isomer, (200 mg, 0.92 mmol) and sodium acetate (160 mg, 1.9493 mmol), provided the product (PRX-P4-001) (132 mg, 44 % yield) as a colorless liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.31 - 7.27 (m, 4H), 7.22 - 7.21 (m, 1H), 5.80 (dd, J = 5.6 & 11.6 Hz, 1H), 4.39 -4.37 (m, 1H), 3.59 (brs, 1H), 3.27 - 3.18 (m, 1H), 2.89 (d, J = 5.2 Hz, 1H), 2.61 (s, 1H), 2.43 (d, J = 3.2 Hz, 1H), 2.12 (s, 3H), 1.75 -1.70 (m, 2H), 1.61 - 1.59 (m, 1H), 1.55 - 1.45 (m, 3H), 1.28 - 1.25 (m, 1H), 1.10 (t, J= 6.8 Hz, 3H)
- [M+ Na]+ = 354.20
-
- Using the general procedure described in Example 14 above employing PRX-002 (-) isomer, (1.5 g, 6.96 mmol) and Decanoic acid (1.76 g, 10.23 mmol), provided the product (PRX-P4-002) (1.23 g, 40 % yield) as a thick transparent liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 5.87 (dd, J = 5.6 & 10.8 Hz, 1H), 4.38 -4.35 (m, 1H), 3.59 (brs, 1H), 3.27 - 3.17 (m, 1H), 2.89 - 2.88 (d, J = 5.2 Hz, 1H), 2.61 (s, 1H), 2.43 (d, J = 3.2 Hz, 1H), 2.37 - 2.32 (m, 2H), 1.78 -1.71 (m, 2H), 1.70 -1.58 (m, 3H), 1.57 - 1.42 (m, 1H), 1.29 -1.25 (m, 15H), 1.09 (t, J = 6.8 Hz, 3H), 0.90 (t, J = 6.4 Hz, 3H).
- [M+ Na]+ = 466.30
-
- Using the general procedure described in Example 14 above employing PRX-002 (-) isomer, (5 g, 23.21 mmol) and octadecanoic acid (9.7 g, 34.11 mmol), provided the product (PRX-P4-003) (4.9 g, 38 % yield) as a colorless liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.31 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 5.80 (dd, J = 5.6 & 10.8 Hz, 1H), 4.38 -4.36 (m, 1H), 3.59 (brs, 1H), 3.26 - 3.18 (m, 1H), 2.90 (d, J = 5.6 Hz, 1H), 2.61 (s, 1H), 2.43(d, J = 3.6 Hz, 1H), 2.36 - 2.32 (m, 2H), 1.75 -1.71 (m, 2H), 1.63 - 1.50 (m, 5H), 1.30 -1.25 (m, 30H), 1.09 (t, J = 6.8 Hz, 3H), 0.90 (t, J = 6.4 Hz, 3H)
- [M+ Na]+= 578.4
-
- Using the general procedure described in Example 14 above employing PRX-002 (-) isomer, (1 g, 4.64 mmol) and oleic acid (2.56 g, 9.09 mmol), provided the product (PRX-P4-004) (0.91 g, 30 % yield) as a colorless liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 5.80 (dd, J = 5.6 & 10.8 Hz, 2H), 5.39 - 5.30 (m, 2H), 4.38 - 4.37 (m, 1H), 3.59 (brs, 1H), 3.26 - 3.17 (m, 1H), 2.90 (d, J = 5.6 Hz, 1H), 2.61 (s, 1H), 2.43 (d, J = 3.6 Hz, 1H), 2.34 (t, J = 7.6 Hz, 2H), 2.01-1.98 (m, 3H), 1.78 -1.74 (m, 2H), 1.63 - 1.51 (m, 4H), 1.28 -1.25 (m, 23 H), 1.09 (t, J = 6.8 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H)
- [M+ H]+= 554.4
-
- Step 1: To a solution of N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine, PRX-002 (+) isomer or (-) isomer, (1 eq) in DCM (10 volumes) under argon atmosphere, was added triethylamine (2 eq) dropwise at ambient temperature. After stirring for 5 minutes, 1-chloroethyl chloroformate (2) (1.5 eq) was added dropwise at 0 - 5 °C and the reaction mixture was further stirred at ambient temperature for 30 min. After the completion of reaction (TLC eluent: 20% EtOAc in petroleum ether) the reaction mixture was quenched in water (20 volumes), extracted with DCM (2 x 20 volumes). The combined organic layer was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain N-(1-Chloroethoxycarbonyl)-N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine (I-9) as a thick brown liquid, which was carried forwarded for the next step without purification.
- Step 2: To a solution of intermediate I-9 (1 eq) in DMF (10 volumes) was added dry Cs2CO3 (2 eq), a fatty acid (R-COOH) (2 eq), and KI (0.2 eq) at ambient temperature and the reaction mixture was heated at 100 - 105 °C and stirred for 4 hours. After completion of reaction (TLC eluent: 10 % EtOAc in n-Hexane), the reaction mixture was quenched in water (20 volumes), extracted with ethyl acetate (2 x 20 volumes). Combined organic layer was washed with water (2 x 10 volumes) and brine solution (10 volumes), further dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude residue obtained was purified by either flash column chromatography / preparative HPLC to yield 1-Acyloxyethoxycarbonyl pro-drugs, including Compounds PRX-P5-001 to PRX-P5-011.
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (200 mg, 0.92 mmol) and sodium acetate (152 mg, 1.86 mmol), provided a the product (PRX-P5-001) (89 mg, 28 % yield) as a pale yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.23 -7.19 (m, 1H), 6.87 (q, 1H), 4.35 - 4.33 (m, 1H), 3.59 - 3.56 (m, 1H), 3.25 - 3.18 (m, 1H), 2.88 - 2.87 (d, J = 5.6 Hz, 1H), 2.62 (s, 1H), 2.44 - 2.42 (m, 1H), 2.07 (s, 3H), 1.75 - 1.69 (m, 2H), 1.61 -1.55 (m, 7H), 1.10 (t, J= 7.2 Hz, 3H).
- [M+ Na]+ = 368.2
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (300 mg, 1.39 mmol) and decanoic acid (482 mg, 2.80 mmol), provided the product (PRX-P5-002) (242 mg, 38 % yield) as a pale yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 - 6.83 (q, J = 5.2 Hz, 1H), 4.35 - 4.32 (m, 1H), 3.58 - 3.54 (m, 1H), 3.25 - 3.18 (m, 1H), 2.89 - 2.88 (d, J = 6 Hz, 1H), 2.61 (s, 1H), 2.44 - 2.43 (m, 1H), 2.32 - 2.27 (m, 2H), 1.75 -1.68 (m, 2H), 1.64 -1.59 (m, 4H), 1.56 - 1.42 (m, 5H), 1.34 -1.26 (m, 10H), 1.10 (t, J = 6.8 Hz, 3H), 0.90 (m, 5H)
- [M+ Na]+ = 480.3
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (330 mg,1.55 mmol) and butanoic acid (274 mg, 3.10 mmol), provided the product (PRX-P5-003) (240 mg, 42 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.35 -7.27 (m, 4H), 7.24 -7.18 (m, 1H), 6.88 (q, 1H), 4.35 (s, 1H), 3.67 - 3.40 (m, 1H), 3.39 - 3.06 (m, 1H), 2.89 (d, J = 6 Hz, 1H), 2.61 (s, 1H), 2.44 - 2.43 (m, 1H), 2.32 - 2.27 (m, 2H), 1.75 - 1.47 (m, 9H), 1.34 -1.24 (m, 2H), 1.10 (t, J = 6.8 Hz, 3H), 0.90 (t, 3H)
- [M+ Na]+ = 396.4
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (330 mg,1.55 mmol) and octanoic acid (447 mg, 3.10 mmol), provided the product (PRX-P5-004) (184 mg, 28 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 - 6.83 (q, J = 5.6 Hz, 1H), 4.35 (d, J = 5.6 Hz, 1H), 3.57 - 3.56 (m, 1H), 3.24 - 3.17 (m, 1H), 2.89 (d, J = 8 Hz, 1H), 2.61 (s, 1H), 2.44 - 2.43 (m, 1H), 2.32 - 2.27 (m, 2H), 1.75 -1.68 (m, 4H), 1.53 -1.45 (m, 4H), 1.28 - 1.26 (m, 11H), 1.09 (t, J = 6.8 Hz, 3H), 0.89 (t, 3H)
- [M+ Na]+ = 452.60
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (330 mg,1.55 mmol) and dodecanoic acid (622 mg, 3.10 mmol), provided the product (PRX-P5-005) (300 mg, 40 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.20 (m, 1H), 6.87 (q, J = 5.6 Hz, 1H), 4.35 -4.33 (m, 1H), 3.23 - 3.21 (m, 1H), 2.89 (d, J = 6 Hz, 1H), 2.61 (s, 1H), 2.44 - 2.43 (m, 1H), 2.32 - 2.27 (m, 2H), 1.87 -1.78 (m, 2H), 1.67 - 1.55 (m, 8H), 1.54 -1.52 (m, 5H), 1.35-1.30 (m, 10H), 1.29 (t, 3H), 0.90-0.89 (m, 6H)
- [M+ Na]+= 508.6
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (5g, 23.22 mmol) and octadecanoic acid (13.27 g, 46.68 mmol), provided the product (PRX-P5-006) (5.82 g, 44 % yield) as a pale yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 (q, J = 5.6 Hz, 1H), 4.35 (d, J = 6 Hz, 1H), 3.57 (d, J = 5.2 Hz, 1H), 3.26 - 3.18 (m, 1H), 2.89 (d, J = 6 Hz, 1H), 2.61 (s, 1H), 2.44 (S, 1H), 2.33 - 2.27 (m, 2H), 1.76 -1.68 (m, 2H), 1.64 - 1.56 (m, 4H), 1.54 -1.47 (m, 5H), 1.42 - 1.26 (m, 23H), 1.13 -1.06 (m, 5H), 0.90 - 0.84 (m, 6H)
- [M+ Na]+= 592.70
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (330 mg,1.55 mmol) and pivalic acid (317 mg,3.11 mmol), provided the product (PRX-P5-007) (236 mg, 40 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.32 - 7.27 (m, 4H), 7.22 - 7.17 (m, 1H), 6.87 (q, J = 5.2 Hz, 1H), 4.35 -4.31 (m, 1H), 3.61 - 3.54 (m, 1H), 3.25 - 3.16 (m, 1H), 2.90 (d, J = 8.0 Hz, 1H), 2.60 (s, 1H), 2.47 - 2.46 (d, J = 3.2 Hz, 1H), 1.78 -1.60 (m, 3H), 1.55 -1.44 ( m, 4H), 1.26 - 1.24 (m, 2H), 1.20 - 1.18 (s, 9H), 1.10 - 1.06 (m, 3H)
- [M+ Na]+ = 410.2
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (0.6 g, 2.79 mmol) and oleic acid (1.58 g, 5.60 mmol), provided the product (PRX-P5-008) (0.55 g, 35 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 (q, J = 5.6 Hz, 1H), 5.36-5.33 (m, 2H), 4.35-4.32 (m, 1H), 3.59 - 3.55 (m, 1H), 3.24 - 3.18 (m, 1H), 2.89-2.88 (d, J = 3.6 Hz, 1H), 2.61 (s, 1H), 2.44 - 2.43 (m, 1H), 2.32 - 2.27 (m, 2H), 2.01-1.98 (m, 4H), 1.76 -1.68 (m, 2H), 1.61 - 1.57 (m, 3H), 1.54 -1.51 (m, 2H), 1.29 - 1.24 (m, 24H), 1.09 (s, J = 6.8 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H)
- [M+ Na]+ = 590.3
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (330 mg,1.55 mmol) and tetradecanoic acid (690 mg, 3.06 mmol), provided the product (PRX-P5-009) (310 mg, 40 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.32 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 (q, J = 5.2 Hz, 1H), 4.35 -4.32 (m, 1H), 3.59 - 3.56 (m, 1H), 3.24 - 3.18 (m, 1H), 2.89 (d, J = 6 Hz, 1H), 2.61 (s, 1H), 2.44 (d, J = 4 Hz, 1H), 2.32 - 2.25 (m, 2H), 1.75 - 1.60 (m, 2H), 1.55 - 1.47 (m, 4H), 1.34 - 1.25 (m, 25H), 1.10 (t, J = 7.2 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H)
- [M+ Na]+ = 536.3
-
- Using the general procedure described in Example 18 above employing PRX-002 (-) isomer, (0.6 g, 2.79 mmol) and hexadecanoic acid (1.43 g, 5.60 mmol), provided the product (PRX-P5-010) (0.6 g, 40 % yield) as a yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.27 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 (q, J = 5.2 Hz, 1H), 4.35 - 4.32 (m, 1H), 3.59 - 3.56 (m, 1H), 3.28 - 3.16 (m, 1H), 2.89 - 2.87 (d, J = 6 Hz, 1H), 2.61 (s, 1H), 2.44 (d, J = 4.4 Hz, 1H), 2.34 - 2.28 (m, 2H), 1.75 - 1.68 (m, 2H), 1.64 -1.58 (m, 1H), 1.54 - 1.47 (m, 4H), 1.34 -1.26 (m, 28H), 1.09 (t, J = 6.8 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H)
- [M+ Na]+= 564.3
-
- Using the general procedure described in Example 18 above employing PRX-002 (+) isomer, (5g, 23.22 mmol) and octadecanoic acid (13.27 g, 46.68 mmol), provided the product (PRX-P5-011) (5.82 g, 44 % yield) as a pale yellow liquid.
- 1H-NMR (CDCl3, 400 MHz) δ 7.33 - 7.28 (m, 4H), 7.22 - 7.18 (m, 1H), 6.87 (q, J = 5.6 Hz, 1H), 4.35 (d, J = 5.6 Hz, 1H), 3.59 (t, J = 6.8 Hz, 1H), 3.24 - 3.18 (m, 1H), 2.89 (d, J = 6.4 Hz, 1H), 2.61 (s, 1H), 2.44 - 2.43 (m, 1H), 2.32 - 2.27 (m, 2H), 1.75 - 1.68 (m, 2H), 1.64 - 1.58 (m, 2H), 1.54 -1.51 (m, 1H), 1.50 - 1.47 (m, 3H), 1.32 -1.25 (m, 31H), 1.09 (t, J = 6.8 Hz, 3H), 0.90 (t, J = 6.8 Hz, 3H)
- [M+ Na]+ = 592.30
- We describe here PK results of prodrugs of PRX-002 (-) or (+) isomers. All doses of prodrugs were administered such that they were equivalent to 5 mg/kg of PRX-002 (-) or (+) for oral studies and 2 mg/kg PRX-002 (-) or (+) for intravenous studies in male Sprague-Dawley (MSD) rats. Higher doses of up to 10 or 15 mg/kg [again equivalent to PRX-002 (-)] were used in some studies (as specified)]. Formulation preparation, dose administration and time of sample collection was as follows.
- Oral Formulation Preparation: Test item was weighed [5 mg equilvalent dose of PRX-002 for prodrugs] and transferred to a graduated tube. Then 10 µL of
Tween 80 was added and vortexed mixed until the test item was completely mixed. Small volume of 0.5% (w/v) carboxymethylcellulose in water solution was then added dropwise with continuous vortex mixing until a uniform suspension was obtained. The final volume was then made up to 10 mL with 0.5% (w/v) carboxymethylcellulose in water with final strength of 0.5 mg/mL. The obtained formulation was found to be uniform suspension. This formulation was freshly prepared before the administration to animals. - Oral Dose Administration: Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Fasted animals were administered test item by oral route with a dose of 5 mg/kg body weight at dose volume of 10 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K2EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4 ºC for 10 minutes and plasma were separated and stored at -80 ºC until analysis.
- Blood was collected as outlined in Table 39.1 (oral).
TABLE 39.1 Group no. Animal ID Blood collection time points (h) 0.08 0.25 0.50 1.00 2.00 4.00 0 24.00 G-X ROOX X X X X X X X X ROOX X X X X X X X X ROOX X X X X X X X X - IV Formulation Preparation: Test item was weighed [(to be equivalent to 2 mg/kg of
PRX 002 dose] and transferred to a graduated tube. Then 500 µL of PEG 400 (v/v) was added and vortex mixed thoroughly until the test item was completely dissolved. Then 1500 µL of Hydroxypropyl-β-cyclodextrin (HPβCD, 50% w/v) was added and vortex mixed thoroughly. The final volume was then made up to 5000 µL with sterile water for injection (SWFI, v/v) with final formulation strength of 0.4 mg/mL. The obtained formulation was found to be clear solution. This formulation was freshly prepared before the administration to animals. - IV Dose Administration: Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Animals were administered the test item by Intravenous bolus route with a dose of 2 mg/kg body weight at dose volume of 5.0 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K2EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4 ºC for 10 minutes and plasma were separated and stored at -80 ºC until analysis.
- Blood was collected as outlined in Table 39.2 (IV).
TABLE 39.2 Group no. Animal ID Blood collection time points (h) 0.08 0.25 0.50 1.00 2.00 4.00 6.00 24.00 G-x R00X X X X X X X X X ROOX X X X X X X X X ROOX X X X X X X X X - Formulation Preparation: Test item PRX-P4-003 was weighed and transferred to a graduated tube. Then 12.42 µL of
Tween 80 was added and vortexed mixed until the test item was completely mixed. Small volume of 0.5% (w/v) Carboxymethylcellulose in water solution was then added dropwise with continuous vortex mixing until a uniform suspension was obtained. The final volume was then made up to 12.42 mL with 0.5% (w/v) Carboxymethylcellulose in water with final strength of 1.0 mgA/mL. The obtained formulation was found to be uniform suspension. This formulation was freshly prepared before the administration to animals. - Dose Administration: Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Fasted animals were administered with a PRX-P4-003 by oral route with a dose of 10 mg/kg body weight at dose volume of 10 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K2EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4ºC for 10 minutes and plasma were separated and stored at -80ºC until analysis.
- Formulation Preparation [PRX-P4-003 dose equivalent of 10 mg/kg PRX-002 (-)]: Test item PRX-P4-003 was weighed and transferred to a graduated tube. Then 600 µL of PEG 400 (v/v) was added and vortex mixed thoroughly until the test item was completely dissolved. Then 1.800 mL of Hydroxypropyl-β-cyclodextrin (HPβCD, 50% w/v) was added and vortex mixed thoroughly. The final volume was then made up to 3.600 mL with sterile water for injection (SWFI, v/v) with final formulation strength of 5.16 mgA/mL. The obtained formulation was found to be colloidal solution. This formulation was freshly prepared before the administration to animals.
- Dose Administration: Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Animals were administered with a PRX-P4-003 by Intravenous bolus route with a dose of 10 mg/kg body weight at dose volume of 5 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K2EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4ºC for 10 minutes and plasma were separated and stored at -80ºC until analysis.
- Formulation Preparation: Test item PRX-P5-006 was weighed and transferred to a graduated tube. Then 10 µL of
Tween 80 was added and vortexed mixed until the test item was completely mixed. Small volume of 0.5% (w/v) Carboxymethylcellulose in water solution was then added dropwise with continuous vortex mixing until a uniform suspension was obtained. The final volume was then made up to 10 mL with 0.5% (w/v) Carboxymethylcellulose in water with final strength of 3.97 mg/ mL. The obtained formulation was found to be uniform suspension. This formulation was freshly prepared before the administration to animals. - Dose Administration: Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Fasted animals were administered with a PRX-P5-006 by oral route with a dose of 15 mg/kg body weight at dose volume of 10 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K2EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4ºC for 10 minutes and plasma were separated and stored at -80ºC until analysis.
- Formulation Preparation: Test item PRX-P5-006 was weighed and transferred to a graduated tube. Then 500 µL of DMSO (v/v) was added vortex mixed thoroughly until the test item was completely dissolved. Then 4000 µL of Hydroxypropyl-β-cyclodextrin (HPβCD, 50% w/v) was added and vortex mixed thoroughly. Then 2500 µL of PEG 400 (v/v) was added and vortex mixed thoroughly. The final volume was then made up to 10000 µL with sterile water for injection (SWFI, v/v) with final formulation strength of 3.97 mg/mL. The obtained formulation was found to be clear solution. This formulation was freshly prepared before the administration to animals.
- Dose Administration: Adult male Sprague Dawley Rats aged 8-10 weeks were used for the study. Animals were administered with a PRX-P5-006 by Intravenous bolus route with a dose of 15 mg/kg body weight at dose volume of 10 mL/kg body weight. Under mild isoflurane anesthesia, blood specimens were collected by retro-orbital puncture method using capillary tubes into pre-labeled tubes containing anticoagulant (K2EDTA-2 mg/mL blood) during the next 24 hours of post dose as mentioned in below table. For blood sampling at multiple time points, right and left eyes were used alternatively for blood collection. Collected blood specimens were centrifuged at 4000 rpm, 4ºC for 10 minutes and plasma were separated and stored at -80ºC until analysis.
- Table 39.3 depicts a set of comparative data of single dose oral and intravenous PK Study of PRX-P4-003. Additional data in this regard is presented in
FIG. 1 .TABLE 39.3 Single Dose Oral and intravenous PK Study of PRX-P4-003 in Male Sprague Dawley Rats Oral Intravenous PK Parameters Mean Plasma PK Parameters of PRX-P4-003 Dose (mg/kg) 5.00 2.00 Cmax (ng/mL) 0.0 ± 0.0 171.963 ± 62.6030 Tmax (hr) 0.0 ± 0.0 0.080 ± 0.0000 AUClast (hr*ng/mL) 0.0 ± 0.0 132.573 ± 32.5110 AUCinf(hr*ng/mL) 0.0 ± 0.0 215.708 ± 83.3890 AUC % extrap (%) 0.0 ± 0.0 32.475 ± 83.3890 Vss (L/kg) 0.0 ± 0.0 41.984 ± 19.8767 CL (mL/min/kg) 0.0 ± 0.0 171.947 ± 69.3217 T1/2 (hr) 0.0 ± 0.0 3.348 ± 2.1780 MRT last (hr) 0.0 ± 0.0 1.836 + 0.7130 -
FIG. 2 is a graph depicting oral and IV pharmacokinetics for PRX-P4-003 in male Sprague Dawley rats. The graph depicts the results for the resulting plasma concentration of PRX-002(-) isomer via oral or IV administration. As can be seen, while oral administration results in a desired plasma concentration for the active/parent drug (here, PRX-002(-) isomer), IV administration results in minimal amounts of any of the PRX-P4-003 being converted from the pro-drug form to the active form. The results are outlined above in Table 39.4 and 39.5.TABLE 39.4: COMPARATIVE DATA: SINGLE DOSE ORAL AND INTRAVENOUS PK STUDY OF PRX-P4-003 IN MALE SPRAGUE DAWLEY RATS. Mean Plasma PK Parameters of PRX-002 (-) Isomer A B C D Dose (mg/kg) 5.00 (oral) 10.00 (oral) 2.00 (IV) 10.00 (IV) Cmax (ng/mL) 156.7030 ± 85.32600 425.0400 ± 40.46000 30.807 ± 10.0830 NC Tmax (hr) 0.8330 ± 0.28900 1.3330 ± 0.57700 0.080 ± 0.0000 NC AUClast (hr*ng/mL) 296.8610 ± 51.2400 1092.8470 ± 169.08500 14.254 ± 3.8510 NC AUCinf(hr*ng/mL) 308.8410 ± 58.24000 1158.6130 ± 137.93700 22.098 ± 7.0600 NC AUC%extrap(%) 3.6430 ± 2.29800 5.9310 ± 3.20800 34.822 ± 6.9490 NC Vss (L/kg) - 86.814 ± 23.2576 NC CL (mL/min/kg) - 1606.391 ± 464.8270 NC T1/2 (hr) 1.8080 ± 0.30700 1.9220 ± 0.09300 0.682 ± 0.2440 NC MRTlast (hr) 1.2770 ± 0.25600 1.2890 ± 0.29000 0.340 ± 0.0190 NC A: Oral PK (5 mg/kg)
B: Oral PK (10 mg/kg)
C: Intravenous PK (2 mg/kg)
D: Intravenous PK (10 mg/kg)
*NC: Not Calculated. PRX-002 (-)Isomer IV 10 mg/kg PK data analysis was not carried out because limited exposure in plasma concentration profileTABLE 39.5 Concentration time profile of PRX-002 (-) after oral and IV dose of PRX-P4-003 Single Dose Oral and Intravenous Pharmacokinetics Study of PRX-P4-003 in Male Sprague Dawley Rats Oral PK Intravenous PK Plasma concetration ef PRX-002 (-) Isomer (ng/mL) Time (h) Mean SD Time (h) Mean ± SD 0.00 0.00 ± 0.00 0.00 ± 0.008 0.00 ± 0.00 0.08 30.81 ± 10.08 0.25 35.89 ± 18.38 0.25 15.63 ± 3.90 0.50 97J6 ± 29.02 0.50 9.14 ± 3.39 1.00 149.74 ± 89.23 1.00 7.82 ± 0.92 2.00 56.12 ± 21.49 2.00 0.00 + 0.00 4.00 25.08 ± 11.71 4.00 0.00 ± 0.00 6.00 6.10 ± 3.79 6.00 0.00 ± 0.00 24.00 0.00 ± 0.00 24.00 0.00 ± 0.00 -
FIG. 3 depicts the results of the comparative data regarding IV PK studies of PRX-P4-003 (2 and 10 mg/kg b.w.) PRX-002(-) isomer (2mg/kg b.w.). As can be observed very limited amount of parent PRX-002 (-) is generated when the prodrug PRX-P4-003 is administered IV even at higher dose of 10 mg/kg. Additional data is summarized in Tables 39.6-39.7. -
FIG. 4 is a graph comparing the oral PK study of PRX-P4-003 to PRX-002(-) isomer, in terms of the amount of resulting PRX-P4-003 or PRX-P4-002(-) isomer present in the plasma. As can be seen from the results, almost none of the prodrug form of the drug (PRX-P4-003) is present in the plasma when administered orally. However, a desired amount of the active compound (PRX-002 (-) Isomer) does form in the plasma. Additional data is presented in Table 39.8-39.9TABLE 39.8: ORAL PK STUDY OF PRX-P4-003 (5 AND 10 MG/KG) AND PRX-002(-) (5 MG/KG)IN MALE SPRAGUE DAWLEYRATS. MEAN PK PARAMETERS OF PRX-P4-003 AND PRX-002 (-) ISOMER Oral PK Study of PRX-P4-003 (5 mg/kg) Oral PK Study of PRX-P4-003 (10 mg/kg) Oral PK Study of PRX-002 (-) Isomer (5 mg/kg) A B C D E Dose (mg/kg) 5.0 5.0 10.0 10.00 5.0 Cmax (ng/mL) 0.0 156.7030 ± 85.32600 0.0 425.0400 ± 40.46000 176.260 ± 47.4850 Oral PK Study of PRX-P4-003 (5 mg/kg) Oral PK Study of PRX-P4-003 (10mg/kg) Oral PK Study of PRX-002 (-) Isomer 5(mg/kg) A B C D E Tmax (hr) 0.0 0.8330 ± 0.28900 0.0 1.3330 ± 0.57700 0.833 ± 0.2890 AUClast (hr*ng/mL) 0.0 296.8610 ± 51.2400 0.0 1092.8470 ± 169.08500 370.968 ± 99.4740 AUCinf(hr*ng/mL) 0.0 308.8410 ± 58.24000 0.0 1158.6130 ± 137.93700 427.201 ± 122.1840 AUC%extrap(%) 0.0 3.6430 ± 2.29800 0.0 5.9310 ± 3.20800 12.904 ± 1.8410 T1/2(hr) 0.0 1.8080 ± 0.30700 0.0 1.9220 ± 0.09300 1.864 ± 0.132 MRTlast(hr) 0.0 1.2770 ± 0.25600 0.0 1.2890 ± 0.29000 1.474 ± 0.1040 A: Mean PK Parameters of PRX-P4-003
B: Mean PK Parameters of PRX-002 (-) Isomer
C: Mean PK Parameters of PRX-P4-003
D: Mean PK Parameters of PRX-002 (-) Isomer
E: Mean PK Parameters of PRX-002 (-) Isomer -
Fig. 5 A and 5B shows comparative Data: Single Dose Oral and Intravenous PK Study of PRX-P5-006. Much higher level of intact PRX-P5-006 was observed when prodrug was administered IV. The data is shown in Table 39.10. Additional data is shown in Tables 39.11-39.12TABLE 39.10 Single Dose Oral and Intravenous PK Study of PRX-P5-006 in Male Sprague Dawley Rats-amount of prodrug remaining in plasma Oral Intravenous PK Parameters Mean Plasma PK Parameters of PRX-P5-006 Dose (mg/kg) 5.00 2.00 Cmax (ng/mL) 61.457 ± 15.4180 9097.783 ± 1947.6780 Tmax (hr) 1.000 ± 0.0000 0.08 ± 0.0000 AUClast (hr*ng/mL) 57.800 ± 10.1940 4267.485 ± 902.3590 AUCinf(hr*ng/mL) 114.633 ± 23.3260 4563.103 ± 894.4610 AUC%extrap(%) 47.896 ± 15.3010 6.602 ± 4.0330 Vss (L/kg) - 1.875 ± 1.4500 CL (mL/min/kg) - 7.478 ± 1.3221 T1/2 (hr) 2.907 ± 0.865 6.304 ± 3.7850 MRTlast(hr) 1.070 ± 0.0250 2.313 ± 1.2350 TABLE 39.11 Single Dose Oral Pharmacokinetics Study of PRX-P5-006 in Male Sprague Dawley Rats (5 mg/kg b.w.) Animal No Cmax (ng/mL) Tmax(hr) AUClast(hr*ng/mL) AUCinf (hr*ng/mL) AUC %extrap MRT last (hr) T1/2(hr) R001 43.87 1.00 46.56 122.60 62.02 1.10 3.50 R002 72.65 1.00 66.44 132.93 50.02 1.07 3.31 R003 67.85 1.00 60.40 88.37 31.64 1.05 1.91 N 3 3 3 3 3 3 3 Animal No Cmax (ng/mL) Tmax(hr) AUC last (hr*ng/mL) AUC inf(hr*ng/mL) AUC % extrap MRT last (hr) T1/2(hr) Mean 61.457 1.000 57.800 114.633 47.896 1.070 2.907 SD 15.4180 0.0000 10.1940 23.3260 15.3010 0.0250 0.865 TABLE 39.12 Single Dose IV Pharmacokinetics Study of PRX-P5-006 in Male Sprague Dawley Rats (2 mg/kg b.w.) Animal No C0(ng/ml) Cmax(ng/mL) Tmax(hr) AUC last (hr/mL) AUC last (hr/mL) AUC%extrap Vss(L/kg) CL (mL/min/kg) MRTlast(hr) T1/2(hr) R001 36229.68 11226.34 0.08 5304.3 5592.69 5.16 1.56 5.96 2.7 7.54 R002 32467.12 8662.3 0.08 3838.58 3977.39 3.49 0.61 8.38 0.93 2.06 R003 21202.31 7404.71 0.08 3659.58 4119.23 11.16 3.46 8.09 3.31 9.32 N 3 3 3 3 3 3 3 3 3 3 Mean 29966.370 9097.783 0.08 4267.485 4563.103 6.602 1.875 7.478 2.313 6.304 SD 7819.5760 1947.6780 0.0000 902.3590 894.4610 4.0330 1.4500 1.3221 1.2350 3.7850 -
FIG. 6A is a graph depicting a comparison of oral and IV pharmacokinetics of PRX-P5-006 in Male Sprague Dwaley rats.FIG. 6B shows an enlarged view of the IV pharmacokinetics for the amount of resulting active in the plasma depicted in 6A. The graph depicts the amount of the active compound found in the plasma over time for the PRX-P5-006 compound. The data is shown in Table 39.13, below. Additional data is shown below in Tables 39.14-39.17.TABLE 39.13: COMPARATIVE DATA: SINGLE DOSE ORAL AND INTRAVENOUS PK STUDY OF PRX-P5-006 Single Dose Oral and Intravenous PK Study of PRX-P5-006 in Male Sprague Dawley Rats Oral Intravenous PK Parameters Mean Plasma PK Parameters of PRX-002 Dose (mg/kg) 5.00 2.00 Cmax (ng/mL) 85.297 ± 24.4150 7.980 ± 1.9800 Tmax (hr) 1.000 ± 0.0000 0.08 ± 0.0000 AUClast (hr*ng/mL) 226.99 ± 92.8790 9.750 ± 1.6650 AUCinf(hr*ng/mL) 241.836 ± 104.0180 21.703 ± 2.1980 AUC%extrap(%) 5.645 ± 1.8560 54.877 ± 7.6450 Vss (L/kg) - 304.212 ± 49.9758 CL (mL/min/kg) - 1547.056 ± 165.4562 T1/2 (hr) 1.290 ± 0.137 2.248 ± 0.2880 MRTlast (hr) 2.061 ± 0.1540 0.874 ± 0.0360 TABLE 39.14 Single Dose Oral Pharmacokinetics Study of PRX-P5-006 in Male Sprague Dawley Rats (5 mg/kg b.w.) Plasma concentration of PRX-002 (ng/mL) Group No. Time (h) R001 R002 R003 Mean SD G-1 0.00 0.00 0.00 0.00 0.000 0.000 0.08 0.00 0.00 0.00 0.000 0.000 0.25 2.82 8.21 4.47 5.167 2.761 0.50 32.44 49.39 53.68 45.169 11.230 1.00 67.50 113.13 75.26 85.296 24.414 2.00 55.44 100.65 36.19 64.096 33.089 4.00 16.59 31.81 13.28 20.561 9.884 6.00 4.82 13.82 4.56 7.735 5.269 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-002 in plasma-2.167 ng/mL TABLE 39.15 Single Dose Oral Pharmacokinetics Study of PRX-P5-006 in Male Sprague Dawley Rats (5 mg/kg b.w.) Animal No Cmax (ng/mL) Tmαx (hr) AUClast(hr*ng/mL) AUCinf(hr*ng/mL) AUC%extrap MRTlast(hr) T1/2(hr) R001 67.50 1.00 184.54 192.44 4.10 2.09 1.14 R002 113.13 1.00 333.51 361.35 7.70 2.20 1.40 R003 75.26 1.00 162.92 171.72 5.13 1.90 1.34 N 3 3 3 3 3 3 3 Mean 85.297 1.000 226.99 241.836 5.645 2.061 1.29 SD 24.4150 0.0000 92.8790 104.0180 1.8560 0.1540 0.137 TABLE 39.16 (PLASMA CONCENTRATION OF ACTIVE) Single Dose Intravenous Pharmacokinetics Study of PRX-P5-006 in Male Sprague Dawley Rats (2 mg/kg b.w.) Plasma concentrationof PRX-002 (ng/mL) Group No. Time (h) R004 R005 R006 Mean SD G-2 0.08 9.53 5.75 8.66 7.981 1.979 0.25 7.02 4.32 4.92 5.419 1.415 0.50 6.49 4.99 3.66 5.047 1.412 1.00 5.60 4.93 3.47 4.666 1.092 2.00 3.82 3.20 4.00 3.673 0.417 4.00 0.00 0.00 0.00 0.000 0.000 6.00 0.00 0.00 0.00 0.000 0.000 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-002 in plasma- 2.167 ng/mL TABLE 39.17 (PLASMA CONCENTRATION OF ACTIVE) Single Dose IV Pharmacokinetics Study of PRX-P5-006 in Male sprague Dawley Rats (2 mg/kg b.w.) Animal No C0 (ng/ml) Cmax (ng/mL) Tmax(hr) AUClast (hr*ng/mL) AUCinf (hr*ng/mL) AUC% extrap Vss (L/kg) CL(mL/min/kg) MRT last(hr) T1/2(hr) R001 11.00 9.53 0.08 11.65 22.61 48.47 246.74 1474.36 0.83 1.99 R002 6.58 5.75 0.08 9.06 19.20 52.82 328.45 1736.41 0.90 2.20 R003 11.30 8.66 0.08 8.54 23.30 63.34 337.45 1430.39 0.89 2.56 N 3 3 3 3 3 3 3 3 3 3 Mean 9.627 7.980 0.080 9.750 21.703 54.877 304.212 1547.056 0.874 2.248 SD 2.6450 1.9800 0.0000 1.6650 2.1980 7.6450 49.9758 165.4562 0.0360 0.2880 -
FIG. 7A and7B show graph depicting the IV pharmacokinetics for PRX-P5-011 in male Sprague Dawley rats. Even though the only difference between PRX-P5-011 and PRX-P5-006 is that the former has positive isomer PRX-002 (+) while the latter has PRX-002 (-) the oral plasma profile is remarkably different. The active compound PRX-002 (+) was not detected in plasma after oral administration. The results are summarized above from table 39.18-39.21TABLE 39.18: SINGLE DOSE ORAL PHARMACOKINETIC STUDY OF PRX-P5-011PLASMA CONCENTRATIONS OF PRX-P5-011 IN MALE SPRAGUE DAWLEY RATS. Plasma concentration of PRX-P5-011 (ng/mL) Time (h) R010 R011 R012 Mean SD 0.00 0.00 0.00 0.00 0.000 0.000 0.08 0.00 0.00 0.00 0.000 0.000 0.25 0.00 0.00 0.00 0.000 0.000 0.50 0.00 0.00 0.00 0.000 0.000 1.00 0.00 0.00 0.00 0.000 0.000 2.00 0.00 0.00 0.00 0.000 0.000 4.00 0.00 0.00 0.00 0.000 0.000 6.00 0.00 0.00 0.00 0.000 0.000 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-P5-011 in plasma-3.373 ng/mL TABLE 39.19: SINGLE DOSE ORAL PHARMACOKINETIC STUDY OF PRX-P5-011 PLASMA CONCENTRATIONS OF PRX-002 (+) ISOMER IN MALE SPRAGUE DAWLEY RATS. Plasma concentration of PRX-002 (+) Isomer (ng/mL) Time (h) R010 R011 R012 Mean SD 0.00 0.00 0.00 0.00 0.000 0.000 0.08 0.00 0.00 0.00 0.000 0.000 0.25 0.00 0.00 0.00 0.000 0.000 0.50 0.00 0.00 0.00 0.000 0.000 1.00 0.00 0.00 0.00 0.000 0.000 2.00 0.00 0.00 0.00 0.000 0.000 4.00 0.00 0.00 0.00 0.000 0.000 6.00 0.00 0.00 0.00 0.000 0.000 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-002 (+) Isomer In plasma-1.779 ng/mL TABLE 39.20 Single Dose Intravenous Pharmacokinetics Study of PRX-P5-011 in Male Sprague Dawley Rats (2 mg/kg b.w.) Plasma concentration of PRX-P5-011 (ng/mL) Group No. Time (h) R013 R014 R015 Mean SD G-2 0.08 114.77 37.09 179.14 110.332 71.132 0.25 56.47 17.98 101.04 58.497 41.563 0.50 0.00 0.00 0.00 0.000 0.000 1.00 0.00 0.00 0.00 0.000 0.000 2.00 0.00 0.00 0.00 0.000 0.000 4.00 0.00 0.00 0.00 0.000 0.000 6.00 0.00 0.00 0.00 0.000 0.000 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantification of PRX-P5-011 in plasma-3.373 ng/mL TABLE 39.21: SINGLE DOSE IV PHARMACOKINETIC STUDY OF PRX-P5-011. PLASMA CONCENTRATIONS OF PRX-002 (+) ISOMER IN MALE SPRAGUE DAWLEY RATS. Single Dose Intravenous Pharmacokinetics Study of PRX-P5-011 in Male Sprague Dawley Rats (2 mg/kg b.w.) Plasma concentration of PRX-002 (+) Insomer (ng/mL) Group No. Time (h) R013 R014 R015 Mean SD G-2 0.08 8.92 2.52 7.77 6.400 3.409 0.25 0.00 0.00 0.00 0.000 0.000 0.50 0.00 0.00 0.00 0.000 0.000 1.00 0.00 0.00 0.00 0.000 0.000 2.00 0.00 0.00 0.00 0.000 0.000 4.00 0.00 0.00 0.00 0.000 0.000 6.00 0.00 0.00 0.00 0.000 0.000 24.00 0.00 0.00 0.00 0.000 0.000 LLOQ - Lower Limit Of Quantilkatian of PRX-002 (+) Isomer in plasma - 1.779 ng/mL -
FIG. 8A is a graph depicting the IV pharmacokinietics of PRX-P6-011 in male Sprague Dawley rats.Fig. 8B is a more closely visualized graph (from 8A) consisting of PRX-P6-011, PRX-002 (+) [compared to the level of PRX-002 (-) after direct administration]. The results are summarized in tables 39.22-39.25. - Tables 39.22-39.25 provide comparative oral pharmacokinetics study results for PRX-P6-011 and PRX-002(+), including mean plasma PK parameters of PRX-P6-011, PRX-P1-006, PRX-002(+) .
TABLE 39.22 Oral PK Study of PRX-P6-011 Oral PK Study of PRX-002(+) Insomer PRX-P6-011 PRX-P1-006(monopeptide) PRX-002(+) Isomer PRX-002(+) Insomer Dose (mg/kg) 5.00 5.00 5.00 5.00 Cmax(ng/mL) 82.223 ± 30.8790 655.283 ± 193.0510 94.637 ± 26.1330 106.727 ± 25.432 Tmax(hr) 0.137 ± 0.0980 0.833 ± 0.2890 0.750 ± 0.4330 0.5 ± 0.0 AUClast (hr*ng/mL) 44.161 ± 17.0700 1664.557 ± 363.7590 277.359 ± 69.7760 127.924 ± 74.239 AUCinf(hr*ng/mL) 57.261 ± 21.2510 1914.634 ± 367.6390 336.298 ± 37.4560 151.444 ± 68.603 AUC%extrap(%) 23.190 ± 3.6640 13.391 ± 2.6780 18.346 ± 13.2530 18.063 ± 11.646 T1,2 (hr) 1.172 ± 0.2110 2.120 ± 0.3850 2.433 ± 1.0880 0.992 ± 0.228 MRTlast(hr) 0.575 ± 0.0370 1.885 ± 0.2180 2.002 ± 0.2090 0.957 ± 0.269 TABLE 39.23 Single Dose Oral Pharmacakinetics Study of PRX-P6-011 in Male Spragune Dawley Rats (5 mg/kg b.w.) Plasma concentration of PRX-P6-011 (ng/mL) Plasma concentration of PRX-P1-006(ng/mL) Plasma concentration of PRX-002 (+) Insomer(ng/mL) Time (h) Mean SD Mean ± SD Mean ± SD 0.00 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 0.08 75.92 ± 32.13 191.07 ± 79.19 48.07 ± 20.49 0.25 62.77 ± 26.46 437.17 ± 222.28 86.02 ± 31.11 0.50 20.78 ± 9.87 61734 ± 209.88 80.97 ± 26.95 1.00 13.01 ± 6.06 645.99 ± 179.41 93.49 ± 25.37 2.00 7.87 ± 293 336.43 ± 133.72 62.66 ± 23.23 4.00 0.00 ± 0.00 122.45 ± 13.35 21.38 ± 3.32 6.00 0.00 ± 0.00 83.31 ± 13.47 16.05 ± 2.98 24.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 TABLE 39.24 Single Dose Oral PK Study of PRX-002 (+ isomer) at 5 mg/kg body weight in Male sprague Dawley Rats Animal ID Cmax (ng/mL) Tmax(hr) AUClast(hr*ng/mL) AUCinf (hr*ng/ML) AUC % extrap MRT last(hr) T1/2(hr) R0175 134.89 0.5 213.62 229.43 6.89 1.26 1.07 R0176 85.44 0.5 87 124.51 30.13 0.86 1.17 R0177 99.85 0.5 83.16 100.4 17.17 0.75 0.74 N 3 3 3 3 3 3 3 Mean 106.727 0.5 127.924 151.444 18.063 0.957 0.992 SD 25.432 0 74.239 68.603 11.646 0.269 0.228 TABLE 39.25 Single Dose Oral PK Study of PRX-002 (+ isomer) at 5 mg/kg body weight in Male Sprague Dawley Rats Mean Plasma PK Parameters Parameters PRX-002 (+ isomer) Dose (mg/kg b.w.) 5.00 Cmax (ng/mL) 106.727 ± 25.432 Tmax(hr) 0.5 ± 0.0 AUC last (hr*ng/mL) 127.924 ± 74.239 AUC inf(hr*ng/mL) 151.444 ± 68.603 AUC %extrap(%) 18.063 ± 11.646 T1/2 (hr) 0.992 ± 0.228 MRTlast(hr) 0.957 ± 0.269 -
-
- The plasma concentrations of fencamfamine were measured by LC-MS/MS over time. TABLE 39.30 and
FIGS. 1-10 demonstrate the different PK curves achieved by the different fencamfamine prodrugs as compared with unconjugated forms and the specific pharmacokinetic parameter data is presented in the Tables above and noted figures. The release of fencamfamine from the prodrugs varied depending on the chain length of the fatty acid linkers attached to fencamfamine. Changes in the amount of fencamfamine released from the prodrugs was measured by the area under the curve and compared to unconjugated fencamfamine. - Various prodrug compositions unexpectedly provided an amount sufficient to provide an extended Tmaxwhen compared to unconjugated fencamfamine when administered at equimolar doses. The prodrug composition showed an extended or controlled release profile as measured by plasma concentrations of released fencamfamine when compared to unconjugated fencamfamine when administered orally at equimolar doses. However, not all of the compounds displayed all or similar such properties.
- In some embodiments, the plasma concentration of fencamfamine released from the prodrug increased more slowly and over a longer period of time after oral administration, resulting in a delay in peak plasma concentration of released fencamfamine and in a longer duration of action when compared to unconjugated fencamfamine.
- In addition, as shown by some of the embodiments above, the form of the isomer would also alter the pharmacokinetic profile in unexpected ways.
- Thus, the type of blocking moiety associated with the drug (e.g., fatty acid or amino acid, etc.), and the particular isomer of fencamfamine used each resulted in varied properties and for the provision of the drug in question.
- A summary of the Oral and IV in vivo data in MSD rats for the various compounds is shown below in Table 39.30, which also demonstrates that alternative candidate prodrugs did not have the desired properties or had different properties. Unless otherwise specified all prodrugs were tested with a dose of 5 mg/ kg orally and 2 mg/kg IV [equivalent to PRX-002 (-)]. The formulation and administration procedure is as described in the beginning of the PK section.
TABLE 39.30. MEAN PLASMA PK PARAMETERS IN SPRAGUE DAWLEY RATS Compound Oral PK Parameters (5mg/kg) IV PK Parameters (2mg/kg) Cmax (ng/mL) AUC (h*ng/mL) T max (h) C max (ng/mL) AUC (h*ng/mL) T max (h) Parent Prodrug Parent Prodrug Parent Prodrug Parent Prodrug Parent Prodrug Parent Prodrug PRX-002 (-) isomer 232 ± 43.3 419 ± 56.7 0.5± 0.4 143 ± 14.7 175 ± 27.2 0.08 PRX-002 (+) isomer 106.7 ± 25.4 127.9 ± 74.2 0.5 ± 0 234.1 ± 37.9 249.7 ± 15.2 0.08 PRX-P1-005 0 32 ± 7.5 0 42 ± 9.4 0 0.5 study not performed PRX-P1-013 0 307 ± 49.6 0 678 ± 101.2 0 0.7 ± 0.3 study not performed PRX-P4-002 347 ± 124.6 0 718 ± 432.2 0 0.8 ± 0.3 0 321 ± 69.2 0 960 ± 201.3 0 1.5 ± 0.9 0 PRX-P4-003 156.7 ± 85.3 0 296.9 ± 51.2 0 0.8 ± 0.3 0 30.8 ± 10.1 172.0 ± 62.6 14.3 ± 3.85 132.6 ± 32.5 0.08 ± 0 0.08± 0 PRX-P5-002 267 ± 80.8 0 234 ± 69.4 0 0.50 ± 0 0 360 ± 104.9 0 161 ± 42.9 0 0.08 ± 0 0 PRX-P5-006 66 ± 16.5 0 186 ± 52.6 0 1.0 ± 0 0 NC 707.2 ± 500 NC 409.6 ± 301.4 NC 0.08 ± 0 PRX-P5-006* 144 ± 41.5 81.6 ± 42.2 459 ± 188.5 477.4 ± 54.4 1.7 ± 0.6 0.8 ± 0.3 36 ± 5.0 16425 ± 7095 125 ± 20.6 8061.3 ± 1764.8 1.0 ± 0 0.08 ± 0 PXR-P5-007 39 ± 15.9 ND 69 ± 32.6 ND 0.5 ± 0 ND NP ND NP ND NP ND PRX-P5-010 59.8 ± 15.0 NC 125.7 ± 22.3 NC 1.0 ± 0 NC study not performed PRX-P5-011 0 0 0 0 0 0 not calculated PXR-P6-005 0 721 ± 35.6 0 2433 ± 174.5 0 1.0 + 0 study not performed PXR-P6-006 39 ± 1.8 198 ± 19.6 45 ± 2.6 271 ± 64.8 0.3 ± 0.1 0.3 ± 0.1 study not performed PRX-P6-011 94.6 ± 26.1 82.2 ± 30.9 227.4 ± 69.8 44.2 ± 17.1 0.75 ± 0.4 0.14 ± 0.1 study not performed * PK studies performed at 15 mg/kg dose both orally and intravenously; NP: study not preformed; NC: parameter not calculated: ND: not determined. - Male Sprague-Dawley (SD) were housed in groups of three under controlled conditions. Water and food were available ad libitum. The rats were kept for 1 week under these conditions before behavioral test. On the day of test rats were allowed to acclimate to the testing room for at least 30 min before test compound administration. Rats were randomly assigned into 4 groups.
- Vehicle was 0.1% Tween-80 and 0.5% carboxymethylcellulose to which respective amount of PRX-P4-003 was added to obtain a clear solution.
- Animals were p.o. administered with Veh or 3 doses of PRX-P4-003 [1, 5 or 10 mg/kg equivalent dose of active compound PRX-002 (-)] at 60 min before spontaneous locomotor activity (sLMA) test.
- The rat was placed at the center of test chamber for the 60 min sLMA video recording. 60 min of spontaneous locomotion activity was video recorded and off line analyzed with Animal Behavior Video Tracking Analysis System (Ji Liang Software Technology Co., Ltd., Shanghai, China). Total traveling distance (cm) and duration (sec) of locomotor activity of every 15 min is presented
FIGs. 11A and11B . - As can be seen in
FIGs. 11A and11B , PRX-P4-003 showed a dose dependent increase in sLMA when given orally. - Male SD rats were intravenously administered with PRX-002(-) (2 mg/kg) and prodrug PRX-P4-003 [(25.8 mg/kg, equivalent to 10 mg/kg of PRX-002 (-)], and vehicle just before sLMA test.
- Vehicle was: 10% PEG 400 (v/v) + 30% (v/v) of (50% w/v) Hydroxypropyl-β-cyclodextrin in water + 60% (v/v) sterile water for injection (SWFI): 1 ml/kg volume.
- PRX-P4-003 solution was: 25.8 mg/ml PRX-P4-003 (25.8 mg/kg: equivalent to 10 mg/ml active drug, i.v. @volume of 1 ml/kg). 42.3 mg PRX-P4-003 was added to vehicle 1.639 ml, vortexed for 30 min under room temperature to get a uniform suspension solution, suspension solution was continuously stirred during dosage.
- The PRX-P4-002(-) solution was: 2 mg/ml PRX-P4-002(-) (2 mg/kg, i.v.@ volume of 1 ml/kg). 4.5 mg PRX-002(-) was added to 2.25 ml Vehicle, vortexed for 30 min under room temperature to get a clear solution, the solution was continuously stirred during dosage.
- Rat was placed at the center of test chamber for the 90 min sLMA video recording. (n=3/group).
- Total traveling distance (cm) and duration (sec) of locomotor activity of every 15 min is presented in
FIGs. 12A and12B . Consistent with the the present disclosures, intravenous PRX-002 (-) significantly increased sLMA but prodrug PRX-P4-003 showed no increase in sLMA (even at a 5 times equivalent dose of active) compared to vehicle, even when given intravenously. - As can be seen in the comparison of the results in Example 40A and Example 40B, the prodrug PRX-P4-003 resulted in higher levels of sLMA activity when administered orally than intravenously. Indeed, while both traveling distance and locomotion duration increased following the oral administration of the prodrug (
FIG. 11A and11B ), intravenous administration resulted in practically no change (in comparison to the administration of the active ingredient itself (PRX-002(-)). Thus, the active drug's availability and impact upon the subject is dependent upon its route of administration of the prodrug. - While the disclosure has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive. The disclosure is not limited to the disclosed embodiments. Variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed disclosure, from a study of the drawings, the disclosure and the appended claims.
- Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to a person of ordinary skill in the art, and are not to be limited to a special or customized meaning unless expressly so defined herein. It should be noted that the use of particular terminology when describing certain features or aspects of the disclosure should not be taken to imply that the terminology is being re-defined herein to be restricted to include any specific characteristics of the features or aspects of the disclosure with which that terminology is associated.
- Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.
- Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term 'including' should be read to mean 'including, without limitation,' 'including but not limited to,' or the like; the term 'comprising' as used herein is synonymous with 'including,' 'containing,' or 'characterized by,' and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term 'having' should be interpreted as 'having at least;' the term 'includes' should be interpreted as 'includes but is not limited to;' the term 'example' is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as 'known', 'normal', 'standard', and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now; and use of terms like 'preferably,' 'preferred,' 'desired,' or 'desirable,' and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the disclosure, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the disclosure. Likewise, a group of items linked with the conjunction 'and' should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as 'and/or' unless expressly stated otherwise. Similarly, a group of items linked with the conjunction 'or' should not be read as requiring mutual exclusivity among that group, but rather should be read as 'and/or' unless expressly stated otherwise.
- With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article "a" or "an" does not exclude a plurality.
Claims (8)
- The prodrug composition of claim 1, further comprising a pharmaceutically acceptable carrier.
- The prodrug composition of any one of the claims 1-2, wherein an oral administration of the prodrug composition results in an increased plasma or blood concentration of a released active form of the at least one compound as compared to an intravenous administration of the prodrug composition when the prodrug composition is administered orally and intravenously in equimolar amounts.
- The prodrug composition of any one of the claims 1-3, wherein the prodrug composition is in the form comprising a tablet, a capsule, elixir, emulsion solution, suspension solution, or syrup.
- The prodrug composition of any one of claims 1-4 for use in a method for treating cancer-related fatigue, the method comprising administering an effective amount of the prodrug composition to a subject in need thereof.
- The prodrug composition for the use of claim 5, wherein the subject is mammalian.
- The prodrug composition for the use of claim 5, wherein the subject is human.
- The prodrug composition of any one of claims 1-4 for use in a method of treating Alzheimer's disease, Parkinson's disease, major depressive disorder, or attention deficit hyperactivity disorder, the method comprising administering an effective amount of the prodrug composition to a subject in need thereof.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562219052P | 2015-09-15 | 2015-09-15 | |
US201662298267P | 2016-02-22 | 2016-02-22 | |
US201662308078P | 2016-03-14 | 2016-03-14 | |
PCT/US2016/051534 WO2017048720A1 (en) | 2015-09-15 | 2016-09-13 | Prodrugs of fencamfamine |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3349853A1 EP3349853A1 (en) | 2018-07-25 |
EP3349853A4 EP3349853A4 (en) | 2019-05-22 |
EP3349853B1 true EP3349853B1 (en) | 2023-12-20 |
Family
ID=58289806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16847141.5A Active EP3349853B1 (en) | 2015-09-15 | 2016-09-13 | Prodrugs of fencamfamine |
Country Status (6)
Country | Link |
---|---|
US (2) | US10662146B2 (en) |
EP (1) | EP3349853B1 (en) |
JP (1) | JP6983161B2 (en) |
CN (1) | CN108348775B (en) |
HK (1) | HK1258512A1 (en) |
WO (1) | WO2017048720A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108348775B (en) | 2015-09-15 | 2021-07-02 | 普瑞西斯生物学研究有限责任公司 | Prodrugs of fenkafamine |
EP4267549A1 (en) | 2020-12-23 | 2023-11-01 | The Broad Institute Inc. | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds |
EP4267548A1 (en) * | 2020-12-23 | 2023-11-01 | The Broad Institute Inc. | Compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1110159B (en) | 1959-08-01 | 1961-07-06 | Merck Ag E | Process for the preparation of analeptically active N-substituted amino orcamphan derivatives or of their acid addition salts and quaternary ammonium compounds |
US3536707A (en) | 1967-06-22 | 1970-10-27 | Miles Lab | 2-(2-aminoalkanoylamino)-3-phenylnorbornanes |
US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US6264917B1 (en) | 1996-10-28 | 2001-07-24 | Nycomed Imaging As | Targeted ultrasound contrast agents |
US5760049A (en) | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
US5824684A (en) | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
US5916903A (en) | 1997-02-28 | 1999-06-29 | Synapse Pahrmaceuticals International, Inc. | Method for reducing the effects of antineoplastic disease treatment |
US5981549A (en) | 1997-02-14 | 1999-11-09 | Synapse Pharmaceutical International | Method for controlling or alleviating the symptoms of respiratory disease and allergies |
US5900418A (en) | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
US6166032A (en) | 1997-02-07 | 2000-12-26 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
TR200100708T2 (en) | 1998-09-10 | 2001-07-23 | Nycomed Danmark A/S | Quick-release pharmaceutical compositions for pharmaceutical agents. |
US8231899B2 (en) | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
US20030170181A1 (en) | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
AU4221300A (en) | 1999-04-06 | 2000-10-23 | Kamal K. Midha | Pharmaceutical dosage form for pulsatile delivery of (d-threo)-methylphenidate and a second cns stimulant |
GB9913458D0 (en) | 1999-06-09 | 1999-08-11 | Medeva Europ Ltd | The therapeutic use of d-threo-methylphenidate |
US8354438B2 (en) | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7906140B2 (en) | 2004-06-17 | 2011-03-15 | Virun, Inc. | Compositions for mucosal delivery of agents |
ME00954B (en) | 2007-05-11 | 2012-06-20 | Pfizer | Amino-heterocyclic compounds |
US20090325999A1 (en) | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
AU2009279372A1 (en) * | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
AU2011243947A1 (en) | 2010-04-23 | 2012-12-06 | Piramal Enterprises Limited | Nitric oxide releasing prodrugs of therapeutic agents |
US20120046232A1 (en) | 2010-06-22 | 2012-02-23 | Medical University Of South Carolina | Compositions and methods for reducing relapse of addictive behavior |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
RU2573835C2 (en) | 2011-07-28 | 2016-01-27 | Кемфарм Инк. | Methylphenidate prodrugs, methods of their obtaining and application |
JP5952912B2 (en) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | Prodrugs of secondary amine compounds |
US9687445B2 (en) | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
WO2014002039A1 (en) | 2012-06-27 | 2014-01-03 | Shire Ag | Amphetamine prodrugs |
CA2889855A1 (en) * | 2012-11-01 | 2014-05-08 | Robert S. Katz | Methods for treating fibromyalgia |
US10420729B2 (en) | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
US20140364367A1 (en) | 2013-06-08 | 2014-12-11 | Sedogen, Llc | Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener |
WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
CN108348775B (en) | 2015-09-15 | 2021-07-02 | 普瑞西斯生物学研究有限责任公司 | Prodrugs of fenkafamine |
-
2016
- 2016-09-13 CN CN201680063327.0A patent/CN108348775B/en active Active
- 2016-09-13 US US15/758,466 patent/US10662146B2/en active Active
- 2016-09-13 WO PCT/US2016/051534 patent/WO2017048720A1/en active Application Filing
- 2016-09-13 JP JP2018532535A patent/JP6983161B2/en active Active
- 2016-09-13 EP EP16847141.5A patent/EP3349853B1/en active Active
-
2019
- 2019-01-17 HK HK19100861.5A patent/HK1258512A1/en unknown
-
2020
- 2020-04-14 US US16/847,988 patent/US11919836B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3349853A1 (en) | 2018-07-25 |
US20190023650A1 (en) | 2019-01-24 |
US10662146B2 (en) | 2020-05-26 |
EP3349853A4 (en) | 2019-05-22 |
CN108348775B (en) | 2021-07-02 |
HK1258512A1 (en) | 2019-11-15 |
JP2018537515A (en) | 2018-12-20 |
US11919836B2 (en) | 2024-03-05 |
CN108348775A (en) | 2018-07-31 |
WO2017048720A1 (en) | 2017-03-23 |
US20200399203A1 (en) | 2020-12-24 |
JP6983161B2 (en) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220213023A1 (en) | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion | |
JP2017128605A (en) | Solid forms of antiviral compound | |
US11919836B2 (en) | Prodrugs of fencamfamine | |
EP1682503B1 (en) | Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
EP1680400B1 (en) | Derivatives of n-[ phenyl(pyrrolidine-2-yl)methyl]benzamide and n-[ (azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | |
EP1551803B1 (en) | Azabicyclo derivatives as muscarinic receptor antagonists | |
TW201213329A (en) | Pyrazine derivatives as ENaC blockers | |
CA2542373A1 (en) | Derivatives of n-phenyl(piperidine-2-yl)methyl benzamide, preparation method thereof and applications of same in therapeutics | |
JPH06505241A (en) | Aliphatic propargylamines as selective MAO-B inhibitors and neuroprotective agents | |
CN110234636B (en) | Compositions comprising methylphenidate prodrugs, methods of making and using the same | |
WO1994015916A1 (en) | Selective ligands of receptors 5-ht1d-5ht1b derived from indole-piperazine useful as medicaments | |
EP3353163B1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
EP2094674B1 (en) | A salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one | |
US20190270698A1 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
US20160022675A1 (en) | Processes for preparing tetrahydroisoquinolines | |
EP3150598B1 (en) | Substituted tropane derivatives | |
JPH05117236A (en) | Dichloroaniline compound | |
AU2019271799B2 (en) | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin | |
US20180055836A1 (en) | Process for the preparation of benzhydrocodone hydrochloride | |
US20180282297A1 (en) | Polymorphs of 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
EP4357335A1 (en) | Azabicyclo[3.1.0]hexane compound | |
WO1997009310A1 (en) | 1-phenyl-3-4-[benzylpiperidinyl-1]-propanol-1 derivatives, preparation thereof and therapeutical application thereof | |
HU205751B (en) | Process for producing new 1,3-oxazines and pharmaceutical compositions comprising same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180319 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190425 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 233/06 20060101ALI20190412BHEP Ipc: A61K 9/00 20060101AFI20190412BHEP Ipc: A61K 47/10 20170101ALI20190412BHEP Ipc: A61P 25/16 20060101ALI20190412BHEP Ipc: C07C 237/22 20060101ALI20190412BHEP Ipc: A61K 47/26 20060101ALI20190412BHEP Ipc: A61K 47/64 20170101ALI20190412BHEP Ipc: A61K 47/38 20060101ALI20190412BHEP Ipc: A61K 31/13 20060101ALI20190412BHEP Ipc: C07C 271/24 20060101ALI20190412BHEP Ipc: C07K 5/00 20060101ALI20190412BHEP Ipc: C07C 271/56 20060101ALI20190412BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1258512 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200929 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref document number: 602016084887 Country of ref document: DE Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0025160000 Ipc: A61K0009000000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 5/062 20060101ALI20230605BHEP Ipc: C07C 237/04 20060101ALI20230605BHEP Ipc: A61P 25/28 20060101ALI20230605BHEP Ipc: A61P 25/00 20060101ALI20230605BHEP Ipc: A61P 25/26 20060101ALI20230605BHEP Ipc: A61P 25/24 20060101ALI20230605BHEP Ipc: A61P 25/16 20060101ALI20230605BHEP Ipc: C07K 5/00 20060101ALI20230605BHEP Ipc: C07C 237/22 20060101ALI20230605BHEP Ipc: C07C 237/20 20060101ALI20230605BHEP Ipc: C07D 237/04 20060101ALI20230605BHEP Ipc: C07C 233/06 20060101ALI20230605BHEP Ipc: C07C 271/56 20060101ALI20230605BHEP Ipc: C07C 271/24 20060101ALI20230605BHEP Ipc: A61K 47/64 20170101ALI20230605BHEP Ipc: A61K 47/54 20170101ALI20230605BHEP Ipc: A61K 47/38 20060101ALI20230605BHEP Ipc: A61K 47/26 20060101ALI20230605BHEP Ipc: A61K 47/10 20170101ALI20230605BHEP Ipc: A61K 9/00 20060101AFI20230605BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230713 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230710 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016084887 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240321 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231220 |